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MoTHer To CHIlD TraNSMISSIoN
Mother-to-child transmission (MTCT) of HIV refers to the transmission of HIV from HIV-
infected mothers to their infants. MTCT can occur during pregnancy, labour and delivery and 
breast-feeding.1 Without the use of preventive measures, the risk of MTCT of HIV-1 is estimated 
to vary between 35 and 40%.2-3 The risk of MTCT can be reduced to less than 2% by interventions 
that include: antiretroviral (ARV) prophylaxis given to women during pregnancy and labour; 
ARV prophylaxis to the infant in the first weeks of life; Obstetrical interventions including 
elective caesarean section; and complete avoidance of breast-feeding.4 
PreVeNTIoN of MoTHer To CHIlD 
TraNSMISSIoN (PMTCT)
ARV drugs reduce MTCT of HIV by inhibiting viral replication and thus lowering plasma viral 
load in pregnant women, both when given during pregnancy and when given during the breast 
feeding period. In newborns receiving post-exposure prophylaxis after delivery, inhibition of 
viral replication contributes to prevent HIV infection.5-6 Several preventive strategies have been 
evaluated, but most of them are too expensive for implementation in resource-limited countries. 
The regimen of a single dose of nevirapine (SD NVP) to the mother just before delivery and SD NVP 
to the newborn within 24-72 hours after birth reduces the risk of MTCT by 50%, is affordable in 
many situations7 and was therefore until recently the standard of care in many Africans countries, 
like Tanzania. The low genetic barrier8 and the long elimination half-life of NVP leads to persistence 
of sub-therapeutic NVP plasma concentrations which leads to primary NVP resistance9-11, detected 
by standard genotyping in 15-75% women. In view of such high percentage of NVP resistance, the 
new 2007 PMTCT Tanzania guideline was followed12 The recommended combination regimen for 
HIV-infected women, who present during pregnancy at the antenatal clinic (ANC) is AZT 300 mg 
BD from 28 weeks of gestation or anytime thereafter, combined with SD NVP 200 mg at onset of 
labour, and AZT 300 mg and 3TC 150 mg given every 12 hours until delivery. During the postpartum 
period, AZT 300 mg BD and 3TC 150 mg BD is continued for 7 days. This combined regimen has 
reduced the MTCT rates to less than 2% when breast-feeding is avoided.13-14 For HIV infected 
pregnant women who were receiving effective ARV treatment continued throughout labor and 
delivery, as well as the postpartum period the regimen on schedule as much as possible to provide 
maximal virologic effect and to minimize the chance of development of drug resistance.15 All infants 
born to HIV-infected women should receive daily NVP as soon as possible after delivery regardless 
of whether the mother has received or not received ARV treatment or prophylaxis. For breastfed 
infants, daily NVP should be given as soon as possible and continued until one week after complete 
cessation of breast-feeding. For formula fed infants and breast fed infant whose mother is on ARV 
therapy; daily NVP should continue for six weeks.16 
NeVIraPINe aND NeVIraPINe re SISTaNCe
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It binds to reverse 
transcriptase (RT) and blocks the RNA-dependent and DNA-dependent polymerase activities 
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by causing disruption of the enzyme’s catalytic site. NVP is used as a single ARV prophylaxis 
during labour because of its potent antiretroviral effect (IC
50
 of 10ng/ml), rapid and almost 
complete absorption after oral intake, its long elimination half-life and its ability to cross 
the placenta.17 Even when using antepartum, intrapartum and postpartum combination ARV 
therapy for PMTCT still NVP resistance of 4-16% occurs.18 Resistance to NVP remains therefore 
a serious concern. NVP resistance has three major implications. Firstly, the efficacy of NVP or 
other NNRTIs in combination ARV therapy may be diminished when a patient harbours resistant 
virus,19 secondly NVP-resistant strains may be transmitted to others, limiting treatment options 
for newly infected patients. Thirdly, NVP resistance could reduce the efficacy of SD NVP in 
subsequent pregnancies.20-21 The risk of development of resistance is increased when sub-
therapeutic NVP concentrations are present in blood for a long time. 
ClINICal PHarMaCology of NeVIraPINe 
IN PMTCT
Small pharmacokinetic studies demonstrated that the elimination half-life after SD NVP is 
approximately 60 hours.22 This implies that sub-therapeutic plasma concentrations of NVP 
will be detectable in mothers for several days after delivery. These plasma levels present the 
perfect environment for the occurrence of resistance as the concentrations are sub-inhibitory 
for several days.
A pilot study in healthy volunteers demonstrated that the elimination half-life of SD 
NVP could be reduced by adding the enzyme inducer carbamazepine.23 This was a phase-I 
single-centre, open-label, two period, nine-group, PK study. A single 200 mg dose of NVP 
was administered to 36 HIV negative non-pregnant women in both period 1 and 2, blood 
samples were taken twice weekly for 21 days. In period 2 additional interventions (single dose 
carbamazepine, phenobarbital or phenytoin; phenytoin for 3 or 7 days; St Johns Wort, vitamin 
A or cholecalciferol for 14 days) were administered to all participants except for the control 
group. Three of the interventions resulted in the half-life of NVP being significantly reduced. 
These included a single 400mg dose of carbamazepine (p=0.002), once a day 184mg phenytoin 
for three days (p=0.001) and once a day 184mg phenytoin for seven days (p=0.002). The half-life 
of NVP was reduced by 35.3%, 38.2% and 35.9%.23
Therapeutic drug monitoring
Therapeutic drug monitoring (TDM) is used to optimize drug regimens for the individual patient 
by increasing efficacy and avoiding drug-related toxicity Patient taking NNRTI are at a greater 
risk for developing resistance and treatment limiting toxicity. Virological suppression can only 
be reached when taking at least 95% of the prescribed doses. Patients at risk for virological failure 
are those with sub-therapeutic plasma concentrations of nevirapine.24 TDM is a well known 
tool for the optimization of NVP dosing in the developed world, but not often performed in 
resource limited settings due to lack of simple and affordable assays to determine the exposure 
to NVP. TDM of ARVs aims to improve ART efficacy and safety by maintaining individual patient 
ARV concentrations within a therapeutic range. Many review articles suggest that ARV TDM 
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may be a useful tool for improving outcomes for HIV-infected individuals. They suggest that 
TDM of ARVs can potentially identify patients with sub-therapeutic, toxic or appropriate drug 
concentrations. In patients with advanced HIV disease, a retrospective analysis found an 
association between subtherapeutic drug concentrations at the commencement of ART and 
poorer immunological outcomes and failure to achieve virologic suppression in the first year of 
treatment.25 ARV TDM is therefore potentially a rational tool to optimise efficacy and minimise 
toxicity of ARV therapy. 
ouTlINe of THe THeSIS 
In Chapter 1, an introduction is given on mother-to-child transmission of HIV and PMTCT, after 
which the outline of the thesis is presented. 
Part I of the thesis focuses on the effects of enzyme inducers on the pharmacokinetics and 
the development of resistance to a SD NVP in perinatal HIV prevention. 
In Chapter 2, a study is presented investigating whether NVP plasma concentrations 
are still detectable more than 2 weeks after administration. The study was conducted in the 
Netherlands in non pregnant healthy Dutch women. 
Chapter 3 presents the results of a phase II trial, investigating whether the addition of single-
dose carbamazepine would diminish NVP resistance development by reducing elimination 
half-life after exposure to SD NVP at onset of labour in HIV-infected women. As reported in 
Chapter 4, we also investigated whether a longer course of an enzyme inducer as opposed to 
only a single-dose might have greater impact on the reduction of NVP elimination half-life and 
resistance development. As reported in Chapter 5 a systematic review and meta-analysis was 
done which compared the different drug interventions used to reduce NVP resistance after 
SD NVP as part of antiretroviral prophylaxis to prevent HIV mother-to-child transmission. 
Part II of the thesis focuses on TDM in HIV– infected adults using a simple and inexpensive 
TLC assay for semi-quantitative measurement of NVP saliva concentrations. 
Chapter 6 describes the validation of a simple and economical thin layer chromatography 
method for semi-synthetic detection of NVP in saliva of HIV- infected adults. In Chapter 7, 
we compare saliva concentrations of NVP with self-reported adherence, in patients on NVP-
containing ARV treatment. 
Finally, in Chapter 8, our research findings are discussed and put into the perspective of 
related research data. In addition, avenues for future research in this area are presented.
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IClINICal PHarMaCology of NeVIraPINe IN PMTCT
Eva Muro
Jacqueline A. H. Droste
Hadewych ter Hofstede
Marjolein Bosch
Wil Dolmans
David M. Burger
2NeVIraPINe Pl aSM a CoNCeNTraTIoNS are STIll DeTeCTable af Ter More THaN 2 weekS IN THe Ma jorIT y of woMeN reCeIVINg SINgle-DoSe NeVIraPINe IMPlICaTIoNS for INTerVeNTIoN STuDIeSJ Acquir Immune Defic Syndr 2005;39:419-421
abSTraCT
background
Single-dose nevirapine is a highly cost-effective strategy to reduce perinatal HIV-1 transmission. 
Its major disadvantage is the selection of nevirapine resistance in 20% to 30% of women, 
probably attributable to the long elimination half-life of nevirapine. To develop intervention 
strategies, it is important to know the interpatient variability in nevirapine half-life in women 
receiving a single dose of nevirapine
Methods
HIV-negative, healthy, nonpregnant Dutch women were eligible for this study. After 
administration of a single 200-mg dose of nevirapine to the subjects, blood was sampled for 
measurement of nevirapine twice a week for a total of 21 days. Nevirapine plasma levels were 
determined by a validated high-performance liquid chromatography method with a lower limit 
of quantification of 0.15 mg/L. The primary end point was the first sample with an undetectable 
nevirapine concentration.
results
Forty-four subjects participated. The median age, height, and body weight (interquartile range) 
were 26 (21–33) years, 1.72 (1.68–1.75) m, and 64 (59–75) kg, respectively. The median elimination 
half-life of nevirapine was 56.7 hours, with a range of 25.6 to 164 hours. The time to the first 
undetectable nevirapine plasma concentration was 10 days in 4 subjects, 14 days in 12 subjects, 
17 days in 12 subjects, and 21 days in 9 subjects. In the remaining 7 subjects, nevirapine was 
still detectable on day 21, the last day of sampling. Time to an undetectable nevirapine plasma 
concentration was influenced by oral contraceptive use but not by age, height, body weight, 
body surface area, alcohol use, or smoking.
Conclusions
Most women who received a single 200-mg nevirapine dose still had detectable plasma 
concentrations of nevirapine after more than 2 weeks. This information is valuable for designing 
intervention studies to prevent the development of nevirapine resistance.
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Without the use of preventive measures, the risk of mother-to-child transmission (MTCT) of HIV-1 
is estimated to vary between 25% and 48%. Several preventive strategies have been evaluated, 
but most of them are too expensive to implement in resource-limited countries. The regimen of a 
single dose of nevirapine to the mother just before delivery and a single dose of nevirapine to the 
newborn between 24 and 72 hours after birth reduces the risk of MTCT by 50% and is affordable 
in many situations.1 Recent studies, however, have shown that this single dose to the mother can 
induce nevirapine resistance in 20% to 30% of the mothers.2 The development of this resistance 
may have major implications. First, it is uncertain whether a subsequent course of nevirapine is 
still effective for the prevention of MTCT when these women become pregnant again. Second, 
the efficacy of subsequent treatment with a nevirapine-based highly active antiretroviral therapy 
(HAART) regimen is diminished when the patient is harboring a resistant virus.3 Finally, nevirapine-
resistant strains may be transmitted to other people. The mechanism of the occurrence of 
nevirapine resistance after a single dose is most likely related to the long elimination half-life 
of nevirapine and the low genetic barrier to resistance. Small pharmacokinetic studies have 
demonstrated that the elimination half-life after a single dose of nevirapine is approximately 
60 hours.4 This implies that plasma concentrations of nevirapine are detectable in mothers for 
several days after delivery. The subtherapeutic but detectable plasma levels present the perfect 
environment for the occurrence of resistance, because the concentrations may be subinhibitory 
for several days. The primary objective of this study was to investigate the intersubject variability 
and potential influencing factors in the decay of plasma nevirapine concentrations after a single 
200-mg dose. A secondary objective was the evaluation of the use of saliva as an alternative to 
blood sampling for measurement of nevirapine concentrations. The study was conducted in The 
Netherlands as a prelude to a similar study in Tanzania.
MeTHoDS
The present study was a single-center, open-label, single-dose, single-period pharmacokinetic 
study. Nonpregnant healthy women aged 18 to 40 years were eligible for enrolment after pre-entry 
and laboratory evaluation. Women who tested positive for HIV and/or hepatitis B or C virus were 
excluded. The study protocol was reviewed and approved by Ethics Committee of the Radboud 
University Medical Centre, Nijmegen, The Netherlands. Informed consent was obtained from all 
women before enrolment. All study subjects received a single oral dose of 200 mg of nevirapine on 
day 0, and the Principal Investigator directly observed medication ingestion. Sampling of blood and 
saliva was done just before and 3, 7, 10, 14, 17, and 21 days after sampling. Stimulated saliva was obtained 
by a salivette (Sarstedt, Etten-Leur, The Netherlands) using a dental cotton roll impregnated with 
citric acid (20 mg), which stimulates the salivary flow. Study subjects were asked to chew on the 
cotton roll for approximately 1 minute. Saliva was obtained by centrifugation of the cotton roll. The 
plasma and saliva samples were stored at _ 400C until analysis. Plasma and saliva concentrations 
of nevirapine were determined by a validated high-performance liquid chromatography (HPLC) 
assay with ultraviolet (UV) detection.5 The lower and upper limits of quantification were 0.15 and 
15 mg/L, respectively. The intra-and interday precision ranged from 1.3% to 3.9% and from 1.9% 
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to 3.0%, respectively. The accuracy of the assay ranged from 91.5% to 102.6%. The typical median 
inhibitory concentration (IC50) value of nevirapine is 0.1 mg/L; corrected for 60% protein binding, 
this corresponds to a plasma level of approximately 0.2 mg/L. It is currently unknown, however, at 
what plasma level nevirapine selects for resistance. Clinical studies have determined that effective 
concentrations of nevirapine are greater than 3 to 4 mg/L, whereas levels less than 0.1 to 0.2 mg/L 
do not have selective pressure. Therefore, any plasma level between 0.2 and 3.0 mg/L has been 
defined by us as subtherapeutic. The following patient factors were tested for an association with 
the time to undetectable nevirapine plasma concentration: age, height, weight, body surface area, 
alcohol use, smoking habits, and oral contraceptive use.
reSulTS
Forty-four nonpregnant healthy women were enrolled in the protocol. The median age, height, 
and body weight (interquartile range) were 26 (21–33) years, 1.72 (1.68–1.75) m, and 64 (59–75) kg, 
respectively. Other than 1 Asian woman and 1 woman of mixed background, the remaining 
42 women were white. The pharmacokinetic parameters of the study subjects are presented in 
Table 1. The median elimination half-life (t½) for nevirapine in plasma was 56.7 hours, with a range 
of 25.6 to 164 hours. Maximum nevirapine plasma levels on day 3 (first postdose measurement) 
ranged from 0.36 to 1.59 mg/L, with a median value of 0.71 mg/L. The median time to the first 
undetectable nevirapine plasma concentration was 17 days. There were 7 subjects in whom 
nevirapine was still detectable on day 21, however, the last day of sampling (Fig. 1).
Except for oral contraceptive use, none of the other patient characteristics seemed to be 
related to the time to an undetectable nevirapine concentration in plasma. There were 17 women 
who reported taking oral contraceptives, and they had a median time to the first undetectable 
nevirapine plasma level of 21 days. This was significantly longer than for the remaining 27 women 
who reported not taking oral contraceptives (14 days; P<0.001). The difference in the median 
plasma half-life of nevirapine in oral contraceptive users versus nonusers was not significant (69.7 
vs. 52.8 hours, respectively; P = 0.053). Saliva nevirapine concentrations were approximately half 
of the values observed in plasma. Nevirapine levels in saliva were significantly correlated with 
nevirapine levels in plasma at the first day of sampling: [NVP] 
saliva
 = 0.002 + 0.495 X [NVP] 
plasma
 
(R2 = 0.531, F = 47.496, P < 0.001). Time to an undetectable nevirapine concentration was shorter 
in saliva than in plasma: median values were 14 and 17 days, respectively (see Fig. 1).
Table 1. Pharmacokinetic Parameters of Nevirapine after a 200-mg Single Oral Dose (median values + 
range)
Plasma Saliva
Cl/f (l/h . kg) 0.04 (0.02-0.10)
T ½ (h) 56.7 (25.6-164.1) 77.1 (35.8-264.7)
Vd/f (l/kg) 2.8 (0.8-5.3)
Cmax (mg/l) 0.71 (0.36-1.59) 0.35 (0.03-0.77)
Time to undetectable concentration (days) 17 (10 to >21) 14 (7-21)
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DISCuSSIoN
In this study of 44 healthy, non-pregnant, HIV-1- uninfected Dutch women, a single dose of 
200 mg of nevirapine had an average half-life of 56.7 hours (or 52.8 hours in women who did 
not use contraceptives). Nevirapine levels remained detectable in plasma for a median of 
17 days (range: 10 to >21 days). In 16% of women, nevirapine was detectable at the last measured 
time point, 21 days after the single dose. Thus, a single dose of nevirapine was associated with 
persistent measurable drug levels beyond 3 weeks after administration. It is clear that our study 
population of healthy nonpregnant Dutch women of childbearing age is not similar to the setting 
in Tanzania (or other sub-Saharan African countries), where HIV-infected pregnant women 
are black and have different dietary habits, body weights, and comedications, for example. 
Nevertheless, the median nevirapine half-life that we observed in our group of 44 subjects 
(56.7 hours) is not too different from the average value as reported by Musoke et al4 in a smaller 
group of pregnant HIV-infected Ugandan women receiving single-dose nevirapine (61.3 hours). 
We were not able to identify any significant patient factor (other than oral contraceptive use) 
that was associated with an influence on nevirapine half-life. Oral contraceptives may be able 
to inhibit hepatic metabolism of nevirapine, although this effect was previously not observed 
(and thus not expected by us) in a formal drug–drug interaction study.6 It must be noted, 
however, that our study was not designed to address causality between oral contraceptive use 
and nevirapine half-life.
Most importantly, our data describe the window of opportunity for the virus to select 
for nevirapine-resistant mutations. The longer the time to an undetectable nevirapine level 
in plasma, the longer the virus has time to replicate. In 2000, Jackson et al7 reported that 
among the 15 women in the HIVNET 006 trial in whom virus was tested for the K103N mutation, 
the 3  women who developed the mutation had a significantly longer elimination half-life of 
nevirapine than the 12 women in whom no resistance was detected (74.8 vs. 51.8 hours; P = 0.01). 
Thus, one of the most rational interventions is the addition of other antiretroviral agents after 
figure 1. Distribution of time to undetectable NVP concentrations (in days) for 44 included subjects.
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delivery to cover this window of opportunity for the virus to select for nevirapine resistance. 
Recently, preliminary data were presented that short courses (4–7 days) of zidovudine plus 
lamivudine (Combivir) added to single-dose nevirapine in the prevention of MTCT significantly 
reduced the development of nevirapine resistance when compared with no intervention.8 One 
could speculate that this may not be sufficient to prevent the development of all nevirapine 
mutations. Indeed, nevirapine resistance was not fully absent in the intervention arms. Extending 
the duration of administering additional antiretroviral agents after delivery may also increase 
the development of resistance to these drugs, however. It may be attractive to use methods 
other than collecting blood samples for measurement of exposure to nevirapine. As reported 
earlier, nevirapine can be detected in saliva.9 In our study, we observed a strong correlation 
between nevirapine levels in saliva versus plasma, and in almost all subjects, an undetectable 
nevirapine level was detected 3 days earlier in saliva than in plasma (see Fig. 1). Collecting saliva 
samples for measurement of nevirapine levels has the advantage of taking samples at home 
(by the patient herself, with no skilled personnel needed), less discomfort for the patient, and 
less infection risk for health care workers who draw the sample. In conclusion, most women 
who received a single nevirapine dose of 200 mg still had detectable plasma concentrations 
of nevirapine after more than 2 weeks. This information is valuable for designing intervention 
studies to prevent the development of nevirapine resistance.
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abSTraCT
background
World Health Organization guidelines recommend zidovudine + lamivudine for 7 days from 
labor onset in HIV-infected women receiving single-dose nevirapine (sdNVP) to cover 
prolonged subtherapeutic nevirapine concentrations. Although effective, this is complicated 
and does not eliminate resistance; alternative strategies could add benefit.
Methods
Antiretroviral-naive HIV-infected pregnant women aged 18–40 years, with CD4 >200 cells 
per cubic millimeter, able to regularly attend the antenatal clinics in Moshi, Tanzania, were 
enrolled 1:1 by alternate allocation to receive 200 mg sdNVP alone or in combination with 
open-label 400-mg single-dose carbamazepine (sdNVP/CBZ) at delivery (ClinicalTrials.gov 
NCT00294892). The coprimary outcomes were nevirapine plasma concentrations 1 week 
and nevirapine resistance mutations 6 weeks postpartum. Analyses were based on those still 
eligible at delivery.
results
Ninety-seven women were assigned to sdNVP and 95 to sdNVP/CBZ during pregnancy, of 
whom 75 sdNVP and 83 sdNVP/CBZ were still eligible at delivery at study sites. The median 
(interquartile range) nevirapine plasma concentration was 1.55 (0.88–1.84) mg/L in sdNVP 
(n = 61) and 1.40 (0.93–1.97) mg/L in sdNVP/CBZ (n = 72) at delivery (P = 0.91), but 1 week later 
was significantly lower in sdNVP/CBZ [n = 63; 0.09 (0.05–0.20) mg/L] than in sdNVP [n = 52; 0.20 
(0.09–0.31) mg/L; rank-sum: P = 0.004] (geometric mean ratio: 0.64, 95% confidence interval: 
0.43 to 0.96; P = 0.03). Six weeks postpartum, nevirapine mutations were observed in 11 of 52 
(21%) in sdNVP and 6 of 55 (11%) in sdNVP/CBZ (odds ratio = 0.46, 95% confidence interval: 0.16 
to 1.34; P = 0.15).
Conclusions
Addition of single-dose carbamazepine to sdNVP at labor onset in HIV-infected, pregnant 
women did not affect nevirapine plasma concentration at delivery, but significantly reduced it 
1 week postpartum, with a trend toward fewer nevirapine resistance mutations.
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INTroDuCTIoN
Without intervention, the risk of mother-to-child HIV transmission in the breastfed population 
is 35%–40%.1,2 Single-dose nevirapine (sdNVP) to the mother at onset of labor and sdNVP to the 
newborn within 24–72 hours after birth remains part of treatment for prevention of mother-
to-child HIV transmission (pMTCT) in most resource-limited countries.2,3 This simple and 
affordable intervention reduces mother-to-child HIV transmission by 40% and has benefited 
thousands of babies since its introduction in 2000. Nevirapine is a nonnucleoside reverse 
transcriptase inhibitor (NNRTI) with potent antiviral activity, but a low genetic barrier, with 
one mutation causing high-level resistance. It is rapidly absorbed when given orally and passes 
quickly through the placenta. The primary elimination pathway for nevirapine is oxidative 
metabolism by cytochrome P-450 3A4 and 2B6 enzymes.4 The drug has a long elimination 
half-life in pregnant women using a single 200-mg dose at labor (median 61–66 hr). This 
leads to persisting subtherapeutic plasma concentrations, which, given its low genetic barrier 
to resistance,5,6 means a single dose can lead to primary nevirapine resistance in 15%–75% 
mothers.7–9 Clinically, nevirapine resistance has 3 major implications. First, the efficacy of 
nevirapine or other NNRTIs in combination antiretroviral therapy (ART) may be diminished 
when a patient harbors resistant virus. Indeed, studies in sub-Saharan Africa suggest that 
recent exposure to sdNVP (<6 months) is associated with increased risk for virological and 
clinical failure.7,10–13 Second, nevirapine-resistant strains may be transmitted to others, limiting 
their treatment options. Third, nevirapine resistance could reduce the efficacy of sdNVP in 
subsequent pregnancies,14,15 although data suggest nevirapine resistance fades in these women 
over time and sdNVP remains effective for prophylaxis in subsequent pregnancies.16,17
Updated World Health Organization (WHO) guidelines therefore now recommend adding 
zidovudine + lamivudine for 7 days postpartum to cover the prolonged presence of subtherapeutic 
nevirapine concentrations after sdNVP at labor onset.18–20 Recent studies show adding single-
dose tenofovir + emtricitabine to sdNVP and short-course zidovudine further reduces NNRTI 
resistance.21–23 Of note, none of these interventions fully eradicated nevirapine resistance,19 
which therefore remains a serious and growing concern. A different approach to limit nevirapine 
resistance development would be a pharmacological intervention to reduce nevirapine elimination 
half-life. Carbamazepine is a low cost widely available anticonvulsant, an inducer of cytochrome 
P-450 3A4 enzymes, which passes into breast milk and might decrease nevirapine elimination 
half-life and resistance development in the mother. A pilot study comparing 8 different CYP3A 
induction strategies with different drugs demonstrated that elimination half-life of sdNVP was 
reduced most (by 35%) by adding single-dose carbamazepine in healthy volunteers.4 In this phase 
II trial, we therefore investigated whether the addition of single-dose carbamazepine, as CYP3A4 
enzyme inducer, would diminish nevirapine resistance development by reducing elimination 
half-life after exposure to sdNVP at onset of labor in HIV-infected, pregnant, Tanzanian women. 
MeTHoDS
Study Participants HIV-1–infected, pregnant women attending antenatal clinics in Moshi, 
Tanzania, were recruited from Kilimanjaro Christian Medical Centre (KCMC) as the consultant 
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hospital, 3 primary and 1 tertiary antenatal care units. Counseling and voluntary HIV testing 
(by the dual rapid-test algorithm) was offered routinely to all pregnant women attending 
antenatal services in these clinics as part of the national pMTCT program. Women testing 
positive received posttest counseling and were informed about the trial. Eligible HIV-
infected women were as follows: aged 18–40 years, CD4 count >200 cells per cubic millimeter 
(ie, did not qualify for ART at the time), antiretroviral (ARV) naive, living within the catchment 
area, not intending to relocate during study participation, willing to adhere to the follow-up 
schedule, able and willing to give informed consent, and to regularly attend the antenatal 
clinic. Exclusion criteria were: previously treated with ARVs including sdNVP in a previous 
pregnancy and serious illness that required systemic treatment/hospitalization. Women who 
qualified for ART (ie, CD4 <200 cells/mm3) were referred for care and not enrolled. Written 
consent was obtained where possible; for eligible women who could not read, consent was 
obtained orally and documented by a witness. The study was approved by institutional review 
boards of KCMC, Moshi, Tanzania, and Radboud University Nijmegen Medical Centre, The 
Netherlands. The study is registered with ClinicalTrials. gov, number NCT00294892. After 
28 weeks gestation, eligible women who had provided informed consent were allocated 1:1 to 
receive either the national standard care at the time of sdNVP (200 mg) or sdNVP plus single-
dose carbamazepine (sdNVP/CBZ, 400 mg) orally at onset of labor (open-label). Nevirapine 
(and carbamazepine if allocated) was handed to the woman at enrolment following standard 
antenatal policy, ideally at 28 weeks of pregnancy at her routine checkup visit and at the latest 
just before delivery following standard antenatal policy. In both groups, sdNVP suspension 
was administered to the baby within 24–72 hours after birth. The randomization list was 
generated as alternate allocations by the study pharmacist (ie, was quasi randomized) and 
was held centrally at the KCMC pharmacy. Allocations were made by local medical officers 
at antenatal clinics phoning the pharmacist: as there were 4 local antenatal clinics, the next 
allocation was concealed to study teams until it was made. Participants were asked to take 
study drugs at onset of labor pain and to come to the labor ward for delivery. If the woman 
vomited within 30 minutes of study drug(s) administration or did not deliver within 48 hours, 
a second single dose of nevirapine (not carbamazepine) was given. When the women 
presented in labor, a study nurse confirmed study drug(s) ingestion by direct observation 
of intake at the clinic or by asking the women when they had taken study drug(s) already 
at home. Replacement drugs were provided for those who had not taken them. The time of 
ingestion of study drugs was recorded in the case report form. As the national guidelines 
recommended, all women (100%) in the trial opted to exclusively breastfeed for 6 months 
and then wean rapidly.
objectives, outcomes, and follow-up
The primary objectives were to determine the effect of adding single-dose carbamazepine 
on sdNVP pharmacokinetics and nevirapine resistance development in the women. The first 
coprimary outcome was therefore nevirapine plasma concentration 1 week postpartum. Blood 
samples were taken 1 week postpartum (and at delivery) for pharmacokinetic evaluation. The 
second coprimary outcome was the proportion of women with any of the following major 
nevirapine resistance mutations L100I, K101P, K103N, V106A/M, V108I, Y181C/I, Y188C/L/H, 
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G190A9,24 on majority sequencing 6 weeks postpartum. Secondary outcomes were any positive 
HIV RNA polymerase chain reaction test of the newborn and adverse events (including any 
grade of toxicity in laboratory safety tests taken 1-week postpartum) possibly/probably/
definitely related to study drugs. Hematology and biochemistry tests were determined at 
enrollment and 1 week postpartum. CD4 cell counts and quantitative plasma HIV-1 RNA were 
assayed just after delivery. Infants were tested just after birth, week 6, and month 4 by HIV-1 
RNA polymerase chain reaction assays.
Blood was taken at delivery and 1 week postpartum, and plasma stored for bioanalysis of 
nevirapine plasma concentrations, done in the Department of Pharmacy, Radboud
University Nijmegen Medical Centre, Nijmegen, The Netherlands, using high-performance 
liquid chromatography (HPLC) (lower limit of quantification 0.05 mg/L).25 Resistance was 
assayed in plasma stored from samples with >500 copies per milliliter at delivery and the 6-week 
antenatal visit at the Department of Virology of the University
Medical Centre Utrecht, The Netherlands (samples with <500 copies/mL, the lower limit of 
quantification of the resistance assay, were assumed to have no important resistance mutations).
The intended sample size of 100 women per group provided 80% power to detect a 2-fold 
reduction in the proportion with resistance (from 36% to 18%) with 2-sided alpha =  0.05. 
Statistical analysis of nevirapine plasma concentrations and mutations was undertaken using 
SPSS, version 13.0 (SPSS Inc). Categorical variables were analyzed with χ2 tests (or exact tests 
for expected cell frequency, 5) and continuous variables with rank-sum tests. Analyses were 
based on women still eligible at delivery (Fig. 1). As the primary outcome measures were 
based on batched laboratory measures, analyses also excluded women who had evidence 
of noncompliance (carbamazepine detected by HPLC in sdNVP group or no carbamazepine 
detected by HPLC in sdNVP/CBZ group).
reSulTS
We screened 354 HIV-infected ARV-naive pregnant women between February 2006 and April 
2009 (Fig. 1). One-hundred ninety-two (54%) were eligible; the remainder were not eligible 
(mostly CD4 <200 cells/mm3) or declined to participate. The study was terminated in April 2009 
after 192 patients had been enrolled when the new WHO pMTCT regimen (with zidovudine 
+ lamivudine tail) was introduced in Moshi. Groups were reasonably balanced for age, body 
mass index, weight, CD4 count, hematology and biochemistry parameters at enrollment and 
delivery (Table 1). Thirty-four women were randomized but did not take study drugs at delivery. 
Four (all sdNVP) had CD4 declines to <200 cells per cubic millimeter and were referred for ART.
Twenty-one (12 sdNVP, 9 sdNVP/CBZ) did not return after enrolment for subsequent 
antenatal visits or delivery, 7 (5 sdNVP, 2 sdNVP/CBZ) delivered at home or at nonstudy sites, 
and 2 (1 sdNVP, 1 sdNVP/CBZ) withdrew or did not want study participation disclosed before 
or at delivery. Thus 75 sdNVP and 83 sdNVP/CBZ women remained in the study at delivery. 
One hundred thirty-three of 158 (84%) delivery samples were available [62/75 (83%) sdNVP, 
72/83 (87%) sdNVP/CBZ]. Missing samples were not taken or had insufficient volume or clotted 
before analysis. One woman in the control group had detectable carbamazepine levels and was 
excluded from analyses.
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 figure 1. Trial profile.
 
   
Excluded (162):
not meeting inclusion criteria 
or declined to participate
Quasi-randomized (192)
Lost to follow up 
after delivery (8)
Attended at week 1 and/or week 6 (71)
•63 attended at week 1 (8 missed visit)
•57 attended at week 6 (14 missed visit)
Lost to follow up 
after delivery (12)    
Attended at week 1 and/or week 6 (67)
•52 attended at week 1 (15 missed visit)
•53 attended at week 6 (14 missed visit)
Assessed for eligibility 
(354)
Allocated to control (97)
Gave birth and received study 
drugs (75)
Excluded from the analysis 
prior to delivery (22)
• CD4 <200 cells/mm3 and 
referred for ART (4)
• absconded before delivery (12) 
• delivered at non study site (5)
• withdrew at delivery (1)
Allocated to intervention (95)
Gave birth and received study 
drugs (83)
Excluded from the analysis 
prior to delivery (12)
• absconded before delivery (9)
• home deliveries (2)
• withdrew before delivery (1)
CBZ detected in 
delivery sample (1)
 Figure 1: Trial profile. 
 
Twenty-one (12 sdNVP, 9 sdNVP/CBZ) did not return after enrolment for subsequent 
antenatal visits or delivery, 7 (5 sdNVP, 2 sdNVP/CBZ) delivered at home or at nonstudy 
sites, and 2 (1 sdNVP, 1 sdNVP/CBZ) withdrew or did not want study participation 
disclosed before or at delivery. Thus 75 sdNVP and 83 sdNVP/CBZ women remained in 
the study at delivery. One hundred thirty-three of 158 (84%) delivery samples were 
available [62/75 (83%) sdNVP, 72/83 (87%) sdNVP/CBZ]. Missing samples were not 
taken or had insufficient volume or clotted before analysis. One woman in the control 
group had detectable carbamazepine levels and was excluded from analyses. 
Pharmacokinetics
Th  median (interquartile range) nevirapine plasma conc ntrations immediately after delivery 
w re 1.55 (0.88–1.84) mg/L for the sdNVP group and 1.40 (0.93–1.97) mg/L for the sdNVP/CBZ 
group (Table 2) (rank-sum P = 0.91) [geometric mean ratio: 1.17, 95% c nfidence i terval (CI): 0.76 
to 1.81; P = 0.48]. As expected, nevirapine plasma concentrations were significantly reduced in 
both groups 1 week after delivery [based on matched pairs of measurements, sdNVP geometric 
mean ratio (1 week:delivery, n = 44) = 0.18, 95% CI: 0.12 to 0.26; sdNVP/CBZ geometric mean 
ratio (1 week:delivery, n = 54) = 0.10, 95% CI: 0.07 to 0.14): results similar using unmatched data]. 
In the sdNVP/CBZ group, week 1 nevirapine plasma concentrations were significantly lower 
compared with the sdNVP group (geometric mean ratio: 0.64, 95% CI: 0.43 to 0.96; P = 0.03; 
Table 2) with median (interquartile range) nevirapine concentration 0.09 (0.05–0.20) mg/L in 
the sdNVP/CBZ group versus 0.20 (0.09–0.31) mg/L in the sdNVP group (rank-sum: P = 0.004). 
Moreover, there was a trend to a greater proportion with undetectable nevirapine levels 
(<0.05 mg/L) in sdNVP/CBZ than sdNVP groups; 15 of 63 (24%) versus 6 of 52 (12%), respectively 
(χ2 P = 0.09).
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Table 1. Characteristics of Women at Enrollment, Delivery, and 1 Week After Delivery
sdNVP sdNVP/Cbz
at enrolment n=97 n=95
age (years) 29 (25-32) 29 (25-31)
weight (kg) 63 (57-73) 65 (56-71)
bMI (kg/m2) 25.7 (23.4-28.5) 26.0 (23.1-29.6)
alkaline phosphatase (u/l) 117 (76-180) 140 (88-185)
bilirubin (µmol/l) 8.6 (<8.6-12.6) <8.6 (<8.6-12.1)
Creatinine (µmol/l) 51.7 (<44.2- 62.1) 51.9 (<44.2-58.9)
aST (u/l) 9.4 (7.9-12.1) 9.5 (8.3-11.2)
alT (u/l) 4.4 (3.4-7.5) 4.7 (3.5-6.4)
Haemoglobin (g/l) 98 (57-109) 97 (53-105)
Platelets(u/l) 261 (220-347) 234 (180-311)
leukocytes (u/l) 6.7 (5.2-8.0) 6.3 (5.1-7.4)
Neutrophils (u/l) 4.1 (3.3-5.1) 3.6 (2.8-4.4)
at delivery n=75 n=83
CD4 (cells/µl) 353 (212-466) 296 (200-531)
HIV-1 rNa (copies/ml) 8533 (3290-48768) 6339 (1311-48865)
birth weight (kg) 3.01 (2.80-3.30) 3.20 (2.90-3.40)
Hours from nevirapine ingestion to delivery 5.02 (3.08-15.50) 3.58 (2.00-8.67)
1 week after delivery n=52 n=63
alkaline phosphatase (u/l) 134 (112-173) 125 (100-185)
bilirubin (µmol/l) 9.1 (<8.6-13.6) 8.8 (<8.6-13.4)
Creatinine (µmol/l) 62.8 (46.5-75.0) 56.3 (47.1-69.3)
aST (u/l) 11.5 (9.6-14.6) 10.8 (8.3-17.4)
alT (u/l) 9.7 (6.6-12.3) 9.8 (6.7-14.7)
Haemoglobin (g/l) 111 (89-122) 108 (96-122)
Platelets(u/l) 401 (277-534) 382 (300-422)
leukocytes (u/l) 7.2 (6.3-10.1) 6.4 (5.5-7.8)
Neutrophils (u/l) 4.5 (3.6-6.4) 3.9 (3.1-5.2)
Values are median (IQR).
BMI, body mass index; IQR, interquartile range.
Nevirapine resistance
At week 6, 110 (53 sdNVP, 57 sdNVP/CBZ) samples were available for HIV genotyping. For 
3 women, plasma volumes were too limited, leaving 107 with valid genotypes. Eleven (21%) of 
the 52 women in the sdNVP group had 1 or more nevirapine-associated resistance mutations, 
compared with 6 of 55 (11%) in the sdNVP/CBZ group (odds ratio =0.46, 95% CI: 0.16-1.34, 
χ2 P = 0.15). Eight women in the sdNVP group had 1 nevirapine mutation and 3 had 2 mutations 
(Fig. 2), compared with 5 and 1, respectively, in the sdNVP/CBZ group [poisson incidence rate 
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ratio for number of mutations in sdNVP/CBZ vs. sdNVP = 0.47 (95% CI:0.19 to 1.17) P = 0.11]. All 
but 2 of the mutations were detected as mixtures with wild-type nucleotide sequence. Only 
1 of 2 mutations in 1 woman in the sdNVP group was already present in a sample stored at the 
enrolment visit. None of the other nevirapine mutations were already present in enrollment 
samples. Figure 3 shows the distribution of the nevirapine mutations 6 weeks after delivery.
Table 2. Maternal NVP Plasma Concentrations at Delivery and 1 Week After Delivery
sdNVP sdNVP/Cbz P
geometric Mean
ratio (95%CI)
at delivery
Samples taken (n) 61 72  —
NVP plasma concentration  
[mg/L; median (IQR)]
1.55 (0.88–1.84) 1.40 (0.93–1.97) 0.91
NVP plasma conc.  
[mg/L; geometric mean (95% CI)] 
0.89 (0.63 - 1.26) 1.04 (0.79 - 1.38) 0.48 1.17 (0.76 - 1.81)
<0.05 mg/L NVP [n (%)] 6 (10%) 4 (6%) 0.51
1 week after delivery
Samples taken (n) 52 63 —
NVP plasma concentration  
[mg/L; median (IQR)] 
0.20 (0.09–0.31) 0.09 (0.05–0.20) 0.004
NVP plasma conc.  
[mg/L; geometric mean (95% CI)] 
0.16 (0.12 - 0.21) 0.10 (0.08 -0.14) 0.03 0.64 (0.43 -0.96)
<0.05 mg/L NVP [n (%)] 6 (12%) 15 (24%) 0.09
NVP plasma concentration 1 week: 
delivery [number of paired 
measurements; GMR (95%CI)]
n=44;
0.18 (0.12-0.26)
n=54;
0.10 (0.07-0.14)
— —
The P values from rank-sum tests for plasma concentration, exact, and χ2 tests for <0.05 mg/L at delivery and week 1, 
respectively.
CI, confidence interval; GMR, geometric mean ratio; IQR, interquartile range.
K103N, Y181C/I, and G190A were the most frequently observed nevirapine mutations. The 
most common mutation was K103N, present in 9 women, alone in 8 women and with G190A in 1.
CoMbINeD PHarMaCokINeTIC 
resistance analysis
Nevirapine plasma concentrations 1-week postpartum were available from 14 of 17 (82%) 
women with mutations versus 71 of 90 (79%) without mutations. Median week-1 nevirapine 
plasma concentrations were similar in women with [median (interquartile range) 0.12 (0.09–
0.29) mg/L] and without [0.11 (0.06–0.22) mg/L] mutations (P = 0.36). However, none of the 
15 women with undetectable nevirapine levels at week 1 developed nevirapine resistance 
compared with 14 of 70 (20%) of those with detectable nevirapine at week 1 (exact P = 0.07). 
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figure 2. Percentage of women with nevirapine mutations.
figure 3. Number of mutation related to nevirapine resistance.
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Thus, irrespective of group assignment, women with undetectable plasma concentrations at 
week 1 were less likely to develop nevirapine-associated mutations after sdNVP for pMTCT.
Safety
Samples were available for viral load testing from 102 newborns (93%), of which, 3 were of 
insufficient quantity or clotted. The overall HIV-1 transmission rate was 6 of 50 (12%) in the 
sdNVP/CBZ group and 3 of 49 (6%) in sdNVP group (exact P = 0.49). Although not all infants 
were tested at delivery, 1 of 6 (17%) and 0 of 3 (0%) infected babies in the sdNVP/CBZ and sdNVP 
groups, respectively, were known to have been infected during the intrauterine period. Three 
babies (1 sdNVP, 2 sdNVP/CBZ) died at delivery, 1(sdNVP/CBZ) died in the first 6 weeks after 
delivery and 1(sdNVP/CBZ) after 4 months of delivery. There were no adverse events in the 
infants possibly/probably/definitely related to study medication(s). Women were similar in all 
laboratory safety parameters at enrollment (P = 0.06 to P = 0.80) (Table 1). Forty-two adverse 
events were reported in the sdNVP group and 40 in the sdNVP/CBZ group between enrollment 
and delivery (ie, before trial intervention), mostly grade 1 (31 sdNVP, 29 sdNVP/CBZ). Only 
7 were grade 4 (3 sdNVP, 4 sdNVP/ CBZ); 6 women had grade 4 anemia (Hb <6.5 g/dL) and 1 
had AST >10.0 x upper limit of normal. One week after delivery, women were also comparable 
in hematology and biochemistry parameters (P >0.26) except for leucocytes (P = 0.002) and 
neutrophils (P = 0.009, Table 1). However, nearly all values [27/27 (100%) sdNVP; 38/39 (97%) 
sdNVP/CBZ) (>2.5 x109/L). After delivery, 6 adverse events were reported in the sdNVP group 
and 21 in the sdNVP/CBZ group. Most events were grade 1 (2 sdNVP; 13 sdNVP/CBZ); of the 
remaining events, 7 were grade 2 (3 sdNVP; 4 sdNVP/CBZ), 3 grade 3 (1sdNVP; 2 sdNVP/CBZ), 
and only 2 were grade 4 (2 sdNVP/CBZ), both anemia (Hb <6.5 g/dL). None of the adverse events 
(including the grade-4 anemias) were considered possibly/probably/definitely drug related. 
DISCuSSIoN
This trial provides the first data on adding a single-dose of an enzyme inducer (carbamazepine) 
to sdNVP for pMTCT in HIV-infected pregnant women. Single-dose carbamazepine 
significantly reduced nevirapine plasma concentrations 1 week after delivery, with a trend 
toward fewer resistance mutations. We also found a trend toward lower rates of nevirapine 
resistance in women with undetectable nevirapine concentrations across the whole 
population, supporting the validity of this approach. Nevirapine plasma concentrations were 
determined in samples obtained immediately after delivery and 1 week postpartum. Overall, 
these plasma concentrations were comparable with previous studies.6,26,27 Adding single-dose 
carbamazepine did not affect nevirapine plasma concentrations immediately after delivery, 
similarly to L’homme et al4 in healthy women. A delay in effect on enzyme induction by single-
dose carbamazepine would be expected because increased protein synthesis is required, 
which takes a few days for maximum impact.4 This is important as the addition of an enzyme 
inducer should not negatively influence the protective effect of sdNVP on HIV mother-to-child 
transmission. The delay in enzyme induction and the low concentrations of carbamazepine in 
breast-milk mean that reductions in infant nevirapine levels are unlikely.28 Indeed, perinatal 
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HIV- 1 transmission rates were similar to rates reported in previous studies of women using 
sdNVP for the first time.2,15,29–31
One week after delivery, nevirapine concentrations were 36% lower in the sdNVP/CBZ 
group, with a trend toward a higher proportion with undetectable plasma concentrations in this 
group. Plasma concentrations 1-week postpartum are determined by nevirapine elimination 
halflife, and, therefore, significantly lower concentrations in the sdNVP/CBZ group directly 
translate into significantly higher elimination half-life. In a previous pilot study4 in healthy 
Dutch female volunteers, the nevirapine elimination half-life declined by 35% with additional 
single-dose carbamazepine, and the median time to undetectable levels was reduced by 23%. 
Our study differed in study design (single sample only) and subject population, but single-
dose carbamazepine seems to reduce nevirapine elimination half-life at least as effectively 
in HIV-infected pregnant Tanzanian women. As our sample size was determined by the 
(binary) nevirapine resistance coprimary endpoint, our power to detect changes in nevirapine 
concentrations was higher, with even 50 patients per group providing at least 80% power to 
detect a 50% relative decrease in 1-week nevirapine concentration based on standard deviations 
observed in the pilot study.4 To reduce the emergence of nevirapine resistance after sdNVP, 
several studies have investigated the addition of other ARVs after delivery. A  meta-analysis 
reported 36% average nevirapine resistance prevalence for women using sdNVP (with or 
without other ARVs).32 For those women receiving ARVs postpartum, this fell to 4.5%. Although 
nevirapine resistance drops dramatically with these new strategies including combination 
“tail” ARVs, the major disadvantages are their complexity and the emergence of lamivudine 
resistance (due to long intracellular elimination half-life), which is associated with virological 
and clinical failure in women starting lamivudine-containing ART for their own health.11,33 To 
preserve its simplicity, Chi et al22 administered a single dose of emtricitabine + tenofovir with 
sdNVP in 400 women, which also halved nevirapine resistance; 25% versus 12%. As it targets 
a different mechanism, the pharmacologic approach described here might have an additive 
effect and also maintains simplicity.
Our study has several limitations. First, we had high loss to follow-up. This is unfortunately 
not uncommon in pMTCT programs in sub-Saharan Africa.34,35 Traditions, stigmatization, and 
fear of harassment and rejection accounted for most of our loss to follow-up. More intensive 
counseling for women using pMTCT prophylaxis and more aggressive methods to identify and 
locate those not returning for appointments should reduce loss to follow-up rates in future 
studies. Second, the randomization list was generated as alternate allocations (ie, was only 
quasi-randomized) by the study pharmacist, who assigned groups centrally and did not include 
patients herself; previous allocations were concealed from the local medical officers enrolling 
patients. This together with the open-label allocation could have led to bias, although not in 
the direct assessment of coprimary outcomes (pharmacokinetics and resistance) which were 
measured on batched stored samples blinded to allocation. The third limitation was the far 
smaller sample size for resistance testing than designed, which limited our power to detect 
differences in resistance between the groups. Finally, the standard HIV genotyping assays could 
only detect viral mutations found in>20% of the overall HIV population and not subpopulations of 
mutants. Deep sequencing is planned for future projects. The original pilot study in healthy Dutch 
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female volunteers was performed to identify enzyme inducers that could reduce nevirapine half-
life. The mechanisms by which the CYP3A4 enzyme are induced involves the activation of the 
transcription factors pregnane X receptor and the constitutive androstane receptor.36 Nevirapine 
is a drug that binds to those receptors, where after activation of the CYP3A4 enzyme starts. From 
the 8 interventions single-dose carbamazepine and phenytoin for 3 or 7 days were shown to 
decrease the nevirapine half-life significantly.5 We, therefore, chose single-dose carbamazepine 
as our study intervention because of its simplicity. Single-dose carbamazepine could lead to 
greater adherence compared with the current national and WHO guidelines and is highly likely 
to reduce emergence of NNRTI resistance even further. Moreover, single-dose carbamazepine 
is a very low-cost intervention and even when NRTIs turn out not to be available, carbamazepine 
is in almost every clinic in resource-limited countries. The current national and WHO guidelines 
for pMTCT recommend new and more effective but also more complex and expensive regimens 
than sdNVP alone; their widespread implementation is challenging. A second pharmacokinetic 
trial (VITA-2;ClinicalTrial.gov ID: NCT01187719) has consequently started to evaluate the effect of 
7 days of phenytoin, a different course of an enzyme inducer, also shown to be effective in the 
previous pilot study, on the pharmacokinetics and resistance of sdNVP in HIV-infected pregnant 
women in combination with the new recommended WHO and national guidelines. Studies, as 
the VITA-2 trial, with different enzyme inducers given for an extended period will be in addition 
to the new WHO pMTCT guidelines combining sdNVP at delivery with zidovudine from the 
second trimester of gestation and zidovudine + lamivudine labor for 7 days postpartum. The 
fact that nevirapine resistance is still observed using these approaches suggests pharmacologic 
interventions such as evaluated in this study may still add benefit.
In conclusion, our study demonstrates that a simple intervention of single-dose 
carbamazepine in addition to sdNVP alone for antiretroviral prophylaxis for pMTCT considerably 
reduces the nevirapine plasma concentrations and likely reduces emergence of nevirapine 
resistance mutations. Enzyme inducers, such as carbamazepine, show new possibilities for 
pMTCT programs to reduce the development of nevirapine resistance in settings where other 
options are limited.
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abSTraCT
objectives
To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination 
half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine 
resistance in pregnant, HIV infected women.
Methods
In a pharmacokinetic pilot trial (NCT01187719), HIV-infected, antiretroviral (ARV)-naive pregnant 
women ≥18 years old from Zambia and Tanzania and with CD4 cell counts >350 cells/mm3 were 
randomized 1:1 to a control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/
lamivudine at delivery and zidovudine/lamivudine for 7 days post-delivery) or an intervention 
(control plus 184 mg of phenytoin once daily for 7 days post-delivery) group. Primary endpoints 
were the pharmacokinetics of and resistance to nevirapine. 
results
Thirty-five and 37 women were allocated to the control and intervention groups, with median 
(IQR) ages of 27 (23–31) and 27 (23–33) years, respectively. Twenty-three and 23 had detectable 
nevirapine levels at delivery and subsequent samples in the control/intervention groups, 
respectively. Geometric mean (GM) (95% CI) plasma levels of nevirapine at delivery were 1.02 
(0.58–1.78) mg/L and 1.14 (0.70–1.86) mg/L in control and intervention groups, respectively 
(P=0.76). One week after delivery, 0/23 (0%) and 15/22 (68%) control and intervention mothers, 
respectively, had undetectable levels of nevirapine (<0.05 mg/L; P <0.001). One week later, the 
figures were 10/21 (48%) and 18/19 (95%) mothers, respectively (P=0.002). The GM (95% CI) 
half-life of nevirapine was 63.2 (52.8–75.7) versus 25.5 (21.6–30.1) h in the control versus the 
intervention group (P <0.001). New nevirapine mutations were found in 0/20 (0%) intervention 
group versus 1/21 (5%) control group mothers. Overall, there was no difference in the number 
of adverse events reported between the control and intervention arms (P >0.28).
Conclusions
Adding 7 days of an enzyme inducer to single-dose nevirapine to prevent mother-to-child 
transmission of HIV significantly reduced subtherapeutic nevirapine levels by shortening the 
half-life of nevirapine. As prolonged subtherapeutic nevirapine dosage leads to the emergence 
of resistance, single-dose nevirapine could be used with phenytoin as an alternative if other 
ARVs were unavailable.
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INTroDuCTIoN
While the risk of HIV mother-to-child transmission (MTCT) is 20%– 40% without treatment,1,2 
a simple cheap intervention—single dose nevirapine at the onset of labour—reduces MTCT 
by ~50%.1,3 Its major disadvantage is the development of nevirapine resistance in both mothers 
(1%–69%) and infants,4 most probably due to its long elimination half-life (61 h),5–7 which leads 
to several days to weeks of subtherapeutic plasma concentrations, coupled with its low genetic 
barrier to resistance.8 Newly emergent resistant HIV may be transmitted to the infant or to 
others, limiting their treatment options, and may also reduce the efficacy of future combination 
antiretroviral therapy (cART) in the mother.9 Given its simplicity and efficacy, single-dose 
nevirapine is nevertheless still endorsed by the WHO as part of the regimen for prevention 
of MTCT(pMTCT) in resource-limited settings, when cART(WHO Option B/B+) is not feasible 
or not available. To cover the prolonged presence of subtherapeutic plasma concentrations 
of nevirapine after single-dose nevirapine at the onset of labour, Option A of the WHO (2012) 
guidelines recommend adding zidovudine/lamivudine for 7 days post-partum.10,11 This approach 
reduces the development of resistance to 4%–16%,4 but does not fully eliminate it.
Nevirapine is extensively metabolized in the liver by cytochrome P450 (CYP) isoenzymes 
3A4 and 2B6.12 A pharmacological, rather than antiretroviral (ARV), approach of adding a 
CYP3A4 enzyme inducer has been shown to decrease the elimination half-life of nevirapine in 
healthy women,13 the greatest reductions being seen with carbamazepine and phenytoin. In our 
previous trial (VITA-1), the addition of single-dose carbamazepine to single-dose nevirapine 
at the onset of labour also significantly reduced plasma concentrations of nevirapine 1 week 
after delivery in HIV-infected women, with a trend towards fewer resistance mutations.14 
The CYP3A4 enzyme inducer phenytoin is a low-cost, widely available anticonvulsant and 
antiarrhythmic drug, which is not secreted into breast milk in clinically important amounts (in 
contrast to carbamazepine) and can therefore be safely given to breast-feeding mothers.15 In 
this pilot study, we investigated the impact of 7 days of phenytoin on the pharmacokinetics 
of and development of resistance to nevirapine after single-dose nevirapine as a component 
of ARV prophylaxis forpMTCT (the VITA-2 trial). The hypothesis was that 7 days of phenytoin 
would reduce the elimination half-life of nevirapine and hence the emergence of nevirapine 
resistance mutations.
MeTHoDS
Study participants
Participants were recruited from the Pasua and Majengo antenatal clinics in Moshi, Tanzania, 
and the University Teaching Hospital in Lusaka, Zambia. Eligible HIV-infected pregnant women 
were aged ≥18 years, ARV-naive, starting ARV prophylaxis for pMTCT, not intending to relocate 
during study participation and willing to attend follow-up visits. Exclusion criteria were serious 
illness requiring systemic treatment or hospitalization, the use of concomitant medication 
that might interfere with ARVs or phenytoin, or a CD4 cell count <350 cells/mm3 (making the 
women eligible for cART). All the women gave written informed consent; illiterate patients 
gave oral consent documented by their own thumbprint and a witness. The study was approved 
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by the institutional review boards of the Kilimanjaro Christian Medical University College, 
Moshi, Tanzania, the National Institute of Medical Research in Dar es Salaam, Tanzania, and the 
University Teaching Hospital, Lusaka, Zambia. The study is registered with http://ClinicalTrials.
gov (NCT01187719). Eligible women received pMTCT ARV prophylaxis as recommended by 
national Tanzanian or Zambian guidelines. Subjects started 300 mg of zidovudine twice daily 
from 28 and 14 weeks of gestation in Tanzania and Zambia, respectively, or as soon as possible 
thereafter pre-delivery. At the onset of labour, women received 200 mg of single-dose 
nevirapine plus 300 mg of oral zidovudine every 3 h and 150 mg of lamivudine every 12 h until 
delivery (Tanzania), or 600 mg of oral zidovudine and 300 mg of lamivudine every 12 h until 
delivery (Zambia). Post-delivery, 300 mg of zidovudine and 150 mg of lamivudine were taken 
twice daily for 7 days. Newborns were given 2 mg/kg of single-dose nevirapine suspension 
within 24–72 h after birth and then 4 mg/kg of zidovudine syrup (Tanzania) or 2 mg/kg of 
nevirapine suspension (Zambia) twice daily for 7 days. All the women in the trial breastfed 
their children for 6 months and then weaned them rapidly. Women were randomized 1:1 in a 
parallel group design to either the national standard of care or the national standard of care 
plus 184 mg of phenytoin (2×92 mg tablets) once daily from the onset of labour for 7 days. 
The randomization sequence was generated by a trial statistician from the MRC using simple 
randomization blocks. Participant codes and allocations were held in secure envelopes stored 
by the project manager at each site. At enrolment (pre-delivery), women were randomized 
by the study doctor at the clinic opening the next envelope. When the woman presented in 
labour at the clinic, a study nurse confirmed and recorded the time of ingestion of the study 
drug(s) by direct observation of intake or by asking the woman if she had already taken the 
study drug(s) at home.
objectives, outcomes and follow-up
The primary objectives of the pilot study were to determine the effect of 7 days of phenytoin 
administration on the elimination half-life of nevirapine and the development of nevirapine 
resistance in HIV-infected, pregnant women receiving a single-dose nevirapine as part of 
perinatal HIV prevention. The primary out comes were the pharmacokinetic parameters of 
nevirapine (elimination half-life and time to achieve an undetectable plasma concentration) 
and nevirapine resistance (primary nevirapine mutations L100I, K101P, K103N/S, V106A/M, 
V108I, Y181C/I, Y188C/L/H and G190A)16 at week 4–6. Secondary outcomes were all adverse 
events (AEs) possibly or probably related to pMTCT ARV prophylaxis or phenytoin, and HIV 
infection of the infant.
Haematology and biochemistry tests were performed at enrolment and 1 week post-
partum. CD4cell counts and viral loads (VL) were assayed at delivery. Infants were tested just 
after birth (<30 min) and at week 4–6 by DNA PCR assays. Blood was taken from the women 
and stored at delivery and days 1, 3, 5, 7 and 14 post-partum, and from the children at delivery 
and on day 7 post-delivery for the retrospective determination of plasma concentrations of 
nevirapine (and phenytoin) at the Department of Pharmacy, Radboud University Nijmegen 
Medical Centre, Nijmegen, The Netherlands. 
Nevirapine assay used HPLC with a lower limit of quantification (LLOQ) of 0.05 mg/L,17 
and phenytoin was determined by a validated immunoassay with an LLOQ of 0.4 mg/L. 
49
4
C
LIN
IC
A
L PH
A
R
M
A
C
O
LO
G
Y
 O
F N
E
V
IR
A
PIN
E IN
 PM
TC
T
Nevirapine resistance was assayed in plasma stored from samples at baseline and at week 4/6 
at the Department of Virology of the University Medical Centre Utrecht, The Netherlands. 
Pharmacokinetic and resistance assays were performed blinded to randomized allocation.
The sample size of 50 subjects (25 per arm) delivering in the study clinic provided >80% power 
to detect a decrease of at least 27% in the elimination half-life of nevirapine associated with 
7 days of phenytoin, allowing a 20% drop-out rate (lack of follow-up samples, based on VITA-1).14 
Safety analyses included all women who were observed or reported taking study medication 
(the safety population). Analyses of pharmacokinetics and resistance included the safety 
population who did not receive a second dose of nevirapine, who delivered vaginally [rather 
than by caesarean section (C/S)] and who had pharmacokinetic evidence (a detectable plasma 
concentration 1 day post-delivery) of taking nevirapine, and phenytoin if this had been allocated 
(the protocol-specified primary pharmacokinetic population). Analyses were also carried out 
that included mothers who delivered by C/S, as no difference in pharmacokinetic parameters 
had been observed between C/S and vaginal deliveries in the VITA-1 trial. Women in the control 
group with phenytoin detected in any sample were excluded from the pharmacokinetic and 
resistance analyses. Pharmacokinetic analysis was performed using Phoenix 64 WinNonlin  6.3 
(Pharsight Corporation, CA, USA) and statistical analysis using SPSS version 18.0 (SPSS Inc.). 
Randomized groups were compared using t-tests for continuous pharmacokinetic variables 
[after transformation to the log scale, i.e. comparing geometric means (GMs)], rank-sum tests 
for all other continuous variables and exact tests for categorical variables.
reSulTS
Study participants
We screened 335 HIV-infected, pregnant women from July 2010 to June 2011; most of the 
262 women not randomized were already on cART (n=94), had a CD4 cell count <350 cells/mm3 
(n=82) or did not return after screening (n=56) (Figure 1). Seventy-three (22%) women were 
randomized: 35 and 37 were allocated to the control and intervention groups, respectively. 
One woman had been randomized twice, so the second randomization was excluded and the 
woman followed the first randomization. The demographic characteristics at enrolment and 
delivery were generally reasonably balanced between the two groups [Table 1 and Table S1 
(available as Supplementary data at JAC Online)], the main difference being the significantly 
shorter time from nevirapine ingestion to delivery in the intervention group, which must 
have occurred by chance. This difference is, however, not expected to have had an impact 
on our pharmacokinetic data, as the elimination half-life of nevirapine is long. In addition, no 
differences were observed between the laboratory values at enrolment and delivery within 
either group (Table S1). The study finished once the recruitment target had been met.
Pharmacokinetics
At delivery, considering only the women who delivered vaginally (and not by C/S), there was 
no significant difference in plasma concentration of nevirapine between the two groups [GM 
(95% CI) was 1.08 (0.63–1.84) mg/L in the control patients versus 1.14 (0.70–1.86) mg/L in the 
intervention patients; GM ratio (GMR) (90%CI) 1.05 (0.58–1.92), P=0.82; t-test].
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Assessed for eligibility
(n=335)Excluded (n= 262)
•On HAART (n=94)
•CD4 <350 cells/mm3 (n=82)
•Did not return to clinic (n=56)
•Declined to participate (n=14)
•Had sdNVP in previous pregnancy 
(n=5)
•Used medication that interferes with 
study drugs (n=3)
•<18 years of age (n=2)
•Not able to understand trial (n=2)
•Not able to adhere to study 
schedule (n=1)
•Took part in other trial (n=1) HIV-infected, ARV-naive, pregnant women ≥18 years with CD4 >350 
cells/mm3 randomized at 26-40 
weeks of gestation
(n=73)
Allocated to Control group 
(n= 35)
Allocated to Intervention Group 
(n=37)
• LTFU before delivery (n=9) 
• Did not report to take study
medication, because they were not 
noticed as VITA-mothers when 
they delivered in clinic (n=2)
• Double randomization (n=1)
• No PK evidence for nevirapine 
(n=2) 
• No PK evidence phenytoin (n=1) 
PK data analyzed (n=23)
Secondary PK population
Resistance data analyzed (n=22)
(missed week 6 visit (n=1))
• LTFU before delivery (n=4) 
• Did not report to take study
medication (n=3)
• No PK evidence for nevirapine 
(n=3) 
• LTFU: do not have PK samples 
(n=2)
Delivered by 
caesarean section (n=7)
PK data analyzed (n=16)
Primary PK population
Delivered in the study clinic (n=28)
Safety population
Delivered in the study clinic (n=26)
Safety population
PK data analyzed (n=23)
Secondary PK population
Resistance data analyzed (n=20)
(missed week 6 visit (n=3))
PK data analyzed (n=23)
Primary PK population
 
Figure 1: Profile of the VITA-2 trial (CONSORT diagram). sdNVP, single-dose 
nevirapine; LTFU, lost  to follow up; PK, pharmacokinetic  
figure 1. Profile of the VITA-2 trial (CONSORT diagram). sdNVP, single-dose nevirapine; LTFU, lost to follow up; 
PK, pharmacokinetic. 
Plasma concentrations of nevirapine subsequently decreased significantly more quickly 
(Figure 2), and undetectable levels were reached significantly earlier (Table 2), in the intervention 
group compared with the control group. All results were similar, including for those women 
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who delivered by C/S, so results from the (larger) group including women who delivered by 
C/S are subsequently presented [see Table S2 (available as Supplementary data at JAC Online) 
for pharmacokinetic results for the (smaller) group excluding women who delivered by C/S].
One week post-delivery, plasma concentrations of nevirapine were reduced in both 
groups, but to a significantly lesser extent in the control group [GMR (1 week: delivery) (90% 
CI) 0.22 (0.18– 0.28), 20 matched pairs] than the intervention group [GMR (1 week: delivery) 
(90%CI) 0.031 (0.026–0.038), 22 matched pairs]. Overall, levels were 85% lower in the 
intervention than the control group [GMR (intervention: control) (90% CI) 0.15 (0.11–0.20), 
P <0.001; t-test]. The GM (95% CI) elimination half-life of nevirapine was 63.2 (52.8–75.7) 
versus 25.5 (21.6–30.1) h in the control and the intervention group, respectively (P <0.001; 
t-test), representing a 60% reduction [GMR (90% CI) 0.40 (0.33–0.49)]. The GM (95% CI) 
time to achieving undetectable nevirapine plasma concentration was 16.3 (13.8–19.3) versus 
6.7 (5.7–7.8) days in the control versus the intervention group (P<0.001; t-test). Consequently, 
a significantly greater proportion of control group women had detectable plasma levels 
of nevirapine at 1 week and 2 weeks post-delivery (Table 2). All 23 (100%) women in the 
control group versus 7/22 (32%) women in the intervention group had a detectable plasma 
concentration of nevirapine at 1 week post-delivery (P <0.001; exact text) as did 11/21 (52%) 
women in the control group versus 1/19 (5%) women in the intervention group at 2 weeks 
post-delivery (P= 0.002; exact test). The median (range) plasma concentration of phenytoin 
in all the samples taken from delivery to 1 week post-delivery in the intervention group was 
1.5 (<0.4–24.7) mg/L. Twenty-one of 22 (95%) mothers had only subtherapeutic phenytoin 
levels (the therapeutic range being defined as 10–20 mg/L).18 One (5%) mother had an 
undetectable plasma concentration at delivery, but her plasma level was detectable on day 1 
and increased to 24.7 mg/L 1 week post-delivery. The median plasma level of phenytoin in the 
infants was <0.4 (range <0.4–1.9) mg/L).
Table 1. Demographic characteristics of the women and infants in the VITA-2 trial
Control (n=28) Intervention (7 days of phenytoin; n=26) P value
At enrolment
Age (years) 27 (23-31) 27 (23-33) 0.74
Weight (kg) 62 (55-73) 66 (56-81) 0.11
BMI (kg/m2) 24.1 (21.7-27.9) 26.2(23.3-30.9) 0.10
At delivery
Gestational age at delivery (weeks) 39 (38-42) 39 (38-41) 0.78
CD4 cell count (cells/mm3) 366 (318-522) 412 (317-518) 0.76
HIV-1 RNA (copies/mL) 2832 (1000-26518) 2420 (1542-11261) 0.99
Birth weight (kg) 3.0 (2.7-3.2) 3.0 (2.7-3.4) 0.87
Time from nevirapine ingestion 
to delivery (h)
9.1 (2.5-12.6) 2.1 (1.0-4.9) 0.003
Data are presented as median (IQR) and were tested using rank-sum
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resistance
Samples taken 4–6 weeks post-delivery were available from 21 control women (as one missed 
the week 6 visit, and for one woman sample amplification failed due to a low VL) and 20 
intervention women (as three missed the week 4-6 visit). One (5%) of the 21 women in the 
control group had one nevirapine associated resistance mutation (elimination half-life 123.5 h) 
that had not been present at baseline, versus 1/20 (5%) with one nevirapine-associated 
resistance mutation in the intervention group. However, the mutation in the patient from the 
intervention group was already present in a sample stored at delivery. Both mutations were 
detected as mixtures with the wild-type nucleotide sequence (V106MV in the control group, 
and K103KN in the intervention group).
figure 2. GM plasma concentrations of nevirapine over time post-delivery (all women who delivered including 
those who delivered by C/S).
Safety
The 28 control and 26 intervention mothers gave birth to 30 (two pairs of twins) and 28 (two 
pairs of twins) babies, respectively. Twenty-one (one pair of twins) and 19 (one pair of twins) 
infants, respectively, were tested just after birth and at week 4–6 post delivery.
The overall transmission rate was 0/21 (0%) in the control group and 1/19 (5%) in the 
intervention group. However, the infected child tested positive at birth and must therefore 
have been infected during the intrauterine period. In the infants, 10 clinical AEs were reported: 
four in the control group (n=1 Grade 1, n=1 Grade 2, n=2 Grade 4) and six in the intervention 
group (n=1 Grade 1, n=1 Grade 2, n=1 Grade 3, n=3 Grade 4).
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Table 2. Maternal nevirapine plasma concentrations at delivery, week 1 and week 2 for women in the 
VITA-2 trial, including women who delivered by C/S
women who delivered, including women who delivered by C/S
Control Intervention P value gMr (90% CI)
samples taken(n) 20 22
nevirapine plasma concentration 
(mg/L), GM (95% CI), 
1.02 (0.58–1.78) 1.14 (0.70–1.86) 0.76a 1.12 (0.61–2.03)
<0.05 mg/L nevirapine (n (%)) 1 (5%) 1 (5%)
1 week after delivery
samples taken (n) 23 22
nevirapine plasma concentration 
(mg/L), GM (95% CI)
0.23 (0.18–0.31) 0.035 (0.027-0.046) 0.001a 0.15 (0.11–0.20)
<0.05 mg/L nevirapine, n (%) 0 (0) 15 (68%) 0.001b
women with 1 week and delivery 
samples(n)
20 22
nevirapine plasma concentration 
1 week: delivery, GMR (90% CI) 
0.22 (0.18-0.28) 0.031 (0.026-0.038)
2 weeks after delivery
samples taken, n 21 19
nevirapine plasma concentration 
(mg/L), GM (95% CI)
0.044 (0.031–0.062) 0.026 (0.024–0.029) 0.006a 0.59 (0.44–0.80)
<0.05 mg/L nevirapine (n (%)) 10 (48) 18 (95) 0.002b
women with week 2 and delivery 
samples(n)
18 18
nevirapine plasma concentration 
2 weeks: delivery, (GMR (90% CI))
0.030 (0.026–0.034) 0.022 (0.015–0.031)
at-test, bExact test. Median nevirapine plasma concentrations are similar to the GM and are therefore not shown in 
Table 2.
The Grade 4 AEs were a hospitalization for overweight after birth and a death just after 
birth due to congenital malformation in the control group, and three stillbirths (two fresh and 
one macerated) in the intervention group. Both platelet (P <0.001) and alanine transaminase; 
P <0.001) levels increased significantly between enrolment and 1 week post- delivery in each 
randomized group, but there was no difference between randomized groups in any laboratory 
safety parameter 1 week post-delivery (P.0.05). In total, 29 laboratory AEs were reported: n=14 
in the control group versus n=15 in the intervention group (P=1.0; exact test). Most were Grade 1 
(n=11 in each group), but four (n =2 in each group) were Grade 2, one was Grade 3 (intervention) 
and two were Grade 4 (haemoglobin <6.5 g/dL; one in each group). Eight clinical AEs were 
reported: three in the control group [n=1 Grade 2, n=1 Grade 3, n=1 Grade 4 (an emergency 
C/S)] and five in the intervention group (n=1Grade 1, n= 3 Grade 2, n=1Grade 3). None of the 
laboratory and clinical AEs in the mothers or infants was judged possibly or probably related to 
the study medication.
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DISCuSSIoN
Here we demonstrate that adding a 7 day course of phenytoin, as an enzyme inducer, from 
the onset of labour produces a large and significant reduction in the elimination half-life of 
nevirapine in HIV-infected, pregnant women using single-dose nevirapine as part of their 
pMTCT ARV prophylaxis. Seven days of phenytoin administration was safe and effective, with 
no new nevirapine resistance mutations observed. Importantly, plasma concentrations of 
nevirapine at delivery were similar in those receiving and not receiving phenytoin, and also 
comparable to those in reported previous studies,5,13 similar to our previous study evaluating 
a single dose of carbamazepine as an enzyme inducer.14 The time lag in enzyme inducer effect 
reflects the time required for transcription of CYP enzymes and protein synthesis. The delay 
in enzyme induction and the knowledge that phenytoin minimally penetrates into breast milk 
therefore ensures that the protective perinatal effect of single-dose nevirapine is maintained. 
The absence of HIV transmission during the postpartum period, similar to or even lower than 
rates in previous studies, 10 also confirms the efficacy of the pMTCT regimen.
Post-delivery, the pharmacokinetic parameters of nevirapine were substantially affected 
by enzyme induction. Adding phenytoin to single-dose nevirapine reduced plasma levels of 
nevirapine by 85% and produced a significantly larger proportion of women with undetectable 
nevirapine levels 1 week and 2 weeks post-delivery. Both effects are a consequence of the 60% 
reduction in the elimination half- life of nevirapine, an absolute difference of 235.8 h. This is 
the largest decline in elimination half-life of nevirapine ever reported, especially in the target 
population of HIV-infected, pregnant women. For example, the pilot study of L’Homme et al.13 
found a median elimination half-life reduction of 38% (-19.4 h) in four healthy Dutch women 
receiving single-dose nevirapine with 7 days of phenytoin administration, and a single-
dose of carbamazepine reduced nevirapine levels by 36% in HIV-infected, pregnant women 
receiving single-dose nevirapine.14 Not surprisingly, a 7 day course of an enzyme inducer has 
a greater effect than a single dose alone on the elimination half-life of nevirapine in HIV-
infected, pregnant women. The mechanisms by which the CYP enzymes are induced involve 
the transcription factors pregnane X receptor and the constitutive androstane receptor. The 
enzyme inducer binds to these receptors, thereby stimulating activation of the CYP enzyme.19
Studies have shown that CYP enzyme induction is correlated with dose and drug level,20 with 
higher doses and a higher plasma level of the enzyme inducer resulting in lower serum levels 
of the test drug. This probably explains why induction of the CYP enzyme has a greater effect 
with a long course of an enzyme inducer than with only the single dose used in our previous 
study. Although current guidelines, including zidovudine monotherapy pre-delivery and 7 days 
of zidovudine/lamivudine post-delivery are complex, they have substantially reduced the 
emergence of nevirapine resistance by protecting the subtherapeutic nevirapine ‘tail’, since 
the lengthy duration of low and subtherapeutic levels of nevirapine in the blood is plausibly 
associated with increases in nevirapine resistance. A meta-analysis estimated that 4.5% of 
women using single-dose nevirapine and additional ARVs postpartum showed nevirapine 
resistance 4 – 8 weeks post-partum.4 In our study, the overall prevalence of new nevirapine 
resistance was 2.4%(1 out of 41 samples); although we observed no nevirapine resistance 
mutations after single-dose nevirapine in combination with 7 days of phenytoin, the numbers 
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are clearly too low to make any conclusions about nevirapine resistance on the basis of this 
study alone. However, it raises the prospect that full elimination of nevirapine resistance could 
be possible. In the VITA-1 trial, we found that women with undetectable nevirapine plasma 
concentrations 1 week post-delivery were less likely to develop nevirapine resistance mutations, 
and that the elimination half-life in women with new nevirapine mutation(s) was almost two 
and five times longer than the median half-lives in the control and intervention groups, 
respectively. Thus, it is plausible that adding a 7 day course of phenytoin at the onset of labour 
might have significant additional benefits in reducing the selection of nevirapine resistance 
mutations, even on top of the current ARV prophylaxis ‘tail’. The main limitation of the study 
was its relatively small size. The trial was designed as a pilot powered to detect a difference 
between the intervention and control groups in the elimination half-life of nevirapine. A much 
larger sample size (approximately 200; 100 per arm) would be needed to detect significant 
differences in the development of nevirapine resistance between the two groups. However, 
this group of women is extremely challenging to recruit and retain (see Figure 1): only 22% of 
those assessed for eligibility pre-delivery were randomized, a further 26% of those randomized 
dropped out before delivery, and a further 24% of those who delivered in the study clinic did 
not provide samples 4 – 6 weeks post-delivery. We would therefore have needed to screen 
approximately 1600 women to achieve 200 women with week 4 – 6 samples. Although a larger 
Phase III trial should ideally confirm the efficacy of 7 days of phenytoin treatment on resistance 
as a primary outcome, the substantial significant reductions in nevirapine half-life, coupled 
with previous clinical and sophisticated modelling studies6,7 demonstrating a causal association 
between the half-life of nevirapine and the emergence of resistance, suggests that it is highly 
likely to be effective. Another limitation was the standard HIV genotyping assay used, which 
only detects mutations present in 20% of the viral population and not subpopulations of 
mutants. Deep sequencing of these samples is planned.
It is estimated that 18%–64% of the women living in Sub- Saharan Africa with HIV are 
receiving cART for pMTCT, as now recommended by the WHO (Option B+). However, this 
means that thousands of women are still receiving single-dose nevirapine21 and demonstrates 
the challenge of widespread implementation of the current guidelines. Phenytoin can be used 
safely during pregnancy and breast-feeding22 and side effects are expected to be infrequent 
using such a low dose for only a short period. Where it is not possible to provide cART, phenytoin 
is cheap and available in almost every clinic. Phenytoin may also be a useful intervention when 
women stop nevirapine at the end of breast-feeding within Option B+. We have demonstrated 
that the implementation of this intervention would substantially and significantly reduce the 
half-life of nevirapine; previous data demonstrating a causal relationship between nevirapine 
half-life and emergence of resistance 6,7,14 suggest that implementation would not only facilitate 
the reduction of nevirapine resistance, but also enable further increases in coverage for 
pregnant women in need of perinatal HIV prophylaxis, while probably retaining the benefits 
of single-dose nevirapine in reducing transmission. This strategy might therefore support 
the overarching goal of the technical consultation of the WHO to reduce the overall HIV 
transmission rate from pMTCT to <5% at the population level by the end of 2015. In summary, 
the addition of an enzyme inducer for 7 days to single-dose nevirapine for pMTCT greatly 
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reduced the presence of subtherapeutic nevirapine levels by significantly shortening the 
elimination half-life of nevirapine, with no new nevirapine resistance mutations observed. 
Since prolonged subtherapeutic nevirapine exposure is known to lead to the emergence of 
nevirapine resistance,6,7,14 and since phenytoin is safely and widely used in women15 to minimize 
HIV transmission from mother to child, single-dose nevirapine could be used with phenytoin as 
an alternative if other ARV drugs were unavailable.
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abSTraCT
objectives
To assess the effectiveness of different drug interventions on nevirapine resistance development 
after use of single-dose nevirapine as part of antiretroviral prophylaxis for prevention of HIV 
mother-to-child transmission (pMTCT).
Design
A systematic review including meta-analyses
Methods
Systematic search of electronic databases (MEDLINE, EMBASE and Cochrane) was performed. 
Studies included HIV-infected, pregnant women, who were administered single-dose nevirapine 
for pMTCT and who were receiving a drug intervention to reduce nevirapine resistance. Primary 
outcome was the proportion of nevirapine resistance detected in plasma samples collected 
≤3 months postpartum. The reducing effect of drug interventions on nevirapine resistance was 
assessed in meta-analyses using random effects models and the GRADE approach for quality 
of evidence.
results
In a total of 18 eligible studies included, the estimated pooled proportion for the detection of 
nevirapine resistance mutations upon single-dose nevirapine at labor was 31% (95%CI 7.6-54); 
this was reduced to 21% (95%CI 8.6-33) with addition of antepartum zidovudine. A combination 
of antepartum zidovudine, single-dose nevirapine and a short (<8 days) postpartum regimen 
resulted in a major reduction in nevirapine resistance to 0.011% (95%CI -0.11-0.13). The summary 
effect of 20-30 days of postpartum drug regimens combined with antepartum zidovudine and 
single-dose nevirapine was associated with a slightly lower incidence of nevirapine resistance, 
namely 0.003% (95%CI -0.054-0.060). 
Conclusions
Antepartum zidovudine plus antiretroviral drugs postpartum have shown to nearly eliminate 
nevirapine resistance. Although 20-30 days post partum regimens might be slightly more 
effective compared to a short (<8 days) postpartum regimen, longer term antiretroviral therapy 
is more complex and more challenging to implement in daily practice. The WHO guideline 
option A (antepartum zidovudine, single-dose nevirapine and one week of lamivudine/
zidovudine postpartum) should be followed to achieve a feasible minimum risk of nevirapine 
resistance in regions where single-dose nevirapine is still being used.
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INTroDuCTIoN
Without antiretroviral drugs, the overall cumulative risk of mother-to-child transmission 
(MTCT) of HIV-1 is 30-45% in the breast-feeding population [1]. Nearly half of the risk is around 
the time of delivery [1] and hence, it has become a major focus in the prevention of MTCT 
(pMTCT). In 2000, a single-dose of nevirapine administered to the mother at onset of labor 
was introduced as a simple and affordable strategy for prevention of perinatal HIV transmission 
in resource-limited settings. It reduces MTCT by ~50% and has benefited thousands of babies.
However, a major disadvantage of single-dose nevirapine is the development of nevirapine 
resistance in mothers and infants [2]. This is clearly due to its long elimination half-life (61 hours 
[3]) and low genetic barrier to resistance leading to several days to weeks of subtherapeutic 
plasma concentrations [4]. Newly emergent resistant HIV may be transmitted to the infant or 
to others, limiting their future treatment options, and may also reduce future combination 
antiretroviral therapy (cART) efficacy in the mother [5]. In a previous meta-analysis, published 
in 2007, the prevalence of nevirapine resistance using a single-dose alone at labour onset 
with or without antepartum antiretroviral drugs was estimated to be 36%[2]. Given that since 
then more effective options have become available, this simple intervention has therefore in 
international guidelines turned into a fading concept, although single-dose nevirapine alone is 
still widely used by thousands of women in resource-constrained settings, particularly in more 
rural areas where access to cART is more limited. 
In order to reduce the emergence of nevirapine resistance, co-interventions, such as 
short-course antiretroviral regimens in combination with single-dose nevirapine, have 
been evaluated. Addition of a short (4-7 days) postpartum course of lamivudine/zidovudine 
to single-dose nevirapine and antepartum zidovudine reduced viral resistance mutations 
tremendously[6] and is currently recommended by WHO (Option A), when long-term cART 
(WHO Option B/B+[7, 8]) is not available or unfeasible. Many other approaches, such as 
extension of the duration of the abovementioned course or use of other drugs, have been 
studied since the introduction of single-dose nevirapine. Until now, an overview of all evaluated 
co-interventions and their effectiveness aiming to reduce nevirapine resistance has not been 
conducted. We therefore performed a systematic review and meta-analyses to assess the effect 
of different drug interventions and duration of intake on nevirapine resistance development 
after use of a single-dose nevirapine as part of antiretroviral prophylaxis for pMTCT. 
MeTHoDS
Search strategy
A literature search for this review was performed in the MEDLINE database, the Cochrane 
Library and the EMBASE database until March 20, 2013. Combinations of the following free 
keywords and medical subject heading terms and variations on these words were used in the 
search strategy: ‘pregnancy’, ‘prevention-of-mother-to-child-transmission’, ‘nevirapine’, ‘viral 
drug resistance’ (detailed search strategy can be found in Supplementary Materials S1). For 
additional studies, the ISI Web of Knowledge citation index and the reference lists of included 
studies were searched.
5C
LIN
IC
A
L PH
A
R
M
A
C
O
LO
G
Y
 O
F N
E
V
IR
A
PIN
E IN
 PM
TC
T
62
Inclusion criteria
Titles and abstracts of all included studies identified by the search strategy were independently 
screened for eligibility by two reviewers (QF, BB). Subsequently, a second screening session by 
two reviewers (QF, BB) was assessed on full texts of the primarily eligible studies. Discrepancies 
were resolved by consensus. Studies were eligible for inclusion if they met the following 
selection criteria: HIV-infected, pregnant women, who were administered nevirapine as 
a single-dose for pMTCT of HIV-1 were enrolled; a drug intervention reducing nevirapine 
resistance development; and a proportion of resistance was determined <3 months after intake 
of single-dose nevirapine. No design, place or language restrictions were set, but full-texts 
were required to be available. Conference abstracts were excluded.
Data extraction
Data for each study were extracted by a single author (QF) on: authors’ name, title, journal, 
year of publication, inclusion criteria, study location, study design, study population, study 
intervention, time of genotypic assessment after intake of single-dose nevirapine and type of 
genotypic assessment (consensus or sensitive), number of samples with nevirapine resistance 
as per intervention arm, total number of measured samples as per intervention arm. Data 
duplicated in different papers were only extracted once. A second reviewer (BB) randomly 
checked the data extraction sheet on appropriate data entry by the first reviewer (QF).
Primary and secondary outcomes
The primary outcome of our interest was the proportion of nevirapine resistant viral mutations 
(primary nevirapine mutations L100I, K101P, K103N/S, V106A/M, V108I, Y181C/I, Y188C/L/H, 
G190A[9]) per drug intervention detected in plasma samples collected <3 months postpartum 
using population sequencing.
Secondary outcomes were: 1) the addition of antepartum zidovudine on the proportion 
of nevirapine resistant viral mutations after single-dose nevirapine alone, 2) the addition of 
antepartum zidovudine on the reducing effect of postpartum interventions on nevirapine 
resistance after single-dose exposure, 3) the effect of short-course postpartum interventions 
on the proportion of nevirapine resistance after single-dose exposure, 4) the effect of the 
duration of postpartum interventions on the proportion of resistance after single-dose 
nevirapine, measured using population sequencing.
Data analysis
The effect of drug interventions in the reduction of nevirapine resistance was assessed in a 
meta-analysis using random effects models. The proportion of nevirapine resistance and its 
95% confidence interval (CI) of each eligible study arm was graphically presented in a forest 
plot. The summary effect per type of intervention to the development of nevirapine resistance 
and its 95% CI were calculated using Microsoft Excel (Microsoft, 2007. Computer Software; 
Redmond, Washington[10]). The presence of statistically significant heterogeneity among 
studies was assessed by Q (significant when p-value <0.05) and the extent of the observed 
heterogeneity was assessed by I2 (ranging from 0-100%). 
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Quality of evidence
The GRADE approach was used as a transparent and structured system of rating quality of 
evidence of research questions and grading strength of recommendations in our systematic 
review. The quality of evidence was considered high (three points), moderate (two points), low 
(one point) or very low (no points) based on five predefined GRADE criteria[11-15], including 
risk of bias, inconsistency, imprecision, indirectness and publication bias. An overview of the 
five predefined GRADE criteria and the system used to establish rating of the quality of evidence 
for these criteria are shown in Table 1. For each outcome measure, all criteria were scored 
independently by two reviewers (QF and BB). Discrepancies were resolved by consensus. 
For quality assessment of randomised clinical trials (RCTs) the guidelines for systematic 
reviews of the Cochrane Collaboration Back Review Group were used[16, 17]. The criteria 
according to the STROBE guidelines were used to assess the quality of observational studies 
(Table 2)[11-15, 18, 19]. The initial quality of evidence for RCTs was considered as high (i.e. 3 points) 
and for observational studies as low (i.e. 1 point)[20].
reSulTS
literature search
Through our literature search strategy 823 articles were identified. Two-hundred and forty-nine 
duplicates were removed. Based on the inclusion and exclusion criteria a total of 556 (501+51+4) 
studies were excluded resulting in 18 eligible studies for our systematic review (Flowchart, see 
Figure 1). Nine were RCTs, one was a random subset of an RCT and eight were observational 
studies. Eleven (24 study arms) of the 18 studies contained nevirapine resistance data measured 
by a population drug resistance assay and eight (18 study arms) by more sensitive drug 
genotypic techniques.
Eleven studies were conducted in Sub-Saharan Africa, one in West Africa, four in Asia and 
two studies had sites in both Asia and Africa. Of the 18 included studies, five had one eligible 
arm, seven studies had two, three studies had three, two had four eligible arms and one study 
had six eligible arms available for analysis. In total, 3,726 patients from 42 study arms were 
included in our analyses (Table 3).
antepartum zidovudine
Since only studies with a drug intervention reducing nevirapine resistance were included in our 
systematic review, no more than three study arms provided a single-dose nevirapine alone. 
The summary proportion of the emergence of nevirapine resistance mutations was 31% (95%CI: 
7.6-54); Figure 2), but statistically significant heterogeneity was observed between these three 
study arms (p<0.005, I²=88%). 
1,218 HIV-infected pregnant women from 11 different study arms (six populations and five 
sensitive sequencing) were on antepartum zidovudine from 28-36 weeks of gestation combined 
with single-dose nevirapine. Hundred sixty-seven of 698 women (summary effect 21% (95% 
CI: 8.6-33)) had nevirapine resistance mutations (Figure 2) measured by population genotypic 
assessments. However, also here a significant difference (p<0.005, I²=97%) was found on the 
effect of antepartum zidovudine on nevirapine resistance. 
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Table 1. Schematic overview for scoring GRADE criterions per outcome measure
graDe-
criterion Method Quality indicator
Cut off quality 
indicator for each 
individual study Score 
risk of bias Quality 
assessment 
of individual 
studies 
(Table 2)
Inappropriate selection of groups
Failure to control for confounding 
(observational studies only)
Selective outcome reporting
Lack of blinding (RCTs only)
High loss to follow up
Lack of allocation concealment 
(RCTs only)
Intention-to-treat principle 
violated (RCTs only)
-1: >75% of the 
prioritized items 
are not adequately 
described and 
>50% of the non-
prioritized items 
are not adequately 
described (Table 2)
-1: >50% of the study 
participants has 
scored -1
Inconsistency Forest plot Extent of CI overlap -1: p<0.05 (and CIs of 
the different studies 
have little or no 
overlap)
Test for 
heterogeneity 
(Q)
p-value 
Imprecision Quality 
assessment 
of individual 
studies 
(Table 2)
Description of power analysis -1: no power 
analysis described
-1: no power analysis 
described in >25% of 
the study participants
or >50% of study 
participants in 
studies with a non-
acceptable drop-out 
rate (i.e. >30%)
or if upper/lower 
range of the CI of any 
study represents the 
risk difference
Drop-out rate -1: non-acceptable 
drop-out rate 
(i.e. >30%)
Forest plot Width of CI
Indirectness Quality 
assessment 
individual 
studies 
(Table 2)
Description of setting, patient 
selection, outcome measures
-1: >50% of the 
scoring items are 
not adequately 
described
-1: majority of study 
participants is a 
‘between’ studies 
comparison (and 
<50% of the scoring 
items are adequately 
described)
Comparison 
within or 
between 
studies
Comparison within or between 
studies
Publication 
bias
Quality 
assessment 
individual 
studies 
(Table 2)
Funding -1: Industry 
sponsoring 
described 
-1: >75% of studies 
sponsored and/or
(if ≥5 studies) 
asymmetrical 
distribution of funnel 
plot Funnel plot Symmetry of the plot
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Database Search
Embase, Medline and 
Cochrane Library
Citations identified
n=823
(n=242 (Medline) + n=485 (Embase) 
+ n=96 (Cochrane)) 
Review of titles and abstracts
n=574
Review of full texts
n=73
Review for duplicated data
n=22
Included in Systematic Review
n=18
n=10 NVP resistance with consensus strategy 
n=7 NVP resistance with sensitive strategy
n=1 NVP resistance with both consensus and 
sensitive strategy
Duplicates: n=249
Excluded: n=501
Excluded: n=51
n=1 no full text available
n=4 congress presentation
n=11 no single-dose nevirapine
n=31 no intervention (or not clear)
n=4 >3 months/ no resistance measured
Excluded: n=4
n=4 duplicated data
 
Figure 1: Flow chart of literature search and selection procedure 
 
Eleven studies were conducted in Sub-Saharan Africa, one in West Africa, four in Asia and 
two studies had sites in both Asia and Africa. Of the 18 included studies, five had one 
eligible arm, seven studies had two, three studies had three, two had four eligible arms and 
figure 1. Flow chart of literature search and selection procedure.
Hence, antepartum zidovudine combined with a single-dose of nevirapine shows a relative 
decrease of 32% in the proportion of nevirapine resistance compared to single-dose nevirapine 
alone. Th  quality of eviden e for this research question was, however, very low (0 points in the 
GRADE range of 0-3).
antepartum zidovudine on the effect of postpartum interventions
In total, there were eleven short-course interventions postpartum, including two single-dose 
drug interventions; four were without antepartum zidovudine and seven interventions were 
with the addition of antepartum zidovudine (Figure 2). Evaluating the effect of antepartum 
zidovudine on nevirapine resistance, five study arms were selected with the same postpartum 
interventions: three intervention arms without antepartum zidovudine and two with 
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Table 2. Overview of quality assessment per individual study
Item quality assessment graDe criterion Study type
rCT observational study
Setting/generalizability Indirectness + + 
Patient selection
Eligibility criteria specified Indirectness + +
Methods of inclusion/selection Risk of bias + +
Treatment allocation and concealment Risk of bias + -
Matched controls, matching criteria Risk of bias - +
Similarity of groups at baseline Risk of bias + +
Potential confounders Risk of bias - +
Report number of individuals at each stage of study Risk of bias + +
Reasons for non-participation Risk of bias + +
intervention
Explicit description of exposure Indirectness + +
Blinding of care provider Risk of bias + -
Avoidance of co-interventions Risk of bias, indirectness + +
Define effect modifiers Risk of bias - +
Acceptable compliance Risk of bias + +
Blinding of patient Risk of bias + -
Outcome measurement
Blinding of outcome assessor Risk of bias + -
Relevance of outcome measures Indirectness + +
Description of adverse effects Risk of bias + +
Description of withdrawal/drop-out rate Risk of bias + +
Acceptable drop-out rate Risk of bias + +
Timing follow-up measurement correct Indirectness + +
Timing of outcome measurement in both groups 
comparable
Indirectness + +
Statistics 
Power analysis Imprecision + +
Intention-to-treat analysis included Risk of bias + -
Presentation of point estimated and measures of 
variability
Imprecision + +
Loss to follow up Risk of bias + +
Sensitivity analysis Risk of bias - +
Effort to address potential sources of bias Risk of bias - +
Funding Publication bias + +
Note 1: ‘+’ item is required to be scored for the type of study, ‘-‘ item is not applicable for type of study. 
Note 2: Bold values are the prioritized items for the quality assessment of GRADE criteria (Table 1).
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antepartum zidovudine as part of their pMTCT prophylaxis. All women in these selected study 
arms received a short (<8 days) postpartum course of lamivudine/zidovudine. The summary 
effect of the proportion of nevirapine resistance without antepartum zidovudine was 11% 
(95% CI: 5.5-17). However, the effect of no antepartum zidovudine on nevirapine resistance 
differed between these three studies (p<0.005, I²=75%). The effect summary of the proportion 
of nevirapine resistance of the two studies using antepartum zidovudine was 1.2% (95% CI: 
-0.48-2.9) with no clear statistical presence of heterogeneity (p>0.05, I²=0%). Therefore, 
antepartum zidovudine shows a ten times lower prevalence of nevirapine resistance compared 
to postpartum interventions where antepartum zidovudine was not provided. However, quality 
of evidence for this question was low (1 point in the GRADE range of 0-3).
effects short-course postpartum drug interventions 
The effectiveness of three different short (<8 days) postpartum drug interventions on the 
occurrence of nevirapine resistance mutations was tested in women who received single-
dose of nevirapine combined with antepartum zidovudine (Figure 2). Three of the six study 
arms used emtricitabine/tenofovir for 7 days, one used 7 days of ritonavir-boosted lopinavir 
and two arms used lamivudine/zidovudine either 3 or 7 days. The overall estimated proportion 
   
   
 
 
Single-dose nevirapine alone Nevirapine resistance (95% CI)
Single-dose nevirapine alone; Muro et al 19% (7.3-31)
Single-dose nevirapine alone; McIntyre et al 59% (41-77)
Single-dose nevirapine alone; Han et al 16% (4.2-28)
Effect Summary 31% (7.6-54)
Antepartum zidovudine
antepartum ZDV; Chaix et al 33% (19-48)
antepartum ZDV; Chi et al 25% (17-32)
antepartum ZDV; Han et al 0% (-)
antepartum ZDV; Lallemant et al 10% (6.1-14.6)
antepartum ZDV; Shapiro et al 45% (34-55)
antepartum ZDV; Van Zyl et al 17% (7.8-26)
Effect Summary 21% (8.6-33)
Single dose interventions (with and without antepartum zidovudine)
sdNVP and sdCBZ; Muro et al 12% (2.3-21)
antepartum ZDV, sdNVP and sdTDF/FTC; Chi et al 12% (6.5-16.6)
Short (<8 days) postpartum regimens without antepartum zidovudine
sdNVP and 4 days 3TC/ZDV; McIntyre et al 10% (4.8-15)
sdNVP and 7 days 3TC/ZDV; Chalermchockcharoenkit et al 18 (12-24)
sdNVP and 7 days 3TC/ZDV; McIntyre et al 7.3% (3.0-12)
Effect summary 11% (5.5-17)
Short (<8 days) postpartum regimens with antepartum zidovudine
antepartum ZDV, sdNVP and 3 days 3TC/ZDV; Chaix et al 1.1% (-1.1-3.4)
antepartum ZDV, sdNVP and 7 days 3TC/ZDV; McMahon et al 1.4% (-1.31-4.1)
antepartum ZDV, sdNVP and 7 days LPV/r; McMahon et al 4.2% (-0.56-9.0)
antepartum ZDV, sdNVP and 7 days TDF/FTC; T. EmAA ANRS 12109 Study Group (Step 1) 0% (-)
antepartum ZDV, sdNVP and 7 days TDF/FTC; T. EmAA ANRS 12109 Study Group (Step 2) 0% (-)
antepartum ZDV, sdNVP and 7 days TDF/FTC; McMahon et al 0% (-)
Effect summary 0.011% (-0.11-0.13)
Long (>8 days) postpartum regimens with antepartum zidovudine
antepartum ZDV, sdNVP and 21 days 3TC/ZDV; McMahon et al 0% (-)
antepartum ZDV, sdNVP and 21 days LPV/r; McMahon et al 1.5% (-1.5-4.6)
antepartum ZDV, sdNVP and 21 days TDF/FTC; McMahon et al 0% (-)
antepartum ZDV, sdNVP and 30 days DDI/ZDV; Lallemant et al 0% (-)
Effect summary 0.0030% (-0.054-0.060)
0 10 20 30 40 50 60 70 80
Nevirapine resistance (%)
 
 
Figure 2: Forest plot of nevirapine resistance in each intervention arm 
 
figure 2. Forest plot of nevirapine resistance in each intervention arm.
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of nevirapine resistance in patients who received a short postpartum drug intervention using 
the random effects model was 0.011% (95% CI: -0.11-0.13) with no significant difference (p>0.05, 
I²=0%) between the five studies, although the GRADE score for quality of evidence for these 
studies was very low (0 points in the range of 0-3).
Duration of long-course postpartum drug interventions
In four study arms postpartum drugs were provided for a longer time period (Figure 2): one 
study arm provided 21 days of lamivudine/zidovudine, or ritonavir/boosted lopinavir, or 
tenofovir/emtricitabine and one study provided didanosine/zidovudine to the women for 30 
days. The estimated pooled proportion of nevirapine resistance was 0.0030% (95% CI: -0.054-
0.060) with no clear evidence (p>0.05, I²=0%) that these four studies differed. Comparing these 
data to short postpartum drug interventions, nevirapine resistance of longer postpartum 
drug regimen appeared to be slightly lower with moderate quality of evidence (2 points in the 
GRADE range of 0-3). Ritonavir-boosted lopinavir appeared to be less effective, since it has 
shown higher nevirapine resistance in both short and long postpartum courses compared to 
other regimens, but this could not be statistically confirmed.
DISCuSSIoN
The present systematic review shows that the summary effect of nevirapine resistance through 
postpartum drug regimens combined with antepartum zidovudine and intrapartum nevirapine 
has been estimated to be <1%. A postpartum regimen of 20-30 days might be slightly more 
effective compared to a short (<8 days) postpartum regimen with a prevalence of nevirapine 
resistance of 0.003% versus 0.011%, respectively.
   
   
0 5 10 15 20
Nevirapine resistance (%)
Short (<8 days) postpartum regimens without antepartum zidovudine Nevirapine resistance(95% CI)
sdNVP and 4 days 3TC/ZDV; McIntyre et al 10% (4.8-15)
sdNVP and 7 days 3TC/ZDV; Chalermchockcharoenkit et al 18 (12-24)
sdNVP and 7 days 3TC/ZDV; McIntyre et al 7.3% (3.0-12)
Effect summary 11% (5.5-17)
Short (<8 days) postpartum regimens with antepartum zidovudine
antepartum ZDV, sdNVP and 3 days 3TC/ZDV; Chaix et al 1.1% (-1.1-3.4)
antepartum ZDV, sdNVP and 7 days 3TC/ZDV; McMahon et al 1.4% (-1.31-4.1)
antepartum ZDV, sdNVP and 7 days LPV/r; McMahon et al 4.2% (-0.56-9.0)
antepartum ZDV, sdNVP and 7 days TDF/FTC; T. EmAA ANRS 12109 Study Group (Step 1) 0% (-)
antepartum ZDV, sdNVP and 7 days TDF/FTC; T. EmAA ANRS 12109 Study Group (Step 2) 0% (-)
antepartum ZDV, sdNVP and 7 days TDF/FTC; McMahon et al 0% (-)
Effect summary 0.011% (-0.11-0.13)
Long (>8 days) postpartum regimens with antepartum zidovudine
antepartum ZDV, sdNVP and 21 days 3TC/ZDV; McMahon et al 0% (-)
antepartum ZDV, sdNVP and 21 days LPV/r; McMahon et al 1.5% (-1.5-4.6)
antepartum ZDV, sdNVP and 21 days TDF/FTC; McMahon et al 0% (-)
antepartum ZDV, sdNVP and 30 days DDI/ZDV; Lallemant et al 0% (-)
Effect summary 0.0030% (-0.054-0.060)
 
 
Figure 3: Forest plot of nevirapine resistance in short and long postpartum antiretroviral 
strat gies 
 
Discussion 
The present systematic review shows that the summary effect of nevirapine resistance 
through postpartum drug regimens combined with antepartum zidovudine and intrapartum 
nevirapine has been estimated to be <1%. A postpartum regimen of 20-30 days might be 
slightly more effective compared to a short (<8 days) postpartum regimen with a prevalence 
of nevirapine resistance of 0.003% versus 0.011%, respectively. 
Nevirapine resistance was estimated to be 31% after single-dose xposure of nevirapine 
alone. However, the number of study arms for this pooled estimate was small, as we 
included only studies containing drug interventions to reduce nevirapine resistance after 
single-dose exposure in our systematic review. Nevirapine resistance of single-dose 
nevirapine combined with antepartum zidovudine was ~30% lower to 21%. Despite of small 
numbers, these values are consistent with previous studies showing 20-69% nevirapine 
resistance and an estimated pooled value of 36% in mothers exposed to single-dose with or 
without antepartum zidovudine[2, 21-26]. Addition of only a seven-day course of ART to 
antepartum zidovudine and single-dose of nevirapine has shown an extensive effect in 
decreasi g nevirapine resistance from 21% to 0.011%, probably due to the effect in 
suppressing viral replication of the seven-day postpartum antiretroviral course. Almost all 
strategies evaluated in this systematic review were supplemental postpartum antiretroviral 
therapies intending to suppress viral replication until nevirapine concentrations are no longer 
figure 3. Forest plot of nevirapine resistance in short and long postpartum antiretroviral strategies.
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Nevirapine resistance was estimated to be 31% after single-dose exposure of nevirapine 
alone. However, the number of study arms for this pooled estimate was small, as we included 
only studies containing drug interventions to reduce nevirapine resistance after single-
dose exposure in our systematic review. Nevirapine resistance of single-dose nevirapine 
combined with antepartum zidovudine was ~30% lower to 21%. Despite of small numbers, 
these values are consistent with previous studies showing 20-69% nevirapine resistance and an 
estimated pooled value of 36% in mothers exposed to single-dose with or without antepartum 
zidovudine[2, 21-26]. Addition of only a seven-day course of ART to antepartum zidovudine and 
single-dose of nevirapine has shown an extensive effect in decreasing nevirapine resistance 
from 21% to 0.011%, probably due to the effect in suppressing viral replication of the seven-day 
postpartum antiretroviral course. Almost all strategies evaluated in this systematic review 
were supplemental postpartum antiretroviral therapies intending to suppress viral replication 
until nevirapine concentrations are no longer sufficient to select for resistant strains, since 
the lengthy duration of low and subtherapeutic levels of nevirapine in blood are plausibly 
associated with increases in nevirapine resistance. The estimated pooled effect was nearly 
0% and most effective by protecting the subtherapeutic nevirapine ‘tail’ when single-dose 
nevirapine was combined with antepartum zidovudine and a long course postpartum regimen. 
This is consistent with a recent study of McMahon et al evaluating long versus short course 
antiretroviral strategies. Noteworthy, they contributed largely in the research question of our 
review, their findings showed that 21-day regimens were significantly better than seven-day 
regimens[27].
The estimated pooled effects in many of the evaluated interventions of our systematic 
review have shown high heterogeneity. An important reason for this could be a difference in 
baseline plasma HIV-1 RNA viral load. Previous studies have shown that higher baseline plasma 
HIV-1 RNA viral load was associated with increase in the proportion of nevirapine resistance [2, 
28], probably due to higher viral load when single-dose nevirapine is used. Also study location, 
which is associated with the presence of difference in viral subtypes, could have played an 
important role in the high heterogeneity we found in our analyses [2].
A limitation in our systematic review is that the number of studies was small, especially for 
the quantification of effect summaries. We also did not calculate proportions related to single-
dose nevirapine alone, but our data were consistent compared with previous reviews [1, 2]. We 
also did not statistically assess potential sources of between-study heterogeneity; variability 
between studies was high and factors of heterogeneity have been evaluated in an earlier study 
[2]. Strength of our study was our validated analysis using the GRADE approach to determine 
the quality of evidence, which was generally low, at evaluating our research questions.
Simple and standardized pMTCT regimens (Option B/B+) need widespread implementation 
in resource limited settings. Due to the challenges in the scale-up of pMTCT programs, thousands 
of women are still using a single-dose nevirapine alone in pMTCT of HIV[29]. Ideally, based on our 
findings, each HIV-infected pregnant woman living in a resource-limited region on single-dose 
nevirapine at labor onset should combine this with antepartum zidovudine plus a postpartum 
antiretroviral strategy of preferably two nucleoside reverse transcriptase inhibitors, which have 
shown to nearly eliminate nevirapine resistance. A major disadvantage of these long-course 
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drug regimens, however, is its complexity and consequently risk to non-adherence, but also 
the emergence of lamivudine resistance (due to long intracellular elimination half-life), which 
is associated with virological and clinical failure in women starting lamivudine-containing ART 
for their own health[30, 31]. The use of shorter postpartum regimens (WHO option A[8]) will 
therefore still be advocated, but might need to be intensified by adding other drugs to achieve 
the smallest possible effect (i.e. elimination) on nevirapine resistance. A single-dose[32] or a 
seven-day course of an enzyme inducer[33] at labour onset might have significant additional 
benefits in reducing selection of nevirapine resistance mutations, even on top of the current 
antiretroviral prophylaxis “tail”. These and other regimens need urgent evaluation. 
Our findings have shown that the optimal management to nearly eliminate nevirapine 
resistance after single-dose exposure is the addition of antepartum zidovudine plus a 20-30 
days course of antiretroviral drugs postpartum, while a seven-day postpartum course already 
have shown a low prevalence of nevirapine resistance <1%. Given its complexity and the current 
challenge in the scale-up of pMTCT programs, the WHO guideline of option A should be 
followed to reach the overarching goal of the WHO to reduce eliminate HIV transmission from 
pMTCT. Intensification of the current postpartum courses or alternative regimens needs to be 
evaluated to achieve the best feasible minimum risk of nevirapine resistance in regions where 
single-dose nevirapine is still being used.
5C
LIN
IC
A
L PH
A
R
M
A
C
O
LO
G
Y
 O
F N
E
V
IR
A
PIN
E IN
 PM
TC
T
77
SuPPleMeNTary MaTerIal S S1
Search strategies for the MeDlINe (PubMed) database, the embase 
database and the Cochrane library:
Search strategy for the MEDLINE (PubMed) database:
(“Pregnancy”[Mesh] OR “Pregnant Women”[Mesh] OR pregnancy[tiab] OR pregnant[tiab] 
OR labor[tiab] OR labour[tiab] OR intrapartum[tiab] OR delivery[tiab] OR “Infectious Disease 
Transmission, Vertical”[Mesh] OR Vertical Infectious Disease Transmission[tiab] OR Vertical 
Infection Transmission[tiab] OR Vertical Transmission of Infectious Disease[tiab] OR Maternal-
Fetal Infection Transmission[tiab] OR Maternal Fetal Infection Transmission[tiab] OR mother-to-
child transmission[tiab] OR mother-to-child-transmission[tiab] OR PMTCT[tiab] OR mtct[tiab] 
OR Mother To Child Transmission[tiab] OR prevention-of-mother-to-child-transmission[tiab]) 
AND (“Nevirapine”[Mesh] OR Nevirapine[tiab] OR viramune[tiab] OR nvp[tiab] OR sdnvp[tiab]) 
AND (“Drug Resistance, Viral”[Mesh] OR Resistance[tiab] OR resistant[tiab])
Search strategy for the embase database:
exp pregnancy/ or labor onset/ or labor onset/or (pregnancy or pregnant or labor or labour or 
intrapartum).ti,ab. or delivery.ti,ab. Or exp vertical transmission/or(Vertical Infectious Disease 
Transmission or Vertical Infection Transmission or Vertical Transmission of Infectious Disease 
or Maternal-Fetal Infection Transmission or Maternal Fetal Infection Transmission or mother-
to-child transmission or mother-to-child-transmission or PMTCT or mtct or Mother To Child 
Transmission or prevention-of-mother-to-child-transmission).ti,ab. Or vertical transmission.
ti,ab. And exp nevirapine/ or (Nevirapine or viramune or nvp or sdnvp).ti,ab. And exp antiviral 
resistance/ resistance.ti,ab. resistant.ti,ab.
Search strategy for the Cochrane library:
MeSH descriptor: [Nevirapine] explode all trees or nevirapine or viramune:ti,ab,kw (Word 
variations have been searched) NVP:ti,ab,kw (Word variations have been searched or 
sdnvp:ti,ab,kw (Word variations have been searched) and MeSH descriptor: [Drug Resistance, 
Viral] explode all trees or resistance or resistant:ti,ab,kw (Word variations have been searched)
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abSTraCT
background
We developed a simple and inexpensive thin-layer chromatography (TLC) assay for 
semiquantitative detection of saliva concentrations of nevirapine in resource-limited settings. 
The method was validated in an African target population.
Methods
Paired plasma and saliva nevirapine concentrations were assayed by high-performance liquid 
chromatography (HPLC); saliva concentrations of nevirapine were also assayed by TLC. The 
rate of false-positive results was the proportion of subtherapeutic nevirapine saliva and plasma 
concentrations determined by HPLC that were judged to be therapeutic in saliva specimens 
by TLC. The rate of false-negative results was the proportion of therapeutic nevirapine saliva 
and plasma concentrations determined by HPLC that were judged to be subtherapeutic in 
saliva specimens by TLC. The extent of agreement in TLC readings between 5 technicians and 
2 batches of TLC sheets was evaluated.
results
Twenty-five (9%) of 286 African adults had a subtherapeutic plasma nevirapine concentration. 
The median ratio of nevirapine concentrations in saliva to those in plasma was 0.51:1. The rate of 
false-positive results for TLC was 0% (0 of 23 specimens) when TLC results were compared with 
HPLC results for saliva specimens and 8% (2 of 25 specimens) when TLC results were compared 
with HPLC results for plasma specimens. The rate of false-negative results for TLC was 1% (3 of 
263 specimens) when TLC results were compared with HPLC results for saliva specimens and 1% 
(3 of 261 specimens) when TLC results were compared with HPLC results for plasma specimens. 
The extent of agreement of TLC results was substantial for the 5 technicians (Fleiss’s kp0.77) and 
for the 2 batches of sheets (Cohen’s kp0.80). 
Conclusions
The TLC assay was found to be sensitive, specific, and robust in the detection of subtherapeutic 
nevirapine concentrations in saliva specimens obtained from African HIV-infected adults. It is 
an attractive alternative to HPLC for therapeutic drug monitoring of nevirapine in resource-
limited settings.
87
6
TH
ER
A
PEU
TIC
 D
R
U
G
 M
O
N
ITO
R
IN
G
 O
F N
E
V
IR
A
PIN
E IN
 SA
LIV
A
INTroDuCTIoN
Nevirapine is widely prescribed in combination with nucleoside reverse-transcriptase inhibitors 
for the treatment of HIV infection in resource-limited countries. Adequate plasma concentrations 
of nevirapine are required to achieve a successful response, whereas subtherapeutic 
concentrations (defined as concentrations <3.0 mg/L) are related to development of mutations 
and virological failure [1–3]. Even in the case of perfect adherence to regimens at standard 
doses, some patients will remain at risk for underdosing because of interpatient variability 
in nevirapine exposure or drug-drug interactions. In the developed world, therapeutic drug 
monitoring (TDM) [3] is a well-known tool for the optimization of nevirapine dosing in HIV-
infected patients. As a result of a lack of simple and affordable methods to determine the 
level of exposure to nevirapine, TDM is hardly ever performed in resource-limited settings. 
Previous studies have suggested that saliva specimens may be used as an alternative body fluid 
sample for TDM of nevirapine [4, 5]. Saliva concentrations of nevirapine in HIV-infected [4] 
and healthy [5] white persons are approximately one-half of the values observed in plasma 
specimens obtained from such persons. We recently developed a thin-layer chromatography 
(TLC) method to provide a simple and economical tool for semiquantitative measurement of 
the saliva concentration of nevirapine. The primary objective of this study was to validate our 
newly developed TLC method for TDM of nevirapine concentrations in saliva samples obtained 
from HIV-infected Africans. Secondary objectives were to determine the relationship between 
saliva and plasma nevirapine concentrations and the proportion of subtherapeutic nevirapine 
concentrations in an African population.
MeTHoDS
Study population
Three hundred HIV-infected adults who had been receiving a regimen that contained nevirapine 
for at least 4 weeks were eligible for enrollment at a routine visit to the adult HIV clinic of the 
Kilimanjaro Christian Medical Centre (Moshi, Tanzania). Patients who had oral lesions or ulcers 
and those who were unable to self-report the date and time of the most recent ingestion of 
nevirapine were excluded from the study. The protocol was reviewed and approved by the 
Ethics Committee of Tumaini University (Moshi). Written informed consent was obtained from 
all subjects before enrollment.
Sample collection and drug concentration assays
At a routine visit to the clinic, unannounced paired blood and saliva samples were collected 
within 5 min of each other. Stimulated saliva specimens were obtained with a salivette 
(Sartstedt; Etten- Leur) using a dental cotton roll impregnated with citric acid (20 mg), which 
stimulates the salivary flow. Study subjects were asked to chew on the roll for ∼ 1 min. Blood 
and saliva samples were stored at 2°C–8°C for a maximum of 8 h. Plasma was separated and 
stored at -80°C until transportation to The Netherlands on dry ice. Saliva was obtained by 
centrifugation of the cotton roll at 800 g for 10 min. Two aliquots were stored at - 80°C: one for 
analysis by TLC in Tanzania, and one for transportation to The Netherlands and analysis by high-
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performance liquid chromatography (HPLC). Saliva and plasma concentrations of nevirapine 
were determined at the Department of Clinical Pharmacy of the Radboud University Nijmegen 
Medical Centre (Nijmegen, The Netherlands) using validated HPLC assays with UV detection, 
as modified from a method described by Hollanders et al. [6]. Samples were pretreated as 
described by Hollanders and colleagues, and preparation of saliva samples did not differ from 
preparation of plasma samples. In brief, 150 μL mL of saliva or plasma was mixed with 150 μL mL 
of perchloric acid, vortexed for 20 s, and centrifuged for 5 min at 12,175 g. Subsequently, 200 mL 
of the clear supernatant was transferred to insert vials and placed in the auto sampler. The 
lower and upper limits of quantification of the modified assays were 0.167 and 16.7 mg/L, 
respectively, for plasma and 0.158 and 15.8 mg/L, respectively, for saliva. The intraday precision 
of the assays ranged from 0.4% to 3.2% for plasma and from 1.3% to 4.1% for saliva. Additional 
variation as a result of performing the assays on different days ranged from 0.0% to 0.4% for 
plasma and from 0.8% to 2.2% for saliva. The accuracy of the assays ranged from 102% to 105% 
for plasma and from 99% to 102% for saliva. Ratios of saliva nevirapine concentration to plasma 
nevirapine concentration and the proportion of subjects with a subtherapeutic nevirapine 
plasma concentration (i.e., <3.0 mg/L) [3] were determined.
In addition, saliva concentrations of nevirapine were semi-quantitatively analyzed at the 
Biotechnology Laboratory of Kilimanjaro Christian Medical Centre using a newly developed TLC 
method.
experimental TlC method
A reference solution of nevirapine (Viramune; Boehringer Ingelheim), 1.75 mg/L, was obtained 
by dilution of a stock solution (nevirapine, 0.875 mg/mL, in dimethylsulfoxide [DMSO]; Merck) 
in blank saliva (i.e., saliva without nevirapine or any other drug). Both were kept at -80°C. The 
reference solution and saliva samples were thawed at room temperature, mixed for 1 min, and 
centrifuged at 9000g for 1 min. Of the reference and samples, 1.0 mL was transferred into a 
10-mL glass test tube. After addition of 0.5 mL of 0.2 M ammonia (diluted from 25% ammonia; 
Labopharma) and 5 mL tert-butylmethylether (Riedel–de Haën), tubes were closed, mixed 
for 1 min, centrifuged at 1150 g for 5 min, and stored at -80°C until the lower layer was frozen 
completely (20 min). The organic layer was poured into a 10-mL glass test tube and was dried 
in 2 days. An eluent (or mobile phase) was prepared (ratio of toluene to ethyl acetate, 1:1; ACME 
Chemicals and Unilab, respectively) and poured into a TLC container. The container was closed 
and left for 1 h. After addition of 50 mL of methanol to the dried test tubes, they were closed 
and mixed for 1 min. One mL of the reference and of the samples was slowly pipetted in small, 
dense dots at least 1.5 cm from the side and 2.0 cm from the bottom of a silica gel TLC sheet 
(height, 10.0 cm; width, 20.0 cm; Merck), as shown in figure 1. After drying, spots were checked 
for similarity of size and shape under UV light (254 nm; CAMAG 022.9120). The TLC sheet was 
placed in the container with eluent for ∼ 12 min (figure 2). 
It was marked for the distance that the eluent had moved and was dried in the air. The 
intensity of the spots was determined under UV light and compared with the reference spot 
(figure 3). A spot that was less intense than the reference was considered to be subtherapeutic. 
A spot that was comparable to or more intense than the reference spot was considered to be 
therapeutic.
89
6
TH
ER
A
PEU
TIC
 D
R
U
G
 M
O
N
ITO
R
IN
G
 O
F N
E
V
IR
A
PIN
E IN
 SA
LIV
A
Technical validation of TlC method 
All saliva samples were used to determine the technical sensitivity and specificity of the TLC 
method. The readings were performed by 1 technician. Saliva nevirapine concentrations 
determined by HPLC were defined as subtherapeutic if they were <1.5 mg/L, which is 
one-half of the cutoff value for plasma specimens (<3.0 mg/L) [3]. The rate of false-positive 
results was defined as the proportion of subtherapeutic saliva concentrations of nevirapine 
(i.e., < 1.5 mg/L), as determined by HPLC [6], that were reported to be therapeutic on the basis 
of TLC of saliva specimens.
The rate of false-negative results was defined as the proportion of therapeutic saliva 
concentrations of nevirapine (≥1.5 mg/L), as determined by HPLC [6], that were reported to 
be subtherapeutic on the basis of TLC of saliva specimens. Twenty-five saliva samples with 
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nevirapine concentrations determined by HPLC [6] closest to the TLC reference value of 
1.75 mg/L were selected to test the robustness of the TLC method. The extent of agreement in 
TLC results between 5 different technicians (Fleiss’s k [7]) and 2 different batches of TLC sheets 
(Cohen’s k [8]) was evaluated in these 25 saliva samples. The stability of the stock solution 
(nevirapine in DMSO) was tested after storage at -40°C for 50 months. The stability of the 
reference solution (nevirapine in blank saliva) was tested after storage at room temperature for 
17 h, after storage at - 40°C for 2 months, and after freezing and thawing twice. Interference of 
possible concurrently used medications was evaluated by comparison of the retention factor 
(i.e., the distance travelled by compound divided by distance travelled by eluent front) of 
extractable and detectable (UV light; 254 nm) compounds with the retention factor value of 
nevirapine. In addition, blank saliva samples obtained from at least 6 subjects who had not been 
taking nevirapine were tested for interference by endogenous substances.
biological validation of TlC method
All plasma and saliva samples were used to determine the biological sensitivity and specificity of 
the TLC method. The rate of false-positive results was defined as the proportion of subtherapeutic 
nevirapine plasma concentrations (<3.0 mg/L [3]) determined by HPLC [6] that were reported to be 
therapeutic on the basis of TLC of saliva specimens. The rate of false-negative results was defined 
as the proportion of therapeutic nevirapine plasma concentrations (≥3.0 mg/L [3]) determined by 
HPLC [6] that were reported to be subtherapeutic on the basis of TLC of saliva specimens.
reSulTS
Of the 300 subjects enrolled in the study, 14 were excluded because of problems with labelling, 
because the saliva volume was too small, or because the saliva specimen was lost. The mean age of 
the remaining 286 African subjects (200 of whom were women) was 41 years (range, 17–71 years). 
All subjects were treated with a nevirapine dosage of 200 mg twice per day, in combination with 
lamivudine and either stavudine or zidovudine. The mean plasma concentration of nevirapine, 
as determined by HPLC, was 7.35 mg/L (range, <0.167 to 28.59 mg/L). Twenty-five (9%) of 286 
subjects had a sub-therapeutic plasma nevirapine concentration (i.e. <3.0 mg/L); 18 of 25 had a 
concentration that was less than the detection limit of the HPLC assay (i.e. <0.15 mg/L). The median 
ratio of saliva nevirapine concentration to plasma nevirapine concentration, as determined by 
HPLC, was 0.51:1 (interquartile range, 0.47:1–0.54-:1), and the median time from the last ingestion 
of medication and to sample collection was 3.40 h (interquartile range, 2.52– 4.37 h). Six subjects 
had a ratio of saliva nevirapine concentration to plasma nevirapine concentration 11.00 (range, 
1.25– 15.68); the median time from last ingestion of medication to sampling for these 6 subjects 
was 1.19 h (interquartile range, 0.85–1.74 h). None of the 23 saliva specimens that were found to 
contain subtherapeutic concentrations of nevirapine (i.e.,<1.5 mg/L) by HPLC were reported to 
have therapeutic values by TLC (rate of false-positive results, 0%); the technical sensitivity of 
the TLC method was 100% (table 1). Three of the 263 saliva specimens that were found to have 
therapeutic concentrations of nevirapine (i.e., ≥ 1.5 mg/L; 1.62, 1.74, and 1.96 mg/L) by HPLC were 
reported to have subtherapeutic values by TLC (rate of false-negative results, 1%); the technical 
specificity of the TLC method was 99% (table 1).
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Table 1. Number of patients (with (sub) therapeutic nevirapine concentrations according to thin-layer 
chromatography (TLD), compared with according to high-performance liquid chromatography (HPLC), 
and sensitivity and specificity of the TLC assay
TlC of saliva specimens
No. of results
Specimen, concentration 
determined by HPLC
Subtherapeutic 
concentration
Therapeutic 
concentration
Sensitivity, % Specificity, %
Saliva
Subtherapeutic concentration 23 0 100 …
Therapeutic concentration 3 260 … 99
Plasma
Subtherapeutic concentration 23 2 92 …
Therapeutic concentration 3 258 … 99
NOTE. Subtherapeutic concentrations of nevirapine were defined as <1.75 mg/L for TLC of saliva specimens, <1.5 mg/L 
for HPLC of saliva specimens, and <3.0 mg/L for HPLC of plasma specimens. Therapeutic concentrations were defined 
as values greater than these cutoff values
The extent of agreement among TLC results (i.e., subtherapeutic or therapeutic nevirapine 
saliva concentrations) for 25 selected samples with a concentration closest to the reference 
sample was substantial for the 5 technicians (Fleiss’s k, 0.77) and 2 batches of TLC sheets 
(Cohen’s k, 0.80).
The stock solution for the TLC method (nevirapine in DMSO) was stable at - 40°C for at 
least 50 months (mean rate of recovery ± SD, 99.7% ± 0.3%). The reference solution (nevirapine 
in blank saliva) was stable at room temperature for at least 17 h (mean rate of recovery ± SD, 
107.6% ± 5.8%) and at - 40° C for at least 2 months (mean rate of recovery ± SD, 94.3% ± 3.2%). 
Freezing and thawing twice had no effect on the stability of nevirapine in blank saliva (mean 
rate of recovery ± SD, 95.1% ± 1.1%). The mean nevirapine retention factor value was 0.29; none 
of the possible comedications that were extractable and detectable had a similar retention 
factor value. Also, no interference by endogenous substances was observed in the blank saliva 
samples obtained from subjects not taking nevirapine. Two of the 25 plasma samples found 
to have subtherapeutic nevirapine concentrations (<3.0 mg/L; 2.61 and 2.91 mg/L) by HPLC 
were reported to have therapeutic concentrations byTLC (rate of false-positive results, 8%); 
the biological sensitivity of the TLC method was 92% (table 1). Three of the 261 plasma samples 
found to have therapeutic nevirapine concentrations (≥ 3.0 mg/L; 3.41, 3.52, and 4.28 mg/L) 
by HPLC were reported to have subtherapeutic concentrations by TLC (rate of false negative 
results, 1%); the biological specificity of the TLC method was 99% (table 1).
DISCuSSIoN
Twenty-five (9%) of 286 HIV-infected African adults had a subtherapeutic plasma concentration 
of nevirapine (i.e., <3.0 mg/L) [3]. Saliva nevirapine concentrations were approximately one-half 
of the values observed in plasma specimens. A TLC method for semiquantitative detection of 
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nevirapine in saliva specimens was found to be sensitive, specific, and robust. This simple and 
economical tool is a good option for TDM of nevirapine in resource-limited settings. Use of saliva 
specimens instead of plasma specimens for TDM of nevirapine implies painless and noninvasive 
sampling, a diminished risk of HIV transmission to health care workers, and a lower cost [4]. 
TLC is a relatively inexpensive assay technique, compared with HPLC [9], which is commonly 
used in the developed world for TDM of nevirapine in plasma samples. An HPLC system for 
TDM of nevirapine costs approximately €40,000, and the costs for consumables per sample 
are estimated to be €15. In contrast, the estimated initial setup cost of a new TLC method for 
semiquantitative measurement of nevirapine in saliva is €800, and the cost of consumables per 
sample is approximately €1.60. Because this simple and inexpensive method was developed to 
perform TDM of nevirapine in resource-limited settings, it was validated in an African target 
population in our study. The percentage of HIV-infected adults in our Tanzanian population 
(9%) with a subtherapeutic plasma concentration of nevirapine [3], as determined by HPLC 
[6], was lower than the percentage in a previous report from Malawi (16%) [10]. This may be 
associated with the unreliable drug supply during the time of the Malawian study (2003), which 
explained more than one-third of the total reported nonadherence to treatment [10]. The fact 
that 18 of the 25 subtherapeutic nevirapine plasma concentrations in our Tanzanian population 
were undetectable indicates nonadherence to treatment, because nevirapine is generally 
detected up to weeks after termination of drug intake because of its long elimination half-life 
[11]. The median ratio of saliva nevirapine concentration to plasma nevirapine concentration of 
0.51:1, as determined by HPLC [6], in our population of HIV-infected Africans was comparable 
to the ratios observed in HIV-infected [4] and healthy [5] white persons. It has been suggested 
that thorough rinsing of the mouth is required before saliva sampling, because remnants of 
orally administered medicines may contaminate saliva specimens and yield spuriously high 
values [12]. Indeed, 6 of 286 subjects in our study had an unexpectedly high ratio of saliva to 
plasma nevirapine concentration of >1:1 [4,12]; this may be because the subjects had chewed 
tablets without rinsing the mouth before samples were obtained. This explanation is supported 
by our observation that the time between last ingestion and sampling was shorter for subjects 
with unexpectedly high nevirapine concentrations in saliva specimens, compared with 
concentrations in plasma specimens. Because the saliva nevirapine concentrations determined 
by HPLC were approximately one-half of the values observed in plasma specimens, they were 
defined as subtherapeutic if they were <1.5 mg/L rather than if they were less than the cutoff value 
for plasma (i.e., 3.0 mg/L) [3]. The main requirement of our TLC method for semiquantitative 
detection of nevirapine in saliva specimens was appropriate sensitivity, meaning detection of 
nevirapine concentrations that were found to be subtherapeutic by HPLC, to pick out subjects 
at risk for nevirapine resistance. During the development of our TLC method, subtherapeutic 
saliva concentrations slightly less than 1.5 mg/L were sufficiently distinguishable from a TLC 
reference value of 1.75 mg/L but not from a reference value of 1.5 mg/L. Therefore, for the 
validation of our TLC method, we chose a reference value of 1.75 mg/L, which led to excellent 
technical sensitivity (100%) and specificity (99%). None of the subtherapeutic nevirapine saliva 
concentrations found by HPLC were reported to be therapeutic by TLC, and the few therapeutic 
saliva concentrations that were reported to be subtherapeutic by TLC were all close to the cutoff 
93
6
TH
ER
A
PEU
TIC
 D
R
U
G
 M
O
N
ITO
R
IN
G
 O
F N
E
V
IR
A
PIN
E IN
 SA
LIV
A
value for saliva (1.5 mg/L). Biological validation compared saliva concentrations of nevirapine 
determined by TLC with plasma concentrations determined by HPLC (either subtherapeutic 
or therapeutic levels), finding acceptable sensitivity (92%) and excellent specificity (99%). 
False-positive and false-negative results were all close to the cutoff value for plasma (3.0 mg/L). 
The somewhat lower biological sensitivity can be explained by the fact that some subjects 
with a subtherapeutic plasma concentration determined by HPLC had a therapeutic saliva 
concentration according to both HPLC and TLC. Although these subjects had a higher ratio 
of saliva to plasma nevirapine concentration than average, none of them had a ratio >1:1. As 
expected, it was found to be most difficult to interpret nevirapine saliva concentrations that 
were closest to the TLC reference value. To test the worst-case scenario robustness of the TLC 
method, we selected 25 samples closest to the reference value. The fact that the extent of 
agreement in TLC results between 5 technicians and 2 batches of TLC sheets was substantial 
provides an indication that the outcome of our TLC method is reliable during normal use.
We are planning to roll out the TLC method in various African countries and in Indonesia. 
This will make it possible to continue to evaluate the method’s robustness and its practical 
application to adherence monitoring. Potentially, the assay could be further developed 
commercially.
In conclusion, we developed a simple and economical TLC method for semiquantitative 
determination of saliva concentrations of nevirapine. The assay was found to be sensitive, 
specific, and robust for detection of subtherapeutic nevirapine concentrations in an African 
population. It is an attractive alternative to HPLC for TDM of nevirapine in resource-limited 
settings.
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abSTraCT
background
Thin layer chromatography (TLC) can be used to perform therapeutic drug monitoring in 
resource-limited settings, where more expensive analytical methods such as high-performance 
liquid chromatography (HPLC) or liquid chromatography mass-spectrometry (LC-MS) are 
not feasible.
objectives
In this cross-sectional study, we aimed at comparing saliva concentrations of nevirapine (NVP) 
with self-reported adherence, in patients on NVP-containing anti-retroviral (ARV) treatment at 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania. 
Methods
We included HIV-infected patients using a combination of zidovudine + lamivudine + NVP, or 
stavudine + lamivudine + NVP, for more than four weeks. Saliva samples were collected using 
dental cotton rolls impregnated with citric acid (20 mg). Saliva NVP concentrations were 
analyzed using TLC. Adherence to ARV medication was assessed by self-reporting using the 
Morisky scale. 
results
Seventy nine (86.8%) of 91 study participants had therapeutic saliva NVP concentrations 
(i.e.  >1.75 mg/L) and 12 (13.2%) had sub-therapeutic concentrations. Self-reported adherence 
among the study participants was high in 62 (68.1%), moderate in 24 (26.4%), and low in 5 (5.5%). 
Fifty seven (91.9%) of the study participants with high self-reported adherence had therapeutic 
saliva NVP concentrations. Of the 5 participants with low self-reported adherence, three had 
therapeutic NVP concentrations.
Conclusions
A high proportion of patients had therapeutic NVP saliva concentrations as measured by TLC, 
which showed good agreement with self-reported adherence.
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INTroDuCTIoN
In Tanzania, antiretroviral (ARV) drugs are given free of charge to eligible HIV-infected patients. 
By the end of 2010 about 42% of HIV infected patients were receiving ARV treatment.1 Nevirapine 
(NVP) is one of the ARV drugs belonging to the class of non-nucleoside reverse transcriptase 
inhibitors (NNRTI). According to Tanzania National Guidelines for the management of HIV and 
AIDS (2009)2, NVP is used as a first-line drug combined with two nucleoside reverse transcriptase 
inhibitors (NRTI) such as zidovudine (AZT) and lamivudine (3TC), or stavudine (d4T) and 3TC, or 
stavudine (d4T) with tenofovir and emtricitabine. 
Adequate plasma concentrations of NVP are required to achieve a successful response, 
whereas sub-therapeutic concentrations, defined as concentrations below 3.0 mg/L, are 
related to development of mutations and virological failure.3-7
Studies have shown that among patients who are highly adherent to regimens at standard 
doses, some will still remain at risk of under exposure because of inter-patient variability in 
NVP concentrations, or due to drug-drug interactions.8 Studies from both resource-rich and 
resource-limited settings have repeatedly demonstrated that high levels of ARV adherence are 
associated with better immunological and virological outcomes, decreased risk of developing 
AIDS-defining illnesses, and improved survival.9 A study in Malawi found that 148 (84%) of study 
patients had NVP plasma concentrations in the therapeutic range or higher, and that those with 
sub-therapeutic concentrations (16%) had a six fold increased risk of developing virological 
failure as compared with those with therapeutic concentrations.10 A study conducted at 
Kilimanjaro Christian Medical Centre (Moshi, Tanzania) found that 25 (9%) of 286 African adults 
had sub-therapeutic plasma NVP concentrations.11 
Saliva can provide a rapid and non-invasive sample for NVP compliance testing, direct 
measurement of adherence, and for pharmacokinetic comparisons.12 A simple and inexpensive 
thin layer chromatography (TLC) assay for semi-quantitative measurement of NVP saliva 
concentrations in resource-limited settings has been validated by our group.11 It was observed 
that the median ratio of saliva-to-plasma NVP concentrations using high-performance liquid 
chromatography (HPLC) was 0.51, i.e. the concentration of NVP in saliva was almost 50% of 
that in plasma.11 Sub-therapeutic saliva concentrations of NVP were defined as <1.75 mg/L using 
TLC, and <1.5 mg/L using HPLC, whereas therapeutic saliva NVP concentrations were defined as 
values greater than 1.75 mg/L and 1.5 mg/L, using TLC and HPLC methods, respectively.11 
Several studies have investigated the relationship between NVP concentrations in saliva 
and plasma using non-invasive procedures (saliva stimulation) and observed that NVP 
plasma concentrations in patients taking 200 mg of NVP twice daily were strongly associated 
with saliva concentrations. The saliva concentration of NVP was independent of the time 
after ingestion.11-15
Therapeutic drug monitoring of NVP by HPLC in resource-limited settings such as Tanzania 
is expensive and can hardly be used in routine care. Therefore the use of relatively inexpensive 
methods such as TLC is highly recommended.
The rational use of drugs comprises taking the right drugs at the correct doses and times of 
administration, so as to achieve adherence levels >95%. In studies on self-reported adherence 
to ARV drugs, >95% adherence levels were found.16-17 
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The primary objectives of this study were to measure saliva NVP concentrations, classify 
them as therapeutic or sub-therapeutic, and to assess self-reported adherence, in patients 
using NVP-containing ARV regimens. 
Secondary objectives were to compare the proportion having therapeutic or sub-therapeutic 
saliva NVP concentrations among participants using different NVP containing regimens, to 
compare self-reported adherence with NVP saliva concentrations, and to determine reasons for 
missed doses.
MeTHoDS
Study design 
This cross-sectional study enrolled HIV-infected patients who attended the adult Care and 
Treatment Clinic (CTC) at Kilimanjaro Christian Medical Centre (KCMC), a tertiary care hospital 
and medical training centre in Moshi, Tanzania between January and April 2012. We selected 
participants who had been on the following NVP-containing ARV regimens; zidovudine + 
lamivudine + NVP, or stavudine + lamivudine + NVP, for more than four weeks.
Study population
101 HIV-infected adults were recruited during routine visits to the CTC. Patients who had eaten 
a major meal, smoked, used dental flossing, tooth brushing, or drunk anything 60 minutes 
prior to saliva collection were excluded. Those who had taken alcohol less than 12 hours before 
saliva sample collection, and those unable to self-report the date and time of the most recent 
ingestion of NVP were also excluded. The protocol was reviewed and approved by the Research 
and Ethics Review Committee of the Kilimanjaro Christian Medical University College, Moshi. 
Written informed consent was obtained from all subjects before enrolment.
Sample collection and drug concentration assays
Cotton gauze was used to remove colour from study participants who had painted their lips. Any 
removable dental prosthesis was also removed. Active smokers and drinkers who had refrained 
from their habit for more than 12 hours before saliva collection were eligible for the study. 
Hands were washed and mouths were rinsed twice with cold water just before saliva collection. 
Stimulated saliva specimens were obtained with a Salivette - a dental cotton roll impregnated with 
20 mg citric acid - (Sartstedt, Etten-Leur, The Netherlands), which stimulates saliva flow. Study 
participants were asked to chew on the roll for approximately 1 min. Saliva samples were stored at 
ambient temperature for a maximum of 2-3 hrs at the study site. NVP in saliva is stable for 17 hours 
at ambient temperature (23°C). Saliva was obtained by centrifugation of the cotton roll at 800g 
for 10 min on the same day and the aliquots were stored at -800C for analysis at the Biotechnology 
Laboratory of KCMC. The centrifugation process removed particulate matter from saliva samples. 
On average, more than 2 mL of saliva was collected at once from each patient.
experimental TlC method
The TLC method applied was as described and validated previously.11 Briefly, one microlitre (μL) 
of the reference solution of 1.75 mg/L NVP, and saliva samples 1 μL were pipetted in small dense 
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dots 1.5 cm from the side and 2.0 cm from the bottom of a silica gel TLC sheet, which was then 
placed in a container with eluent (Toluene: Ethyl acetate=1:1) for approximately 12  minutes. 
When the solvent front reached its maximum distance, the TLC plate was removed and marked 
for the distance the eluent had moved. After drying, the spots were checked for similarity of 
size and shape under UV light (254 nm, CAMAG 022.9120) and compared with the reference 
spot. A spot less intense than the reference was considered to be sub-therapeutic. A spot 
comparable to or more intense than the reference spot was considered to be therapeutic. 
adherence measurement by self-reporting
Adherence to intake of a NVP-containing regimen was measured using a self-reported 
questionnaire, which consisted of 4 closed questions (Morisky scale).18 The questions were in 
the native language and measured both intentional and non-intentional non-adherence, based 
on forgetting, carelessness and stopping medication when feeling better or worse. 
Statistical analysis
Data were entered in SPSS version 16 and analysed by SPSS and STATA version 12. Categorical 
variables were expressed in proportions and percentages. Comparison between groups was 
performed by using Fisher’s exact test.
Logistic regression analysis was performed and an odds ratio (OR) with 95% confidence 
interval (CI) determined to find the association between saliva NVP concentration (sub-
therapeutic level) and factors such as body mass index (BMI), reasons for missed doses, 
adherence level, and sex. A p-value of <0.05 (2-tailed) was used to indicate statistical significance. 
reSulTS 
We included 101 HIV- infected adults, 15 to 49 years of age taking NVP-containing ARV regimens 
for more than four weeks. Ten patients (9.9%) were excluded as the volume of saliva obtained 
after centrifugation was insufficient for the assay (<0.5 mL), leaving saliva from 91 patients 
for analysis.
Of the study participants 78% were women. A higher proportion of the study participants 
(80.2%) was on a fixed combination comprising AZT 200mg, 3TC 150mg, and NVP 200mg; 
19.8% was on a d4T 30 mg, 3TC 150mg and NVP 200mg regimen (Table 1). The enrolled study 
participants had been on the ARV combination medications for a period of between one 
month and more than five years. The average time from last intake of NVP to saliva collection 
was 3.06 hrs (SD ± 2.52). Thirteen participants were using other drugs apart from ARV’s for 
the management of opportunistic infections, hypertension, epilepsy and / or peripheral 
neuropathy. The majority of participants were not smoking (98.9%) nor drinking alcohol (89%. 
Self-reported adherence was high, moderate or low in 68.1%, 26.4% and 5.5% of participants, 
respectively (Table 1). Reasons for missed doses mentioned by participants were forgetting 
(33%) work (4.4%) and side effects (5.5%). The remaining could not give a particular reason.
Seventy nine (86.8%) of participants had saliva NVP concentrations at the therapeutic level 
(1.75 mg/L) or higher, and 12 (13.2%) had sub-therapeutic concentrations (Table 2). Of the 
patients on the NVP + AZT + 3TC regimen, 86.3% had saliva NVP concentrations at therapeutic 
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NVP + 3TC + d4T regimen (88.9%; p=0.56). 
The association between self-reported adherence and saliva NVP concentration is 
summarized in Table 2. In 57 of 62 participants (91.9%) with high self-reported adherence, saliva 
NVP concentrations were at the therapeutic concentration or higher (>1.75 mg/L), while 5 (8.1%) 
had sub-therapeutic concentrations. Three of 5 participants with low self-reported adherence, 
had saliva NVP concentrations at therapeutic level. The association between self-reported 
adherence and saliva NVP concentrations was close to statistical significance (p=0.057).
The majority of participants who were using ARV alone had saliva NVP concentrations at the 
therapeutic level or higher (91%). 
Table 1. Demographic characteristics and self-reported adherence of participants (N=91)
Characteristics Particulars N (%)
Age (years) 15-29 10 (11)
30-39 26 (28.6)
40-49 55 (60.4)
Gender Female 71 (78)
Standard ART regimen d4T+3TC+NVP 18 (19.8)
AZT+3TC+NVP 73 (80.2)
Co-medication Yes 13 (14.3)
No 78 (85.7)
Body mass index (kg/m2) <18.5 4 (4.4)
18.5-24.9 47 (51.7)
>24.9 27 (29.7)
>30 13 (14.3)
Smoking Yes >12hrs 1 (1.1)
  No 99 (98.9)
Alcohol intake Yes >12hrs 10 (11)
  No 81 (89)
Duration on ART >1Month-1Year 12 (13.2)
>1Year-2Years 9 (9.9)
>2years-5Years 26 (28.6)
  >5Years 44 (48.4)
Self-reported adherence (*)
Low 5 (5.5)
Moderate 24 (26.4)
High 62 (68.1)
N (%), number and percent; d4T,stavudine 30mg; 3TC, lamivudine 150mg; NVP, nevirapine 200mg; the fixed dose 
combination is called Triomune 30; AZT, zidovudine 300mg; 3TC, lamivudine 150mg; NVP, nevirapine 200mg; the fixed 
dose combination is called Duovir N.
(*) Classified by Morisky scale.18
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Table 2. Association between self-reported adherence and saliva nevirapine concentrations
Saliva NVP concentration
>1.75 mg/l
N=79
<1.75mg/l
N=12
Total
N=91 P value
Adherence (*) N (%)
Low adherence 3 (60.0) 2 (40.0) 5 (100)
Moderate adherence 19 (79.2) 5 (20.8) 24 (100) 0.057†
High adherence 57 (91.9) 5 (8.1) 62 (100)
† Fisher’s exact test (significance level less than or equal to 5%); 
(*) Self-reported adherence classified using Morisky scale.18
Logistic regression was performed to determine the association between saliva NVP 
concentrations (sub-therapeutic concentration) and various factors. Participants with high self-
reported adherence were 87% less likely to have a sub-therapeutic saliva NVP concentration 
compared to those with low self-reported adherence (OR 0.13 (95%CI 0.02-0.98, p=0.05). BMI 
and gender were not associated with sub-therapeutic saliva NVP concentrations. 
DISCuSSIoN 
This study demonstrated high adherence among the participants. Therapeutic saliva NVP 
concentrations (>1.75 mg/L or higher) were observed in 86.8% of participants and sub-
therapeutic concentrations were observed in 13.2% of the participants. Our findings were 
comparable to those obtained by L’homme et al.11 The proportion of participants with therapeutic 
NVP concentrations on the two fixed-dose NVP-containing regimens, i.e. d4T+3TC+NVP, and 
AZT+3TC+NVP was comparable (88.9% and 86.3%, respectively). 
There is scarce information regarding the NVP saliva or plasma concentration relationships 
between the two NVP-containing fixed-combination regimens. Dubuisson et al.19 found that 
concomitant AZT use may confound the TLC assay results because AZT has a retardation factor 
(RF) value similar to the NVP reference standard. Jean-Baptiste R,20 observed that adherence 
rates were much higher in combination regimens containing d4T compared to patients on 
AZT containing combinations, suggesting that combination type as opposed to pill burden 
was associated with adherence. This can be explained by the different toxicity profiles of the 
medications, because those who experience higher rate of adverse events are mostly likely to 
skip or stop taking medications. 
Self-reported adherence observed in our study was comparable to that observed in Rwanda 
(73%)13 where pill count and a questionnaire were used to measure adherence, and in Botswana 
(81.3%)16 where self-reported adherence was assessed using the Morisky scale. We observed 
that 91.9% of participants with self-reported high adherence also had therapeutic or higher 
saliva NVP concentrations, while 8.1% the same group had sub-therapeutic NVP concentrations. 
HIV-infected patients taking ARVs often use non-ARV co-medication for other indications 
such as opportunistic infections. This increases the probability of drug-drug interactions 
which may affect ARV treatment by affecting drug concentrations or adherence. Because the 
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number of patients using co medications was small (3 on antihypertensives, 6 on drugs against 
opportunistic infection, and 4 on anti-epileptics), a larger study powered to address the impact 
of pharmacokinetic interactions is warranted. 
HIV patients are committed to take their ARV medications for life, but due to various reasons 
they may skip some doses. In our study, 57.1% reported no clear reasons for not taking their 
medications and 33% reported forgetting as the main reason. Our data are in line with other 
studies which reported “simply forgetting” as the main reason behind missed doses in Malawi.10
Our study has some limitations. The TLC assay only measures the amount of NVP in saliva 
semi-quantitatively and the exact concentrations of NVP were not calculated. Self-reported 
adherence may be biased by over or under reporting, as the Morisky scale is only a reflection 
of the true ARV intake. Other adherence measurement tools such as the Medication Event 
Monitoring System (MEMS), may be biased as well, because patients may change their 
medication behaviour because they knew they were being monitored, and because opening or 
closing the bottles does not confirm drug intake.21
Also, in the present study adherence was measured mostly in female patients (71/91 of study 
subjects). C. Ortego et al 22 found higher rates of adherence in Africa, Asia, and South America, 
amongst women, when the sample included more widows. 
CoNCluSIoNS
A high proportion of patients in this study had therapeutic NVP saliva concentrations as 
measured by TLC, and saliva concentrations generally were in agreement with self-reported 
adherence.
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Introduction
This thesis presents the first output in clinical pharmacological research on adding an enzyme 
inducer to the prophylaxis regimen used for prevention of mother-to-child transmission 
(pMTCT) and the use of thin layer chromatography for therapeutic drug monitoring in HIV-
infected adult patients. In this thesis, collaboration between partners from The Netherlands, 
United Kingdom, Zambia and Tanzania has led to clinical pharmacological research on HIV-
infected patients that are specifically relevant for resource-limited countries. Part I deals with 
clinical pharmacological aspects of nevirapine (NVP) use in pMTCT. In particular, the effects 
are presented of adding a short course of different enzyme inducers to the pMTCT prophylaxis 
regimen on the development of resistance1 by reducing the elimination half life of NVP in 
HIV-infected pregnant women. Part II focuses on validating and using the newly developed 
Thin Layer Chromatography for Therapeutic Drug Monitoring of NVP in saliva of HIV- infected 
individuals at the adult care and treatment clinic at Kilimanjaro Christian Medical Centre 
(KCMC), Moshi, Tanzania.
In 2010, an estimated 3.4 million children under 15 years were living with HIV/AIDS worldwide 
and at least 250 000 died of AIDS. Transmission around the time of delivery accounted for nearly 
half of overall MTCT in breast-feeding populations,2;3 and this peri-partum period has become 
the major focus of prevention of MTCT (pMTCT) strategies, especially with antiretroviral drugs 
(ARVs). The regimen is cheap and relatively easy to administer. Since 2000, Sd-NVP has been 
endorsed by the World Health Organization (WHO) as one of several recommended ARV 
regimens for pMTCT in resource-limited settings.6 Studies in the early 2000s, however, have 
shown that Sd-NVP to the mother can induce the occurrence of NVP resistance in mothers and 
infants. The estimated resistance prevalence ranging from 1 to 69% for women and from 0 to 87% 
for neonates.7 Studies have suggested that NVP induced resistance after exposure for pMTCT 
may impair virological response to the subsequently used non nucleoside reverse transcriptase 
inhibitors (NNRTIs) in mothers and infants,8;9 The most frequently detected mutations were 
the K103N and Y181C. The two drugs most likely to select for resistance in these regimens are 
NVP and lamivudine (3TC), both of which require only one point mutation in the viral codon 
to confer resistance. And with the introduction of antepartum, intrapartum and postpartum 
combination therapy for pMTCT to reduce NVP resistance there is still found a prevalence of 
NVP resistance of 4-16%.7 The long term implications of the emergence of resistant mutations 
following the use of these short course regimens require further study. 
In developed-country settings, MTCT of HIV is a rare event, given the wide availability of 
a comprehensive package of MTCT prevention interventions. In contrast, in many resource-
limited settings many pregnant, HIV-infected women cannot access even basic pMTCT 
interventions, such as counselling and testing and ARV prophylaxis. Data from developed-
country settings suggest that the effectiveness of pMTCT regimens that use three ARVs is 
superior to regimens that use only one or two. 
In chapter 2 we have shown that most of the healthy HIV-uninfected Dutch women who 
received a single 200-mg nevirapine dose had detectable NVP plasma concentrations after 
more than 2 weeks.10 The median NVP half-life observed in the 44 subjects was 56.7h, a finding 
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which is similar to Musoke et al.11 In resource limited settings, where many women present late 
for the antenatal clinic and too few are screened for CD4 cell count, Sd-NVP will most likely 
remain an important intervention for the prevention of mother to child transmission. Also, 
in Tanzania the antenatal HIV screening and ARV prophylaxis coverage is still low, with one 
third of women still on Sd-NVP for pMTCT according to UNAIDS report on the Global AIDS 
Epidemic,2010.12 The sub-therapeutic detectable NVP plasma concentrations present the 
perfect environment for the occurrence of resistance, because the concentrations may be 
sub-inhibitory for several days, a finding which has been reported by Jackson et al.13 However, 
some recent studies suggest that the use of Sd-NVP given to the delivering woman and to 
the neonate within 72 h of birth has been proven to be a safe and effective intervention to 
prevent MTCT.4;5 This information is valuable for designing intervention studies to prevent the 
development of resistance.
In chapter 3 describes an innovative study to investigate whether the use of single dose 
of carbamazepine, a CYP3A4 enzyme inducer, added to the pMTCT regimen, diminishes NVP 
resistance by accelerating elimination of NVP after exposure to Sd-NVP14 at onset of labor 
in HIV-infected, pregnant women. We found that addition of single-dose carbamazepine 
did not affect NVP plasma concentration at delivery and these plasma concentrations were 
comparable with previous studies11;15-17, but significantly reduced NVP plasma concentrations 
one week postpartum. At week 6 after delivery HIV genotyping was done and observed NVP 
mutations K103N, present in 9 women, alone in 8 women and with G190A in 1. The standard 
HIV genotyping assays could only detect viral mutations found in 20% of the overall HIV 
population and not subpopulations of mutants. Deep sequencing should be planned for 
future projects. We also found a trend towards lower rates of NVP resistance in women with 
undetectable NVP concentrations across the whole population, supporting the validity of this 
approach. The infants NVP concentrations were not likely reduced due to the delayed enzyme 
induction and the low concentrations of carbamazepine in breast-milk.18 Indeed, perinatal 
HIV- 1 transmission rates were similar to rates reported in previous studies of women using 
Sd-NVP for the first time.4;19 Other findings used short course interventions and significantly 
reduced the development of NVP resistance14;20-22 although the prevalence of resistance 
mutations decreased with time after exposure to Sd-NVP, there is some evidence that women 
with pre-existing mutations as well as those exposed to Sd-NVP but without mutations respond 
less well to antiretroviral treatment.23 The major disadvantages are their complexity and the 
emergence of 3TC resistance which is associated with virological and clinical failure in women 
starting 3TC-containing ART for their own health leading to recommendations that this dual 
therapy AZT/3TC regimens should be used with caution.24;25 To preserve its simplicity, another 
finding by Chi et al26 administered a single dose of emtricitabine + tenofovir with Sd-NVP in 
400 women, which also halved NVP resistance; 25% versus 12%. A recent study in Malawi27 has 
shown that WHO option B+ has rapidly increased access to efficacious ART for HIV+ pregnant 
women. However, each intervention has its advantages and disadvantages and currently there 
are raised concerns about HIV drug resistance with long term use of ART when initiated in 
early HIV disease, safety of increased ARV exposure for the fetus/infant, acceptability and 
equity. This study shows possibilities for pMTCT programs of adding an enzyme inducer to 
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reduce the development of NVP resistance in settings where other options are limited. In 
addition to the initiatives of WHO, these findings apart from being new in the field of pMTCT 
also showed that the pharmacological approach described might have an additive effect and 
also maintains simplicity and effectiveness when used for pMTCT in subsequent pregnancies 
in resource limited setting where access to care and treatment is not accessible thus Sd-NVP 
will still remain the first option for pMTCT. 
Chapter 4 describes a study on the use of a short (seven days) postpartum course of an 
enzyme inducer, phenytoin to accelerate elimination of NVP, with the aim of decreasing the 
frequency of development of NVP resistance postpartum. Nevirapine plasma concentrations at 
delivery were similar in those receiving and not receiving phenytoin, and also comparable with 
previous studies.11;17 Post-delivery, nevirapine pharmacokinetic parameters were substantially 
affected by enzyme induction. Adding phenytoin to Sd-NVP reduced nevirapine plasma levels 
by 85% and produced a significantly larger proportion of women with undetectable NVP levels 
one and two weeks post-delivery. These effects reduced the NVP elimination half-life by 60%, 
an absolute difference of -35.8 hours. This is the largest decline in NVP elimination half-life ever 
reported, especially in the target population of HIV-infected, pregnant women. Currently a one 
week course of AZT/3TC is recommended to reduce NVP resistance in HIV-infected women 
who receive single dose NVP during labor as part of pMTCT ARV prophylaxis. 6;28-30 We found 
that adding a seven-day course of phenytoin at onset of labor lead to a significant reduction in 
the elimination half-life of NVP. Furthermore, seven days postpartum phenytoin was safe with 
no new NVP resistance mutations observed. We recommend however this to be confirmed in 
a prospective larger study powered to demonstrate that phenytoin significantly accelerates 
NVP elimination and hastens its disappearance postpartum.  However, thousands of women 
are still receiving Sd-NVP31, and demonstrates the challenge of implementation of the current 
guidelines. Phenytoin can be used safely during pregnancy and breast-feeding32 and side-
effects are expected to be infrequent with such a low dose for a short period. The addition of an 
enzyme inducer for seven days to Sd-NVP for pMTCT reduced the presence of subtherapeutic 
NVP concentrations by significantly shortening the NVP elimination half-life, with no new 
nevirapine resistance mutations observed. Since prolonged subtherapeutic NVP exposure is 
known to lead to emergence of NVP resistance, and since phenytoin is safe, single dose NVP 
could be used with phenytoin if other ARV drugs are unavailable and should be investigated 
further in a larger phase III trial.
In chapter 5 we performed a systematic review and meta-analysis to assess the effect of 
different drug interventions and duration of intake on NVP resistance development after use 
of a single-dose NVP as part of antiretroviral prophylaxis for pMTCT. Studies have shown that 
antepartum AZT plus short course (<8 days) antiretroviral drugs postpartum have been shown 
to nearly eliminate NVP resistance (<0.02%). Furthermore, 20-30 days33;34 post partum regimens 
were slightly more effective compared to a (<8 days postpartum regimen (0.003%)30;34, however, 
longer term antiretroviral therapy is more complex and challenging to implement in daily 
practice in resource limited settings. The WHO guideline option A (antepartum AZT, Sd-NVP 
and one week of 3TC/AZT postpartum)28 should be followed to achieve a feasible minimum risk 
of NVP resistance in regions where Sd-NVP is still being used. 
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In chapter 6 describes a study on therapeutic drug monitoring (TDM) of NVP. Most of the 
generic antiretroviral regimens that are available in developing countries combine the NNRTI 
nevirapine with two NRTIs. A disadvantage of NVP is the low genetic barrier for the development 
of resistance.35 Resistant strains against NVP- based regimens provided in national programmes 
of developing countries could be spread through the population. This is a concern as there 
are few second line options for antiretroviral treatment in resource-limited countries. From 
a pharmacological point of view, TDM would be an important tool to identify patients with an 
inappropriate exposure to drugs such as NVP and thus at risk for virological failure and resistance 
development. To facilitate the implementation of TDM in developing countries, alternative 
options for sampling and assay technique were investigated. Previous studies have shown that 
saliva may be used as an alternative body fluid to plasma for TDM of NVP, implying painless and 
non-invasive sampling with diminished risk of HIV-transmission to health care workers, and 
at a low cost.36 As an alternative to HPLC, a relatively inexpensive thin layer chromatography 
(TLC) technique has been investigated for the detection of NVP in plasma.37 We developed a 
cheap and simple TLC method for semi-quantitative detection of NVP in saliva. The assay was 
validated in HIV-infected Tanzanian adults on NVP containing regimens at KCMC and was found 
to be sensitive, specific and robust in the detection of sub-therapeutic NVP concentrations. 
Global provision of HIV care and treatment would benefit from the transfer of this technique to 
other developing countries. We recommend this cheap and simple TLC technique for detecting 
NVP saliva concentration to be used as a tool for TDM in resource limited countries. 
In chapter 7 we compared saliva concentrations of NVP with self-reported adherence in 
patients on NVP-containing anti-retroviral (ARV) treatment at KCMC, Tanzania. Rational use of 
drugs comprises taking the right drugs at right doses, right quantities and right time so as to 
achieve adherence concentrations >95%. In studies on self-reported adherence to ARV drugs, 
>95% adherence concentrations were found.38;39 Self-reported adherence observed in our 
study was comparable to that observed in Rwanda40 where pill count and a questionnaire were 
used to measure adherence, and in Botswana where self-reported adherence was assessed 
using the Morisky scale.38 Furthermore the proportion of participants with therapeutic NVP 
concentrations on the two fixed-dose NVP-containing regimens, i.e. d4T+3TC+NVP, and 
AZT+3TC+NVP were comparable in our study. A disadvantage of drug-drug interaction in 
HIV-infected patients is the risk of development of subtherapeutic saliva concentrations of 
antiretroviral drugs. As the number of patients using co-medications was small (3 on anti-
hypertensives, 6 on drugs against opportunistic infection, and 4 on anti-epileptics), it was 
difficult to draw conclusions. We recommend a larger prospective study powered to address 
the pharmacokinetics interactions. Therapeutic drug monitoring of NVP by HPLC in resource-
limited settings like Tanzania is expensive, and can hardly be used in routine care. Resistance 
to ART and treatment failure, as consequences of sub-optimal adherence, are often difficult 
to diagnose and manage in routine clinical care in resource-limited settings. Since second-
line ART is expensive and not often readily available in these settings, effective treatment 
of HIV becomes a challenge when first-line drug failure is detected. TDM of plasma drug 
concentrations can be a valuable tool to directly measure adherence, though results can vary 
between patients based on rates of absorption and drug interactions. Cost constraints have also 
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prevented TDM from being incorporated into routine patient management even in resource-
rich settings. The use of relatively inexpensive, non-invasive and less expensive methods like 
TLC is highly recommended in a resource limited setting. 
Chapter 8 summarizes our main findings in part I &II of our thesis. 
fuTure PerSPeCTIVeS
Our results on the use of enzyme inducers stimulate further research on pharmacogenetics. 
Genetic  differences in  metabolic pathways  can affect individual responses to drugs, both 
in terms of therapeutic effect as well as adverse effects. NVP has been demonstrated to be 
dominantly metabolized by CYP3A and CYP2B6.41 These enzymes exhibit inter-individual 
differences in the expression or activity levels which likely contribute to the variability of NVP 
pharmacokinetics. The CYP2B6 gene is highly polymorphic with numerous single nucleotide 
polymorphisms (SNPs) and associated haplotypes. This variability is largely due to the genetic 
polymorphisms in the cytochrome enzymes which metabolize NVP.42;43 
We recommend the following for future research in Tanzania: Genotyping of gene variants 
associated with altered expression of CYP2B6 and CYP3A5. Stratification of patients according 
to the gene variant predicted CYP2B6 and CYP3A5 expression levels and IL-6 may help to detect 
the effect of enzyme induction on NVP disposition.42-44
Our findings in part II of the thesis showed that the validated method using TLC for the TDM 
of HIV treatment has bridged the gap between laboratory and the clinics. 
We recommend the following:
•	 The quality control of NVP extracted from saliva using TLC for TDM should be encouraged 
in all care and treatment clinic in developing countries, including Tanzania, on a regular 
basis to assess adherence to therapy, improve efficacy and preserve treatment options.
•	 Furthermore, research is needed to find out whether approved antiretroviral drug other 
than NVP can be extracted from saliva and could also be measured using TLC. 
Use of Sd-NVP for pMTCT, which reduces mother-to-child transmission to 11-13%, remains 
an option for resource limited settings, although wider use of more complicated methods based 
on combination ARV’s in pregnancy after week 14 and after delivery (reducing mother-to-child 
transmission to 1-2%) should be considered. In this exercise, not only the extra expenses for 
the more complex approach (material costs and manpower) should be weighted, but also the 
extra number of HIV infections in neonates prevented, as less HIV infections reduce health care 
expenses, this apart from reducing human suffering. 
•	 Therefore, we recommend as well that such cost-benefit analysis for the best approach to 
pMTCT should be performed for resource limited settings, including Tanzania.
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MuHTaSarI 
Repoti hii inatoa taarifa ya kwanza ya utafiti wa kifamacologia kwa wajawazito inayohusu 
kuongezwa kwa dawa inayosababisha uzalishaji wa kimeng’enya (enzyme inducer) kwenye dawa 
inayotumika kuzuia maambukizo kutoka kwa mama kwenda kwa mtoto (PMTCT). Pia kueleza 
matumizi ya teknolojia ya TLC (Thin Layer Chromatography) kufuatilia kwa ukaribu kiasi cha 
dawa mwilini zinazotumika kupunguza makali ya virusi (HIV) visababishavyo ukimwi kwa watu 
wazima. Ripoti hii, kwa ushirikiano wa Uholanzi, Uingereza, Zambia na Tanzania imeonesha 
umhimu wa utafiti wa kifamisia hasa kwa watu wanaoishi na virusi (HIV) visababishavyo ukimwi 
katika nchi zisizo na rasimali za kutosha. 
Sehemu ya kwanza ya ripoti ya utafiti huu imejikita katika kueleza matumizi ya dawa ya 
Nevirapine (NVP) inayotumika kuzia maambukizo kutoka kwa mjamzito kwenda kwa mtoto 
(PMTCT). Hasa hasa, kueleza matokeo ya kuongezwa kwa dawa inayosababisha uzalishaji wa 
kimeng’enya (enzyme inducer) ili kuzuia ongezeko la usugu1 (development of resistance) wa 
virusi (HIV) kwa kupunguza muda wa kuondoa (elimination half life) Nevirapine (NVP) mwilini 
mwa wajawazito wanaoishi na virusi (HIV) visababishavyo ukimwi.
Sehemu ya pili ya ripoti hii inathibitisha na kuonesha matumizi ya teknolojia ya TLC (Thin 
Layer Chromatography) namna inavyoweza kutumiwa kufuatilia kwa ukaribu kiasi cha dawa 
ya Nevirapine (NVP) katika mate ya wagonjwa waiishio na virusi (HIV) visababishavyo ukimwi 
wanaopata huduma ya CTC (care and treatment clinic) katika hospitali ya rufaa KCMC iliyopo 
mjiini Moshi mkoani Kilimanjaro nchini Tanzania.
Mwaka 2010, duniani kote ilikadiriwa kuwa watoto milioni 3.4 walio na umri chini ya miaka 
15 walikuwa wanaishi na virusi (HIV) na kwa uchache watoto 250,000 walikufa kwa UKIMWI. 
Maambukizi ya virusi (HIV) wakati wa kujifungua yakichangia karibu nusu ya maambukizi yote 
toka kwa mama kwenda kwa mtoto (MTCT) katika jamii zenye tabia ya kunyonyesha watoto 2;3 
(breast-feeding populations) na kipindi hiki ndicho kimekuwa kikitiliwa mkazo zaidi miongoni 
mwa mikakati ya kuzuia maambukizi toka kwa mama kwenda kwa mtoto (pMTCT) hasa kwa 
kutumia dawa za ARVs ili kupunguza makali ya virusi (HIV). Dozi hii ni ya gharama nafuu na rahisi 
kuitoa ukilinganisha na zingine. Tangu mwaka 2000, Sd-NVP imeruhusiwa ili kutumika na shirika 
la afya la kimataifa (WHO) kama mojawapo ya dozi za ARV dhidi ya pMTCT katika nchi zisizo 
na rasimali za kutosha6. Hata hivyo tafiti nyingi mwanzoni mwa miaka ya 2000, zimeonesha 
kwamba matumizi ya Sd-NVP kwa akina mama inaweza sababisha ongezeko la usugu wa NVP 
(resistance) kwa akina mama na vichanga vyao. 
Kiasi cha ongezeko la usugu wa NVP (resistance) kinakadiriwa kuwa ni kuanzia 1 hadi 69% 
kwa akina mama na kuanzia 0 hadi 87% kwa vichanga.7 Tafiti zimeonesha kwamba usugu 
usababishwao na NVP baada ya matumizi yake dhidi ya ya pMTCT unaweza kupunguza nguvu 
ya dawa aina ya non nucleoside reverse transcriptase inhibitors (NNRTIs) inayotumiwa 
baadaye na akina mama na vichanga dhidi ya virusi (HIV)8;9 Mara nyingi mabadiliko ya vinasaba 
yasababishayo usugu huu yamegundulika kuwa katika K103N na Y181C.
Dawa mbili ambazo angalau mara zote ni chaguo la usugu katika matibabu ni NVP na 
lamivudine (3TC), ambapo dawa zote mbili huhitaji badiliko kwenye nafasi moja pekee katika 
vinasaba vya kirusi (HIV) ili kusababisha usugu. Pamoja na uanzishaji wa matumizi mseto ya 
matibabu kabla, wakati na baada ya kujifungua dhidi ya pMTCT ili kupunguza usugu wa NVP 
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bado kiwango cha usugu wa NVP ni kati ya 4-16%.7 Madhara ya muda mrefu yatokanayo na 
kuibuka kwa vinasaba sugu kufuatia matumizi ya muda mfupi wa matibabu haya yanahitaji utafiti 
wa kina zaidi. 
Katika nchi zilizoendelea, MTCT ni tukio la nadra sana, ikizingatia kwamba kuna upatikanaji 
bora wa huduma kama kinga dhidi ya MTCT. Kinyume chake katika nchi zisizo na rasimali za 
kutosha wajawazito wengi waiishio na virusi (HIV) hawawezi kupata hata huduma za msingi za 
pMTCT kama vile ushauri, kupima na kuanza matumizi ya dawa za kinga (ARV). Takwimu kutoka 
nchi zisizo na rasimali za kutosha zinaonesha kwamba matibabu dhidi ya pMTCT yanayotumia 
dawa tatu za ARVs ni bora zaidi ukilinganisha na matumizi ya dawa moja au mbili. 
katika sura ya pili (2) ya ripoti hii tumeonesha kuwa wanawake wa kiholanzi wasiokuwa 
na maambukizi ya virusi (HIV) waliotumia dozi moja ya nevirapine ya miligramu 200 (200mg 
Sd-NVP) wana kiasi kikubwa cha NVP mwilini hata baada ya zaidi ya majuma mawili kupita tangu 
walipotumia dawa hii.10 Kwa wastani muda (half life) wa kuondoa dawa ya Nevirapine (NVP) 
mwilini katika watu 44 waliofanyiwa utafiti ulikuwa saa 56.7, kiasi ambacho pia kilionekana katika 
utafiti uliofanywa na Musoke na wenzake.11
Katika nchi zisizo na rasimali za kutosha ambapo wanawake wengi wanachelewa kuja ili 
kupata huduma za ANC (antenatal clinic), hata wakija kwenye kliniki pia wachache sana ndio 
wanaopata huduma ya kipimo cha CD4, hivyo basi Sd-NVP itabaki kuwa ndiyo kinga muhimu 
dhidi ya maambukizi ya virusi (HIV) yatokayo kwa mama kwenda kwa mtoto. Nchini Tanzania 
huduma za ANC za kupima virusi (HIV) na ugawaji wa ARVs kama kinga dhidi ya maambukizi 
toka kwa mama kwenda kwa mototo bado iko chini, ikiwa theluthi moja (1/3)ya wanawake 
ndiyo wanapata matibabu ya Sd-NVP kwa ajili ya pMTCT, hii ni kulingana na ripoti ya shirika la 
kimaifa linalopambana na UKIMWI duniani kote12 (UNAIDS report on the Global AIDS Epidemic, 
2010). Kiasi cha dawa ya NVP chini ya kiwango kinachotakiwa mwilini (sub-therapeutic) ndicho 
kinachotengeneza mazingira mazuri kwa usugu wa dawa kujitokeza; kwa sababu kiwango hiki 
cha dawa kinakuwa na uwezo ulio chini ya kiwango (sub-inhibitory) kinachotakiwa ili kupambana 
na virusi (HIV) kwa muda mrefu sana, matokeo hayo yameonekana katika utafiti uliofanywa na 
Jackson na wenzake.13
Ingawaje, tafiti za hivi karibuni zimeonesha kwamba matumizi ya dawa ya Sd-NVP kwa 
wanawake wanapojifungua na vichanga vyao ndani ya saa 72 tangu kuzaliwa ni kinga salama 
na madhibuti dhidi ya MTCT.4;5 Tafiti hizi zimetoa taarifa muhimu na yenye thamani sana 
itakayosaidia kuandaa na kufanya tafiti ambazo zitatoa taarifa na njia bora dhidi ya ongezeko la 
usugu wa dawa ya NVP.
katika sura ya tatu (3) ya ripoti hii ya uatfiti tumeeleza na kuonesha matumizi ya dozi 
moja ya carbamazepine (CYP3A4 enzyme inducer) inayosababisha uzalishaji wa kimeng’enya 
atumiapo kinga dhidi ya pMTCT ili kuona kama usugu wa dawa ya NVP unapunguzwa kwa 
kuongeza utoaji wa NVP mwilini mara itumikapo dawa ya Sd-NVP14 mara tu uchungu wa uzazi 
unapoanza kwa mjamzito aishiye na virusi (HIV). Tumegundua kuwa matumizi ya dozi moja 
ya carbamazepine (CYP3A4 enzyme inducer) haukubadili kiwango cha dawa ya NVP mwilini 
wakati wa kujifungua na kiwango hicho cha dawa kinalingana na kile kilichoonekana katika 
tafiti zilizopita11;15-17, lakini imeonekana kupunguza kwa kiwango kikubwa dawa ya NVP mwilini 
juma moja baada ya kujifungua. Katika juma la sita baada ya kujifungua kipimo cha utambuzi wa 
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mabaliko ya vinasaba ya kirusi (HIV) kutokana na NVP katika K103N ulifanyika na ikagundulika 
kuwa upo kwa wanawake 9 ambapo 8 pekee kwenye Y181C/I na 1 kwenye G190A. Kwa kawaida 
kipimo cha utambuzi wa mabadiliko ya vinasaba ya virusi (HIV) iliweza kugundua mabadiliko 
hayo kwa 20% miongoni mwa wote waishio na virusi (HIV) na siyo kwenye makundi madogo 
madogo yenye mabadiliko hayo. Kipimo kingine (deep sequencing) ambacho kina uwezo 
wa kutambua hata mabadiliko madogo ya vinasaba ni muhimu itumike kwa tafiti za usoni. Pia 
tumeona kiasi kikipungua cha usugu wa dawa ya NVP miongoni mwa wanawake wenye kiwango 
kidogo sana (undetectable) cha NVP katika jamii nzima, hii ikithibitisha uwezo na usahihi wa 
technolojia tuliotumia katika utafiti wetu.
Kiwango cha NVP kwa vichanga haikuonekana kupungua kwa sababu ya kiwango kidogo 
cha carbamazepine kwenye maziwa ya mama hivyo kupelekea ucheleweshwaji wa kuzalisha 
kimeng’enya (delayed enzyme induction) mwilini.18 Hata hivyo kiwango cha maambukizi ya 
virusi (HIV- 1) mara baada ya kuzaliwa kichanga kinaonekana kufanana na tafiti zilizopita wakati 
wajawazito walipotumia Sd-NVP kwa mara ya kwanza.4;19 
Matokeo ya tafiti zingine kuhusu kinga za muda mfupi yameonesha kupunguza ongezeko 
la usugu wa dawa ya NVP14;20-22 kwa kiasi kikubwa, ingawaje kiasi cha mabadiliko ya vinasaba 
yasababishayo usugu wa dawa ya Sd-NVP yamepungua baada ya muda fulani, lakini bado kuna 
ushahidi unaonekana kwa baadhi ya wanawake kuwa tayari na mabadiliko hayo hata kabla 
ya matumizi ya Sd-NVP na hata baadhi ya wasio na mabadiliko ya vinasaba miili yao huwa ina 
mwitikio mdogo sana kwa dawa za ARVs zitumikazo kupunguza makali ya virusi ya HIV.23 Tatizo 
la dawa za ARV zenye 3TC kwa wanawake wanapoanza nazo ni ugumu na kujitokeza kwa usugu 
mwilini ambalo linapelekewa na kushindwa kwa dawa kupambana na virusi hivyo nao mwili 
kushindwa kutengeneza kinga baada ya kuzidiwa na virusi, kwa kuzingatia hayo tunashauri 
kwamba matumizi ya hizi dawa mbili za AZT/3TC yafanyike kwa uangalifu zaidi.24 25 Ili kuendelea 
kutunza urahisi wa matumizi ya dozi moja ya NVP, matokeo mengine ya utafiti wa Chi na 
wenzake26 aliyetoa dozi moja yenye Sd-NVP, emtricitabine na tenofovir kwa wanawake 400, 
ulipunguza usugu wa dawa ya NVP kwa nusu toka 25% hadi 12%. Utafiti wa hivi karibuni nchini 
Malawi27 umeonesha kwamba chaguo la B+ la WHO umeongeza kwa kiasi kikubwa utumiaji wa 
dawa madhubuti kwa wanawake wajawazito waishio na virusi vya HIV. Ingawaje, kila dawa ina 
uzuri na ubaya wake na kwa sasa changamoto iliyojitokeza ni kuhusu usugu wa dawa za virusi 
kufuatia matumizi mrefu ya ARV kwa watumiaji, usalama wa matumizi ya ARV kwa vichanga, 
mapokeo na usawa wa dawa. Utafiti huu umeonesha uwezekano kwa programu za pMTCT 
kuongeza dawa inayosababisha uzalishaji wa kimeng’enya (enzyme inducer) ili kupunguza 
ongezeko la usugu wa dawa za NVP katika jamii zenye dawa chache za kuchagua. Pamoja na 
jitihada za WHO, matokeo ya utafiti huu mbali na kuwa mapya katika nyanja za pMTCT pia 
yameonesha kwamba utafiti huu wa kifamacologia una faida ya ziada pamoja na urahisi na kuwa 
kinga bora itumikapo dhidi ya pMTCT katika mimba zinazofuata kwenye nchi zisizo na rasilimali 
za kutosha ambapo upatikanaji wa huduma za CTC haupo na hivyo dawa ya Sd-NVP itabaki kuwa 
ni chaguo la kwanza dhidi ya pMTCT. 
Sura ya nne (4) inaonesha matokeo ya utafiti juu ya matumizi ya muda mfupi (seven 
days) baada ya kujifungua ya dawa ya phenytoin inayoongeza utoaji mwilini wa NVP, kwa 
lengo la kupunguza kiwango cha ongezeko la usugu wa NVP baada ya kujifungua. Kiwango 
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cha Nevirapine mwilini wakati wa kujifungua umeonekana kufanana na wale wasiotumia 
phenytoin, na matokeo haya pia yakilingana na matokeo ya tafiti zingine zilizopita11;17 Baada 
ya kujifungua, vipimo vingine vya kifamacologia ya dawa ya nevirapine vilionekana kuathiriwa 
kwa kiasi kikubwa na kemikali (enzyme inducer). Baada ya kuongeza phenytoin kwenye 
dawa ya Sd-NVP ilipunguza kiwango cha nevirapine mwilini kwa 85% na kuonesha kwamba 
kiasi kikubwa cha wanawake kuwa na kiwango kidogo sana (undetectable) mwilini cha NVP 
juma la kwanza na la pili baada ya kujifungua. Hii imepunguza muda (half-life) wa kuondoa 
NVP kwa 60%, ikiwa ni pungufu ya masaa 35.8. Huu ni upungufu mkubwa wa muda (half-life) 
kuliko yote kuwahi kuripotiwa hasa kwa wanawake wajawazito waishio na virusi (HIV). Kwa 
sasa matumizi ya juma moja ya dawa ya AZT/3TC inashauriwa kupunguza usugu wa NVP kwa 
wajawazito wenye virusi wanaotumia Sd-NVP wakati wa kujifungua ikiwa ni kama sehemu ya 
kinga dhidi ya pMTCT6;28-30 Tumegungua kwamba dawa ya phenytoin ikiongezwa kwenye dozi 
ya siku 7 pindi uchungu wa kujifungua unapoanza inaweza kupunguza kwa kiasi kikubwa muda 
wa uondoshaji wa dawa ya NVP mwilini. Aidha dozi ya phenytoin ya siku 7 baada ya kujifungua 
imeonekana kuwa salama tena bila kuonesha mabadiliko mapya ya vinasaba yasababishayo 
usugu dhidi ya dawa ya NVP. Hata hivyo tunashauri tafiti kubwa zaidi kufanyika ili kuweza 
kuonesha na kuthibitisha kwamba dawa ya phenytoin kwa kiasi kikubwa inaongeza utoaji 
wa dawa ya NVP mwilini na kuharakisha upoteaji wake mara baada ya kujifungua. Ingawa, 
maelfu ya wajawazito bado wanatumia dawa ya Sd-NVP31, hii inaonesha changamoto ya 
utekelekezaji wa miongozo ya sasa. Phenytoin ni salama kuweza kutumika wakati wa ujauzito 
na unyonyeshaji32 na madhara kuwa machache sana kwa vile dozi ni ndogo na inatumika kwa 
muda mfupi sana. Uongezaji wa dawa inayosababisha uzalishaji wa kimeng’enya (an enzyme 
inducer) kwa siku 7 kwenye dawa ya Sd-NVP dhidi ya pMTCT imepunguza uwepo wa kiwango 
chini ya kinachitakiwa (sub therapeutic) mwilini cha NVP kwa kupunguza muda wa uondoaji 
wa NVP mwilini kwa kiasi kikubwa bila kuonesha mabadiliko mapya ya vinasaba yasababishayo 
usugu wa virusi. Kwa kuwa uwepo kwa kiwango chini (sub therapeutic) mwilini cha NVP kwa 
muda mrefu unajulikana kupelekea kutokea kwa usugu dhidi ya NVP, na kwa kuwa phenytoin 
ni salama, Sd-NVP ingeweza kutumiwa ikiwa pamoja na phenytoin itokeapo kuwa dawa 
zingine za ARV hazipatikani na utumizi wake ukichunguzwa kwanza kwa kina katika tafiti 
kubwa zaidi (phase III trial).
katika sura ya tano (5) tumefanya upembuzi na marejeo ya kina ya tafiti zingine ili 
kuchunguza madhara ya dawa kadha wa kadha na kipindi cha matumiazi ya NVP na kujitokeza 
kwa usugu dhidi ya Sd-NVP kama sehemu ya kinga dhidii ya pMTCT. Tafiti zimeonesha kwamba 
utumiaji wa AZT kabla ya kujifungua ikijumlishwa na utumiaji wa ARV kwa muda mfupi (chini 
ya siku 8) baada ya kujifungua zimeonesha kwamba zimeondosha usugu dhidi ya NVP chini 
ya 0.02%. Aidha dawa zilizotumika kwa siku, 20-3033;34 baada ya kujifungua zimeonesha uwezo 
mkubwa zaidi ikilinganishwa na zile za muda mfupi (chini ya siku 8) kwa kiasi cha 0.03%30;34, 
ingawaje matumizi ya ARV kwa muda mrefu ni magumu na yana changamoto kubwa zaidi 
kiutekelezaji katika nchi zisizo na rasilimali za kutosha. Miongozo ya WHO ya utumiaji wa 
chaguo A (kabla ya kujifungua AZT, Sd-NVP na juma moja baada ya kujifungua 3TC/AZT)28 lazima 
ifuatwe ili kupunguza kwa kiasi kikubwa madhara yaletayo usugu dhidi ya NVP kwenye maeneo 
ambapo dawa ya Sd-NVP bado inatumika. 
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katika sura ya sita (6) tumeeleza matokeo ya utafiti kuhusu namna ya ufuatialiji wa kiwango 
cha dawa ya NVP kinachotakiwa mwilini (therapeutic drug monitoring (TDM)). Dawa nyingi za 
ARV zinazopatikana katika nchi nyingi zinazoendelea ni mseto wa NNRTI nevirapine na zingine 
mbili aina ya NRTIs. Tatizo kubwa la dawa ya NVP kuwa na uwezo mdogo sana wa vinasaba wa 
kujikinga dhidi ya ongezeko la usugu wa virusi35 Aina sugu ya virusi dhidi ya NVP iliyotokeza 
na kusambaa kwenye jamii imetokana na program zinazoruhusu matumizi hayo katika nchi 
zinazoendelea. Hii imekuwa tatizo sana katika nchi zisizo na rasilimali za kutosha kwa vile kuna 
dawa chache sana za ARV ambazo hutumika kama chaguo la pili. Kwa upande wa kifamacologia, 
TDM inaweza kuwa ni chombo muhimu sana kitakacho tumika kuwatambua wagonjwa wasio na 
kiwango kinachotakiwa cha dawa kama vile NVP mwilini ambao wako katika hatari ya kushindwa 
kuondoa virusi mwilini hivyo kusababisha ongezeko la usugu dhidi ya dawa. Ili kuwezesha 
utumiaji wa TDM katika nchi zinazoendelea, njia mbadala za kuchukua sampuli na kufanya vipimo 
tulizitumia na kuzichunguza. Tafiti zilizopita zimeonesha kwamba mate yanaweza kutumika 
kama sampuli mbadala wa sampuli za damu kwa ajili ya TDM ili kuangalia NVP mwilini, hii njia 
haiumizi ni salama, haina gharama na inapunguza hatari ya kuambukiza virusi wafanyakazi wa 
afya wanapochukua sampuli kutoka kwa wagonjwa wa HIV 36 Kama teknolojia mbadala wa HPLC, 
tumetumia teknolojia rahisi yenye gharama ndogo ya TLC ili kufuatilia kiasi cha dawa za NVP 
mwilini37 Tulitengeneza TLC rahisi yenye uwezo wa kutambua kiwango (semi-quantitative) cha 
NVP iliyopo kwenye mate. Njia hii tuliijaribu na kuitumia kwa watu wazima wenye virusi vya HIV 
Tanzania wanaotumia dawa za NVP katika hospitali ya KCMC na iligundulika kuwa na uwezo 
mkubwa sana wa kutambua na kugundua kiwango hata kile kidogo cha dawa za NVP mwilini 
(sub-therapeutic). Utoaji wa huduma za kitabibu kwa wagonjwa wa HIV duniani kote watafaidika 
na teknolojia hii kama itahamishiwa hasa kwenye nchi zingine zinazoendelea. Tunashauri hii 
teknolojia ya TLC ambayo ni rahisi na yenye gharama nafuu itumike kufuatilia kiwango (TDM) 
cha NVP mwilini kupitia mate katika nchi zisizo na rasilimali za kutosha. 
katika sura ya saba (7) tulilinganisha kiwango cha NVP kwenye mate kwa wagonjwa 
wanaotumia ARV zenye NVP katika hospitali ya KCMC nchini Tanzania. Matumizi bora ya 
dawa ni pamoja na utumiaji wa dawa sahihi, dozi sahihi, kiwango sahihi na kwa muda sahihi 
ili kiwango cha dawa mwilini cha >95%. Katika tafiti kuhusu wagonjwa walioripoti wenyewe 
uaminifu kwenye matumizi sahihi ya ARV, kiwango cha dawa mwilini kilikuwa >95%38;39 Taarifa za 
uaminifu juu ya matumizi ya sahihi katika utafiti wetu zimeonekana kulingana zile zilizopatikana 
nchini Rwanda40 ambapo uhesabuji wa vidonge na maswali kwa mgonjwa vilitumika kupima 
uaminifu juu ya matumizi sahihi ya dawa na zile za nchini Botswana ambako uaminifu juu ya 
matumizi sahihi ulipimwa kutumia kipimo cha Morisky (Morisky scale).38 Aidha kiasi cha 
wagonjwa wenye kiwango cha kutosha cha dawa mwilini kwa waliotumia dozi hizi mbili za 
NVP i.e. d4T+3TC+NVP, and AZT+3TC+NVP walionekana kutotofautiana kwa utafiti wetu. Tatizo 
kubwa la mpambano wa dawa na dawa kwa wagonjwa wa HIV ni hatari ya ongezeko la kiwango 
cha dawa za ARV kilicho chini ya kinachotakiwa kwenye mate. Kwa kuwa kiasi cha wagonjwa 
waliokuwa wanatumia dawa zaidi ya moja kuwa ni ndogo sana (3 walitumia dawa za shinikizo, 
6 dawa za magonjwa nyemelezi na 4 dawa za kifafa), ilituwia vigumu sana kutoa hitimisho 
juu ya mpambano wa dawa na dawa. Tunashauri zifanyike tafiti kubwa ambazo zinauwezo 
wa kufuatilia ama kuchunguza na kutoa taarifa juu ya mpambano wa dawa na dawa mwilini 
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(pharmacokinetics interactions). TDM ya kiwango cha dawa za NVP mwilini kwa teknolojia ya 
HPLC kwa nchi zisizo na rasilimali za kutosha kama Tanzania ni ghali, na ni ngumu kuitumia 
kwa matumizi ya kawaida kwa wagonjwa kila siku. Usugu wa virusi dhidi ya ARV na kushindwa 
kufanya kazi kwa matibabu kwa sababu ya kutozingatia masharti ya matumizi ya dawa, mara 
nyingi ni vigumu sana kupima na kukabiliana nayo katika utoaji wa matibabu ya kila siku 
katika nchi zisizo na rasilimali za kutosha. Kwa kuwa chaguo la pili la dawa za ARV ni ghali na 
hazipatikani kwa urahisi katika nchi hizi, tiba madhubuti kwa wagonjwa wa HIV yanakuwa ni 
changamoto hasa pale dawa za chagua la kwanza zinaposhindwa kufanya kazi bila kugundulika 
kama zimeshindwa. TDM ya kiwango cha dawa mwilini itakuwa ni kifaa chenye thamani kwani 
kitakuwa na uwezo wa kupima moja kwa moja kiwango cha uzingativu wa masharti ya matumizi 
ya dawa, ingawa kiwango na kasi ya kuchukua dawa toka tumboni na mpambano wa dawa na 
dawa unatofautiana kati ya mgonjwa mmoja na mwingine. Pia matatizo ya gharama za vipimo 
yamepelekea kipimo cha TDM kutojumuishwa miongoni mwa vipimo vinavyohitajika katika 
utoaji wa matibabu ya kila siku hata nchi zilizo na rasilimali za kutosha. Utumiaji wa teknolojia 
kama TLC ambayo haina gharama, isiyosababishia maumivu kwa mgonjwa inashauriwa itumike 
katika nchi zisizo na rasilimali za kutosha. 
Sura ya nane (8) inatoa majumuisho ya matokeo yote muhimu ya utafiti wetu kwenye 
sehemu ya kwanza na ya pili ya ripoti hii. 
MITa z a Mo ya ba aDaye
Matokeo ya utafiti wetu kuhusu uongezaji wa dawa isababishayo uzalishaji wa kimeng’enya 
(enzyme inducer) uchochee utafiti zaidi katika nyanja za vinasaba (pharmacogenetics). Utofauti 
wa vinasaba katika mifumo ya kimmeng’enyo (metabolic pathways) inaweza sababisha miitikio 
tofauti kwa dawa, hii ikiwa ni pamoja na matokeo tarajiwa na madhara mengine yaletwayo na 
matumizi ya dawa. Dawa ya NVP imeoneshwa katika tafiti nyingi kwamba kwa kiasi kikubwa 
huvunjwa vunjwa na mifumo ya metaboliki ya CYP3A na CYP2B6.41 Vimeng’nya hivi hutofautiana 
sana kati ya mtu mmoja na mwingine katika utendaji kazi wake na hii kwa kiasi kikubwa inapelekea 
kutokea kwa utofauti wa kiwango cha dawa ya NVP mwilini. Vinasaba vya CYP2B6 hutofautiana 
kwa kiasi kikubwa sana na utofauti wake wa herufi moja (single nucleotide polymorphisms, 
SNPs) tu unatosha kuleta mabadilko makubwa katika mfumo mzima. Utofauti huu kwa kiasi 
kikubwa unasababishwa na kutofautiana kwa vinasaba katika cytochrome zinazotengeneza 
vimeng’enya vitumikavyo kumeng’enya dawa za NVP.42;43 
Tunashauri kufanya yafuatayo kwa tafiti zitakazofanyika hapo baadaye nchini Tanzania: 
Kufanyika kipimo kitachoweza kutambua tofauti ya vinasaba (Genotyping of gene variants) 
visababishavyo mabadiliko katika utendaji kazi wa CYP2B6 na CYP3A5. Kutofautisha kati ya 
wagonjwa wenye tofauti za vinasaba visababishavyo mabadiliko ya CYP2B6 na CYP3A5 katika 
kiwango cha uzalishaji wa vimeng’nya na IL-6 inaweza kusaidia kutambua madhara ya uzalishaji 
huo dhidi ya dawa za NVP.42-44
Matokeo ya utafiti wetu kwenye sehemu ya pili ya ripoti hii tumeonesha kwamba teknolojia 
ya TLC kwa ajili ya kufuatilia kiwango cha dawa mwilini (TDM) kwa matibabu ya wagonjwa wa HIV 
yamesaidia kuziba pengo lililokuwepo kati ya maabara na kliniki. 
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Hivyo tunashauri yafuatayo:
•	 Udhibiti ubora wa kiasi cha dawa za NVP kwenye mate kwa teknolojia ya TLC dhidi ya TDM ni 
lazima ipewe msisitizo kwenye huduma zote za CTC kwa nchi zote zinazoendelea ikiwemo 
Tanzania katika matumizi ya kila siku ili kufuatilia uzingativu na matumizi bora ya dawa ili 
kuboresha umadhubuti wa tiba na kutunza chaguzi za dawa.
•	 Zaidi sana, tafiti zinatakiwa kuchunguza endapo dawa zaingine za ARV zilizoruhusiwa 
kutumika mbali na NVP kama zinaweza kupatikana kwenye mate na pia kuweza kupimwa 
kwa teknolojia ya TLC. 
Matumizi ya dawa ya Sd-NVP dhidi ya pMTCT, ambazo hupunguza maambukizi toka kwa 
mama kwenda kwa mtoto kwa kiwango cha 11-13%, itabaki ndiyo chaguo pekee kwa nchi zisizo 
na rasilimali za kutosha, ingawa matumizi makubwa zaidi ya njia ngumu za dawa mseto za ARV 
baada ya juma la 14 la ujauzito na baada ya kujifungua (zikipunguza maambukizi kwa 1-2%) lazima 
pia zijumuishwe. Katika zoezi hili, siyo tu gharama za ziada kwa tafiti ngumu (gharama za vifaa na 
rasilimali watu) ndiyo za kupimwa, lakini pia idadi kubwa ya maabukizi ya HIV dhidi ya vichanga 
inayozuiliwa, kwa kuwa kama maambukizi ya HIV yanakuwa chini na gharama za huduma za tiba 
zinapungua mbali na kupunguza idadi ya wahudumu wa afya. 
•	 Hivyo tunashauri pia uchambuzi wa kina wa gharama (cost-benefit analysis) uwe ni sehemu 
katika utoaji wa huduma za pMTCT kwa nchi zisizo na rasilimali za kutosha ikiwemo Tanzania.
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Sa MeNVaT TINg 
Introductie
In dit proefschrift worden de eerste resultaten gepresenteerd van klinisch farmacologisch 
onderzoek naar het effect van toevoeging van een enzym inducer aan de geneesmiddelencom-
binatie voor preventie van moeder-op-kind HIV transmissie (pMTCT) en van de toepassing van 
dunne laag chromatografie (TLC) voor het monitoren van behandeling met geneesmiddelen 
(therapeutic drug monitoring - TDM) bij HIV-geïnfecteerde volwassenen. Bij dit onderzoek 
heeft samenwerking tussen partners uit Nederland, het Verenigd Koningrijk, Zambia en 
Tanzania geleid tot klinisch farmacologisch onderzoek bij HIV-geïnfecteerde patiënten dat met 
name relevant is voor ontwikkelingslanden. Deel I gaat over klinisch farmacologische aspecten 
van het gebruik van nevirapine (NVP) bij pMTCT. Met name wordt het effect gepresenteerd van 
toevoeging van een korte kuur van verschillende enzym inducers aan de pMTCT prophylaxe 
op de ontwikkeling van resistentie1 door verkorting van de eliminatiehalfwaardetijd van NVP 
bij HIV-geïnfecteerde zwangere vrouwen. Deel II focust op de validatie en de toepassing van 
de nieuw ontwikkelde TLC-techniek voor TDM in speeksel van HIV-geïnfecteerde patiënten 
van de Adult Care and Treatment Clinic in Kilimanjaro Christian Medical Centre (KCMC), 
Moshi, Tanzania.
In 2010 leefden naar schatting 3,4 miljoen kinderen onder de 15 jaar met HIV/AIDS wereldwijd 
en tenminste 250.000 stierven aan AIDS. HIV transmissie rond de bevalling maakt bijna de 
helft uit van de transmissie van moeder naar kind (MTCT) bij bevolkingen waar borstvoeding 
gebruikelijk is,2;3 en deze tijd rond de bevalling is daarom het voornaamste aandachtsgebied 
geworden voor pMTCT strategieën, met name door gebruik van antiretrovirale geneesmiddelen 
(ARV’s). Van single-dose nevirapine (sd-NVP) toegediend aan de vrouw tijdens de bevalling en 
aan de neonaat binnen 72 uur na de geboorte is aangetoond dat het veilig is en effectief voor 
pMTCT.4;5 Het regiem is goedkoop en vrij gemakkelijk toe te dienen. Sinds 2000 wordt sd-NVP 
door de Wereld Gezondheidsorganisatie (WHO) aanbevolen als een van de ARV strategieën 
voor pMTCT in ontwikkelingslanden.6 Onderzoek in het begin van de 21ste eeuw heeft echter 
aangetoond dat sd-NVP toegediend aan de moeder NVP resistentie kan doen ontstaan zowel 
bij moeder als bij haar kind. NVP resistentie komt in die omstandigheden naar schatting voor 
bij tot maximaal 69% van de vrouwen en maximaal 87% van de nieuwgeborenen.7 Ook gaven 
studies aan dat NVP resistentie na blootstelling aan NVP in het kader van pMTCT de virologische 
respons op later toegediende non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
bij moeders en kinderen verminderde.8;9 De meest waargenomen mutaties waren K103N 
en Y181C. De twee ARV’s met de grootste kans op resistentieontwikkeling bij gebruik in het 
kader van pMTCT zijn NVP en lamivudine (3TC), dit omdat hiervoor bij deze middelen slechts 
een enkele punt-mutatie in het virale codon nodig is. Ook bij antepartum, intrapartum en 
postpartum combinatietherapie met NVP voor pMTCT wordt nog steeds een prevalentie van 
NVP resistentie van 4-16% gevonden.7 De implicaties voor de lange termijn van het optreden 
van resistentie-mutaties na gebruik van korte therapie-schema’s voor pMTCT moeten nader 
onderzocht worden. 
In meer ontwikkelde landen komt HIV transmissie van moeder naar kind tijdens de 
zwangerschap en rond de bevalling weinig voor omdat er een veelomvattend pakket van 
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pMTCT maatregelen beschikbaar is. In ontwikkelingslanden daarentegen hebben vele met 
HIV geïnfecteerde vrouwen geen toegang tot zelfs de meest basale vormen van pMTCT, zoals 
counselling, een HIV test en ARV prophylaxe. Data uit ontwikkelde landen suggereren dat de 
effectiviteit van pMTCT regiems waarbij drie ARV’s worden toegepast groter is dan bij gebruik 
van slechts een of twee middelen. 
In hoofdstuk 2 laten wij zien dat de meeste gezonde en niet met HIV geïnfecteerde 
Nederlandse vrouwen aan wie een enkele dosis van 200 mg nevirapine (sd-NVP) werd 
toegediend nog aantoonbare concentraties van NVP in hun bloed hadden na meer dan 
2  weken.10 De mediane NVP halfwaardetijd, gevonden in de 44 onderzochte personen, was 
56,7 uur. Een vergelijkbare waarde werd gevonden door Musoke et al.11 In omstandigheden met 
beperkte financiële middelen, waar veel vrouwen pas laat in de zwangerschap voor het eerst 
een zwangerschapspolikliniek bezoeken, en slechts bij weinigen een onderzoek naar het aantal 
CD4 cellen in het bloed wordt verricht, zal sd-NVP waarschijnlijk nog lange tijd een belangrijke 
interventie blijven voor pMTCT. Ook in Tanzania heeft nog slechts een beperkt deel van de 
zwangere vrouwen toegang tot onderzoek op HIV in de zwangerschap en prophylaxe met 
ARV’s. Een op de drie vrouwen krijgt nog sd-NVP voor pMTCT volgens het Global AIDS Epidemic 
Report van UNAIDS, 2010.12 Door de sub-therapeutische NVP plasma concentraties die hierbij 
voorkomen, ontstaat makkelijk NVP resistentie, omdat de concentraties gedurende meerdere 
dagen lager zijn dat benodigd voor het remmen van de HIV replicatie, zoals gerapporteerd werd 
door Jackson et al.13 Dit is van belang voor de opzet van interventie-studies om de ontwikkeling 
van NVP resistentie te voorkomen.
In hoofdstuk 3 beschrijven wij een innovatief onderzoek naar de toepassing van een 
enkele dosis carbamazepine, een CYP3A4 enzym inducer, die werd toegevoegd aan de 
pMTCT medicatie. Wij vonden dat hierdoor NVP resistentie minder vaak optrad doordat NVP 
sneller werd geëlimineerd na toediening van sd-NVP14 bij het begin van de bevalling bij HIV-
geïnfecteerde vrouwen. We vonden dat toevoeging van één dosis carbamazepine de NVP 
plasma concentraties tijdens de bevalling niet beïnvloedde en dat deze plasma concentraties 
vergelijkbaar waren met die welke in eerdere studies waren gevonden11;15-17. Echter de NVP plasma 
concentraties een week na de bevalling waren significant lager. Zes weken na de bevalling werd 
HIV genotypering gedaan. De meest voorkomende mutaties waren K103N, Y181C/I en G190A. 
Van deze kwam K103N het meest voor (bij 9 vrouwen), en wel als de enige mutatie bij 8 van de 
9 vrouwen, en in combinatie met G190A bij 1 vrouw. Met standaard HIV genotypering assays 
werden slechts bij 20% van de HIV populatie virus mutaties gevonden, en geen subpopulaties 
van mutanten. Verdergaande genotypering (deep sequencing) moet bij toekomstig onderzoek 
worden overwogen. We vonden ook een aanwijzing dat bij vrouwen met ondetecteerbare NVP 
concentraties NVP resistentie minder voorkwam, hetgeen het belang van deze benadering 
ondersteunt. De NVP concentraties bij de pasgeborenen waren waarschijnlijk niet gereduceerd 
vanwege de vertraagde enzym inductie en de lage concentraties van carbamazepine in de 
moedermelk.18 In overeenstemming hiermee was de perinatale HIV-1 transmissie vergelijkbaar 
met die welke was gerapporteerd uit eerdere studies bij vrouwen die sd-NVP voor de eerste maal 
gebruikten.4;19 Anderen gebruikten kortdurende interventies en reduceerden het optreden van 
NVP resistentie in belangrijke mate14;20-22 ofschoon de prevalentie van resistentie mutaties afnam 
127
8
C
LIN
IC
A
L PH
A
R
M
A
C
O
LO
G
Y
 O
F N
E
V
IR
A
PIN
E IN
 H
IV
-IN
FEC
TED
 PA
TIEN
T
S IN
 TA
N
Z
A
N
IA
naarmate de expositie aan sd-NVP langer geleden was. Toch bestaan er enkele aanwijzingen 
dat vrouwen met pre-existente mutaties alsook vrouwen blootgesteld aan sd-NVP maar zonder 
mutaties minder goed op ARV behandeling reageren.23 Het grootste problem is de complexiteit 
van deze behandelingsmethoden, alsook het optreden van lamivudine (3TC) resistentie, welke 
gepaard gaat met virologisch en klinisch falen van de behandeling bij vrouwen die beginnen 
met 3TC-bevattende ARV combinatietherapie voor hun eigen gezondheid. Dit heeft geleid 
tot de aanbeveling terughoudend te zijn met de toepassing van AZT/3TC bevattende ARV 
behandelingsschema’s.24;25 Om de eenvoud van de behandeling te behouden, pasten Chi et 
al.26 een enkele dosis emtricitabine + tenofovir toe samen met sd-NVP bij 400 vrouwen. Dit 
halveerde eveneens het optreden van NVP resistentie (25% versus 12%). Een recent onderzoek 
in Malawi27 toonde aan dat de WHO optie B+ van pMTCT de toegang tot effectieve ARV 
behandeling voor HIV- geïnfecteerde zwangere vrouwen snel heeft doen toenemen. Echter 
elke interventie heeft zijn voor- en nadelen en momenteel zijn er toenemende zorgen over 
het ontstaan van resistentie tegen HIV geneesmiddelen bij langdurig gebruik als deze vroeg 
in het beloop van een HIV infectie worden toegepast. Ook de veiligheid van toepassing van 
ARV’s voor de foetus, resp. de baby, en acceptatie en gelijke toegang tot deze middelen, blijven 
punten van aandacht. Ons onderzoek laat zien dat het mogelijk is om in pMTCT programma’s 
een enzym inducer toe te voegen ter vermindering van de ontwikkeling van NVP resistentie in 
omstandigheden waar andere uitgebreidere behandelingsmogelijkheden (nog) niet haalbaar 
zijn. Als aanvulling op de initiatieven van de WHO tonen onze bevindingen, die nieuw zijn op 
het gebied van de pMTCT, aan dat de farmacologische benadering zoals door ons beschreven, 
mogelijk een extra effect heeft, terwijl toch de eenvoud van de behandeling behouden blijft. 
Ook blijft bij deze sd-NVP vorm van pMTCT de effectiviteit behouden als het middel opnieuw 
in volgende zwangerschappen wordt toegepast. Dit alles geldt voor omstandigheden waar 
toegang tot het volledige programma van ARV combinatietherapie nog niet mogelijk is. 
In hoofdstuk 4 wordt een onderzoek beschreven naar het effect van toediening van 
fenytoine gedurende 7 dagen na de bevalling bij vrouwen die sd-NVP gebruiken in het kader van 
pMTCT. Fenytoine is een enzym inducer die daardoor de eliminatie van NVP versnelt, met als 
gevolg dat ontwikkeling van NVP resistentie wordt tegengegaan. Wij vonden dat de NVP plasma 
concentraties bij de bevalling op hetzelfde niveau lagen bij de vrouwen die fenytoine kregen 
als bij degenen die het niet kregen, en de waarden die wij vonden waren goed vergelijkbaar 
met die gevonden bij eerder onderzoek.11;17 Na de bevalling waren de NVP farmacokinetische 
parameters substantieel veranderd door de enzym inductie. Door toevoeging van fenytoine 
aan sd-NVP waren de NVP concentraties in het plasma 85% lager, en een significant groter 
deel van de vrouwen had ondetecteerbare NVP concentraties één en twee weken na de 
bevalling. Hierdoor was de NVP eliminatie halfwaardetijd 60% korter (in absolute waarden 
35,8 uren korter). Dit is de sterkste verkorting van de NVP eliminatie halfwaardetijd die ooit 
werd gerapporteerd, met name in de doelgroep van HIV-geïnfecteerde zwangere vrouwen. 
Momenteel wordt een kuur van een week zidovudine/lamivudine aanbevolen om het ontstaan 
van NVP resistentie te voorkomen bij HIV-geïnfecteerde vrouwen die sd-NVP ontvangen 
tijdens de bevalling als onderdeel van pMTCT.6;28-30 Wij vonden dat toevoeging van een korte 
kuur van 7 dagen fenytoine aan het begin van de bevalling een significante verkorting van de 
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eliminatie halfwaardetijd van NVP gaf. Zeven dagen fenytoine toedienen na de bevalling leidde 
niet tot nieuwe NVP resistentie mutataties. Wij bevelen echter aan dat dit wordt bevestigd in 
een groter prospectief onderzoek met voldoende power om aan te tonen dat fenytoine de 
verdwijning van NVP uit het bloed significant versnelt na de bevalling.  Duizenden vrouwen 
krijgen nog steeds sd-NVP toegediend31, hetgeen laat zien dat de implementatie van de nieuwe 
richtlijnen niet eenvoudig is. Fenytoine kan veilig in de zwangerschap worden toegepast, en 
ook tijdens borstvoeding32 en er zijn bij zo’n kortdurend gebruik met zo’n lage dosis weining 
bijwerkingen te verwachten. De toevoeging van een enzym inducer aan sd-NVP voor pMTCT 
gedurende zeven dagen reduceerde het optreden van subtherapeutische NVP concentraties 
door een significante verkorting van de NVP eliminatie halfwaardetijd, terwijl geen nieuwe 
NVP resistentie mutaties werden gevonden. Omdat blootstelling aan subtherapeutische NVP 
concentraties kan leiden tot het ontstaan van NVP resistentie, en omdat fenytoine veilig is, kan 
sd-NVP met fenytoine worden toegepast als andere ARV middelen niet beschikbaar zijn. Deze 
toepassing dient in een groter fase III onderzoek nader te worden onderzocht.
In hoofdstuk 5 worden de resultaten gepresenteerd van een systematisch overzicht en een 
meta-analyse betreffende de effecten van interventies met verschillende geneesmiddelen, 
en de duur van de inname ervan, op het ontstaan van NVP resistentie na gebruik van sd-NVP 
als onderdeel van ARV prophylaxe in het kader van pMTCT. In verschillende studies werd 
aangetoond dat inname van zidovudine vóór de bevalling plus een korte kuur (<8 dagen) met 
ARV’s ná de bevalling het ontstaan van NVP resistentie bijna elimineerde (<0.02%). Bovendien 
werd aangetoond dat een kuur met ARV’s gedurende 20-30 dagen na de bevalling33;34 iets 
meer effectief was vergeleken met gebruik gedurende <8 dagen na de bevalling (0.003%)30;34, 
echter een langduriger ARV behandeling is meer complex en moeilijker te implementeren in de 
dagelijkse praktijk in ontwikkelingslanden. De WHO richtlijn optie A (antepartum zidovudine, 
sd-NVP en een week zidovudine/lamivudine postpartum)28 moet gevolgd worden om een 
aanvaardbaar minimaal risico van NVP resistentie te hebben in gebieden waar sd-NVP nog 
wordt toegepast. 
In hoofdstuk 6 beschrijven wij een onderzoek naar therapie monitoring van 
geneesmiddelen (TDM) van NVP. In de meeste generieke ARV combinaties die beschikbaar 
zijn in ontwikkelingslanden wordt het NNRTI nevirapine gecombineerd met twee nucleoside 
reverse transcriptase inhibitors (NRTIs). Een nadeel van NVP is dat het een lage genetische 
barriere heft tegen de ontwikkeling van resistentie.35 HIV stammen die resistent zijn tegen 
NVP bevattende ARV combinatietherapie die verstrekt wordt in het kader van nationale AIDS 
bestrijdingsprogramma’s in ontwikkelingslanden, zouden zich kunnen verspreiden in de algemene 
bevolking. Dit is zorgwekkend omdat er maar weinig tweedelijns geneesmiddelenopties zijn in 
ontwikkelingslanden. Vanuit farmacologisch perspectief zou TDM een belangrijk middel kunnen 
zijn om patiënten met een onjuiste expositie aan geneesmiddelen zoals NVP te identificeren, 
en daarmee ook het risico op virologisch therapiefalen en de ontwikkeling van resistentie op te 
sporen. Om de implementatie van TDM in ontwikkelingslanden te faciliteren, onderzochten wij 
alternatieve mogelijkheden voor het afnemen van materiaal bij de patiënt, en werd een andere 
techniek voor de bepaling onderzocht. Bij eerder onderzoek was aangetoond dat speeksel kan 
gebruikt worden als alternatief materiaal in plaats van plasma voor TDM van NVP. Dit is een 
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pijnloze en niet-invasieve methode van monsterafname met bovendien een lager risico van 
HIV-transmissie naar de gezondheidswerkers, en het kost weinig geld.36 Als alternatief voor 
HPLC werd de relatief goedkope dunne laag chromatografie (thin layer chromatography -TLC) 
techniek onderzocht voor het meten van NVP in plasma.37 Wij ontwikkelden een goedkope en 
eenvoudige TLC methode voor het semi-kwantitatief meten van NVP in speeksel. De methode 
werd gevalideerd in HIV-geïnfecteerde Tanzaniaanse volwassenen die met NVP bevattende 
ARV combinaties werden behandeld in KCMC. We vonden dat de methode sensitief, specifiek 
en betrouwbaar was voor het aantonen van sub-therapeutische NVP concentraties. Als deze 
techniek ook naar andere ontwikkelingslanden zou kunnen worden overgebracht, zou dit de 
verstrekking van HIV zorg en behandeling wereldwijd ten goede komen. Wij bevelen daarom 
aan dat deze goedkope en eenvoudige TLC techniek toegepast gaat worden voor het meten 
van NVP in speeksel in ontwikkelingslanden. 
In de studie beschreven in hoofdstuk 7 vergeleken wij NVP concentraties gemeten in 
speeksel met therapietrouw door de patiënten zelf gerapporteerd, bij patienten die met NVP-
bevattende ARV’s werden behandeld in KCMC, Tanzania. Rationeel gebruik van geneesmiddelen 
omvat het nemen van het geneesmiddel in de juiste dosering, de juiste hoeveelheid en op de 
juiste tijd zodanig dat de juiste concentraties worden bereikt bij >95% van de patiënten. In 
studies naar zelf gerapporteerde therapietrouw bij patiënten die ARV’s gebruikten, werd bij 
> 95% adherentieconcentraties gevonden.38;39 De zelf gerapporteerde therapietrouw die wij in 
onze studie vonden, was vergelijkbaar met die gevonden in Rwanda40 waar het tellen van de 
pillen en een vragenlijst werden gebruikt om de adherentie te meten, en in Botswana waar 
zelf-gerapporteerde therapietrouw werd gemeten op de schaal van Morisky.38 Bovendien was 
in onze studie onder de deelnemers die één van de twee NVP bevattende ARV combinaties 
gebruikten (d4T+3TC+NVP, respectievelijk AZT+3TC+NVP) de proportie met therapeutische 
NVP concentraties vrijwel gelijk. Door geneesmiddeleninteracties die kunnen voorkomen 
bij HIV-geïnfecteerde patiënten kunnen sub-therapeutische speekselconcentraties van 
ARV’s ontstaan. Omdat het aantal patiënten dat niet-ARV co-medicatie gebruikte klein 
was, (3  patiënten gebruikten anti-hypertensiva, 6 geneesmiddelen tegen opportunistische 
infecties, en 4 anti-epileptica), was het moeilijk hierover conclusies te trekken in ons 
onderzoek. We bevelen daarom aan een grotere prospectieve studie te doen met voldoende 
power om farmacokinetische interacties vast te stellen. TDM van NVP via HPLC is erg kostbaar 
in ontwikkelingslanden zoals Tanzania, en is nauwelijks toepasbaar bij routine medische zorg. 
ARV resistentie en falen van de behandeling als consequentie van sub-optimale therapietrouw, 
zijn vaak moeilijk vast te stellen en niet gemakkelijk goed aan te pakken tijdens routinematige 
klinische patiëntenzorg in ontwikkelingslanden. Omdat behandeling met tweedelijns 
ARV’s duur is en de medicijnen daarvoor niet altijd makkelijk beschikbaar, is effectieve 
behandeling van HIV infectie moeilijk als de eerstelijnsmedicatie niet werkt. TDM door het 
meten van geneesmiddelenconcentraties in het plasma kan nuttig zijn om op directe wijze de 
therapietrouw vast te stellen, echter de concentraties variëren tussen patiënten ten gevolge 
van wisselende absorptie, en door geneesmiddeleninteracties. Door de hoge kosten is het niet 
gelukt om TDM op te nemen in de routine patiëntenzorg, zelfs in ontwikkelde landen met een 
130
8
C
LIN
IC
A
L PH
A
R
M
A
C
O
LO
G
Y
 O
F N
E
V
IR
A
PIN
E IN
 H
IV
-IN
FEC
TED
 PA
TIEN
T
S IN
 TA
N
Z
A
N
IA
ruimer budget voor medische zorg. Daarom bevelen wij voor ontwikkelingslanden aan gebruik 
te maken van de relatief goedkope en niet-invasieve TLC methode. 
Hoofdstuk 8 bevat een samenvatting van de voornaamste bevindingen in deel I & deel II 
van het proefschrift. 
ToekoMSTPerSPeCTIeVeN
Onze resultaten op het gebied van enzym inducers vormen een stimulans tot nader 
farmacogenetisch onderzoek. Genetische verschillen in  metabolisme kunnen de individuele 
respons op geneesmiddelen beïnvloeden, zowel wat betreft het therapeutisch effect, als wat 
bijwerkingen betreft. NVP wordt voornamelijk gemetaboliseerd door CYP3A en CYP2B6.41 
Deze enzymen vertonen inter-individuele verschillen in expressie of in mate van activiteit, 
die waarschijnlijk bijdragen aan de farmacokinetische variabiliteit van NVP. Het CYP2B6 gen is 
zeer polymorf met talloze single nucleotide polymorfismen (SNPs) en daarmee geassocieerde 
haplotypen. Deze variabiliteit is grotendeels het gevolg van genetische polymorfismen in de 
cytochroom enzymen die NVP metaboliseren.42;43 
Wij bevelen daarom het volgende wetenschappelijk onderzoek aan in Tanzania: 
•	 GGenotypering van genetische varianten die zijn geassocieerd met een veranderde 
expressive van CYP2B6 en CYP3A5. Stratificatie van de patiënten op basis van de volgens de 
genetische variant voorspelde CYP2B6 en CYP3A5 expressie niveau’s kan helpen het effect 
van enzym inductie op de NVP dispositie te ontdekken.42-44
Onze resultaten gepresenteerd in deel II van het proefschrift, laten zien dat de gevalideerde 
methode van TLC voor TDM tijdens behandeling van patiënten met HIV infectie de kloof tussen 
het laboratorium en de klinische praktijk kan overbruggen. 
Wij bevelen daarom het volgende aan:
•	 Kwaliteitscontrole in de vorm van TDM tijdens behandeling door het meten van 
NVP in speeksel met behulp van TLC moet worden aangemoedigd in alle centra in 
ontwikkelingslanden waar medische HIV zorg verleend wordt, ook in Tanzania, en wel 
routinematig, met als doel de therapietrouw te meten, de effectiviteit van behandeling te 
verbeteren en behandelinsmogelijkheden te behouden voor de toekomst. 
•	 Daarnaast is onderzoek nodig om vast te stellen of andere toegepaste ARV’s dan NVP in 
speeksel kunnen worden gemeten met behulp van TLC. 
De toepassing van sd-NVP voor pMTCT, waardoor de moeder-kind transmissie van 
HIV teruggebracht wordt tot 11-13%, blijft een optie voor ontwikkelingslanden, ofschoon 
een bredere toepassing van meer complexe schema’s van ARV combinaties vanaf de 
14e  zwangerschapsweek en na de bevalling dient te worden overwogen. Hierdoor wordt de 
HIV-transmissie van moeder op kind teruggebracht tot 1-2%. Hierbij dienen niet alleen de extra 
uitgaven voor de meer complexe benadering (materiaalkosten en personeelskosten) in acht te 
worden genomen, maar ook het aantal additioneel voorkomen HIV infecties bij pasgeborenen. 
Immers, door minder HIV infecties verminderen de uitgaven voor de gezondheidszorg, dit nog 
ongeacht de vermindering van menselijk lijden die het teweeg brengt. 
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•	 Wij bevelen daarom aan een kosten-baten analyse uit te voeren teneinde de best haalbare 
benadering voor pMTCT te vinden voor toepassing in ontwikkelingslanden, inclusief 
Tanzania.
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